<SEC-DOCUMENT>0001731122-23-001412.txt : 20230808
<SEC-HEADER>0001731122-23-001412.hdr.sgml : 20230808
<ACCEPTANCE-DATETIME>20230808163053
ACCESSION NUMBER:		0001731122-23-001412
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230808
DATE AS OF CHANGE:		20230808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		231151919

	BUSINESS ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111
		BUSINESS PHONE:		844-689-3939

	MAIL ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e4887_10-q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:avxl="http://anavex.com/20230630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_avxl_anavex.com_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20221001_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-06-30" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-09-30" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2021-10-012022-06-30" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2021-10-012022-06-30" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUnder2023PurchaseAgreement" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-01to2023-06-30" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptions" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2021-10-012022-06-30" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2021-10-012022-06-30" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-10-01to2023-06-30" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20230630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-10-01to2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_MichaelJFoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_ThirdPartyPayorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 10pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>&#160;SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20221001__20230630_zOHfTASpQt0f"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><span id="xdx_90D_edei--DocumentQuarterlyReport_c20221001__20230630_zhtMW4d3oqka"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_902_edei--DocumentPeriodEndDate_c20221001__20230630_zGFDbqYx7Zr7"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2023</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><span id="xdx_90A_edei--DocumentTransitionReport_c20221001__20230630_zOonxUoVOOre"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the transition period from _____to _____</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
File Number: <span style="text-decoration: underline"><span id="xdx_907_edei--EntityFileNumber_c20221001__20230630_z3YajJp86zD3"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20221001__20230630_z1t6w70zGRx2"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20221001__20230630_zWTm9Kq9x9Gl"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20221001__20230630_zpvWSm9i51Y1"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressAddressLine1_c20221001__20230630_zng7kNMCRSrb"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20221001__20230630_zCvu7eZdlfUg"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20221001__20230630_zimarGIsIyZ3"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20221001__20230630_zBDXBleEN54" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressCountry_c20221001__20230630" title="Entity Address, Country"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A <span id="xdx_901_edei--EntityAddressPostalZipCode_c20221001__20230630_z75rbw1chRQj"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">1-<span id="xdx_90A_edei--CityAreaCode_c20221001__20230630_znOqOCuXeXo3"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_906_edei--LocalPhoneNumber_c20221001__20230630_zQ5kH3gYex3b"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Securities
Registered Pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Each Class</span></td>
<td style="vertical-align: top; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
Symbol</span></td>
<td style="vertical-align: top; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Each Exchange on Which Registered</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20221001__20230630_zgIUGtFRqorf"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20221001__20230630_zBU6aOPo4Z4i"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
<td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SecurityExchangeName_c20221001__20230630_zXjjuaMzDjsg"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;&#160;<b><span id="xdx_902_edei--EntityCurrentReportingStatus_c20221001__20230630_zSG01Y3SCIN8"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9744;
No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;
<b><span id="xdx_905_edei--EntityInteractiveDataCurrent_c20221001__20230630_zANaXi5ENJu1"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20221001__20230630_zKQb84ThaGRe"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="width: 44%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntitySmallBusiness_c20221001__20230630_zPrwLPLlEY14"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20221001__20230630_zeK1UMDCc2Yf"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Segoe UI Symbol,sans-serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>&#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9744;
Yes &#9746; <span id="xdx_903_edei--EntityShellCompany_c20221001__20230630" title="Entity Shell Company"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of Common Stock, as of the latest practicable date: <span style="color: black"><span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20230808_z2aTvfRUFme8" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,951,115</ix:nonFraction></span>
</span>shares of Common Stock outstanding as of August 8, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
                OF CONTENTS</b></span></p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART I &#8211;</b></span></td>
<td style="width: 85%"><a href="#a_001"><span style="font: 10pt Times New Roman, Times, Serif">FINANCIAL INFORMATION<span style="text-underline-style: none"><b>&#9;</b></span>PART
I &#8211; FINANCIAL INFORMATION</span></a></td>
<td style="width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;4</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 1.</span></td>
<td><a href="#a_002"><span style="font: 10pt Times New Roman, Times, Serif">FINANCIAL STATEMENTS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;4</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 2.</span></td>
<td><a href="#a_003"><span style="font: 10pt Times New Roman, Times, Serif">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;18</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 3.</span></td>
<td><a href="#a_004"><span style="font: 10pt Times New Roman, Times, Serif">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISKS.</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;37</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 4.</span></td>
<td><a href="#a_005"><span style="font: 10pt Times New Roman, Times, Serif">CONTROLS AND PROCEDURES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;37</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif"><b>PART II &#8211;</b></span></td>
<td><a href="#a_006"><span style="font: 10pt Times New Roman, Times, Serif">OTHER INFORMATION</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 1.</span></td>
<td><a href="#a_014"><span style="font: 10pt Times New Roman, Times, Serif">LEGAL PROCEEDINGS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 2.</span></td>
<td><a href="#a_007"><span style="font: 10pt Times New Roman, Times, Serif">RISK FACTORS&#9;</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 3.</span></td>
<td><a href="#a_008"><span style="font: 10pt Times New Roman, Times, Serif">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 4.</span></td>
<td><a href="#a_009"><span style="font: 10pt Times New Roman, Times, Serif">DEFAULTS UPON SENIOR SECURITIES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 5.</span></td>
<td><a href="#a_010"><span style="font: 10pt Times New Roman, Times, Serif">MINE SAFETY DISCLOSURES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 6.</span></td>
<td><a href="#a_011"><span style="font: 10pt Times New Roman, Times, Serif">OTHER INFORMATION</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;38</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">ITEM 7.</span></td>
<td><a href="#a_012"><span style="font: 10pt Times New Roman, Times, Serif">EXHIBIT</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;39</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
<td><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td><a href="#a_013"><span style="font: 10pt Times New Roman, Times, Serif">SIGNATURES</span></a></td>
<td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;40</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Condensed Interim Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">June 30, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
    Life Sciences Corp.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed
    Consolidated Balance Sheets</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>As
    at June 30, 2023 and September 30, 2022</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zIRITGmfkTdj" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230630_z2IvYsaEBupa" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220930" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June
    30</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September
    30,</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2023</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2022</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsAbstract_iB_zrvqJox0rM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Assets</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zblq4R3uLEl5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Current</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzbDa_zNTcRzBuTW63" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; width: 8%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10.5pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,817,164</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; width: 8%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesReceivable_i02I_maCzbDa_znTG7J3Okzi7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Incentive
    and tax receivables</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,165,127</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,192,580</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzbDa_zdF7SbOvYv8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,572</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,162</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_mtCzbDa_zwgVAOq6mOZ" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Assets</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,809,863</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zWaBocROBoPg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Liabilities
    and Stockholders' Equity</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_zKhj6qEOTvTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Current
    Liabilities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maCz6hG_ze6zJUVw927f" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,152,846</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,777</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz6hG_maCz6hG_zhwBjAWdy0Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    liabilities - Note 4</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,985,658</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,944,953</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeCurrent_i02I_maCz6hG_zQzbIlmgHxJ7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
    grant income - Note 3</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">916,763</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,831</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i02TI_mtCz6hG_maCzYsh_zrgNvcaHiFJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,055,267</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,213,561</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_zXHvZPf2Eq2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Commitments
    and Contingencies - Note 6</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">-</span><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">-</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Capital
    stock</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Authorized:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20230630_pdd" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20220930_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>
    preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230630_pdd" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220930_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td id="xdx_988_eus-gaap--PreferredStockValue_iI_pp0p0_maCzUbT_c20230630_zz7XBMjXAI8e" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091">-</span><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--PreferredStockValue_iI_pp0p0_maCzUbT_c20220930_zV3j4JRt4ynj" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: rgb(204,238,255); text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20230630_pdd" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220930_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span>
    common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230630_pdd" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_c20220930_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Issued
    and outstanding:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20230630_pdd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20230630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,390,916</ix:nonFraction></ix:nonFraction></span></span>
    common shares (September 30, 2022 -<span id="xdx_90A_eus-gaap--CommonStockSharesIssued_c20220930_pdd" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_c20220930_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></ix:nonFraction></span></span>)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td id="xdx_986_eus-gaap--CommonStockValue_iI_pp0p0_maCzUbT_c20230630_zNYyFR7otL1l" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 81,390,916 common shares (September 30, 2022 - 77,942,815)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,391</ix:nonFraction></b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--CommonStockValue_iI_pp0p0_maCzUbT_c20220930_zpLjX3FASqoe" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 81,390,916 common shares (September 30, 2022 - 77,942,815)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,944</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzUbT_z6SKF5VDgk0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,595,961</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzUbT_zfJaSAgqhY5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">282,922,756</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_iTI_mtCzUbT_maCzYsh_z9VyQIodRs25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Stockholders' Equity</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,754,596</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzYsh_z89yPGm119h8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding: 0pt 0pt 1pt; text-align: left; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Liabilities and Stockholders' Equity</span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font: bold 10.5pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,809,863</ix:nonFraction></b></span></td><td style="font: bold 10.5pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font: 10.5pt Arial, Helvetica, Sans-Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,704,603</ix:nonFraction></span></td><td style="font: 10.5pt Arial, Helvetica, Sans-Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
Accompanying Notes to Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed
Interim Consolidated Statements of Operations and Comprehensive Loss</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the three and nine months ended June 30, 2023 and 2022</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_zsFmbHHC9Su" summary="xdx: Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20230401__20230630_zZ0kJeZJFEXg" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220401__20220630_z8yt2ydV3lsi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_495_20221001_20230630" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20211001__20220630_zGqT6hqvemf4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    months ended June 30,</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine
    months ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_znWL5A7mXXp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    expenses</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzheM_ztW0fgoxu5k2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</span></td><td style="width: 3%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="width: 10%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,247,843</ix:nonFraction></b></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,185,451</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 3%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="width: 10%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,447,447</ix:nonFraction></b></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,167,560</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzheM_z3l45dWHAodk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,282,854</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,273,269</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,656,364</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,534,297</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtCzheM_msCzIsI_zXJdPgpkzU3b" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,530,697</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,458,720</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,103,811</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,701,857</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_i01T_mtCzIsI_maCzKXa_zZc7GhwfHD98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    loss</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,530,697</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,458,720</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,103,811</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,701,857</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zVxCAtDPIUZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    income (expenses)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--NonOperatingIncomeFromGrants_i01_maCzwJp_zfFuzDjsZmf2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Grant
    income</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="-sec-ix-hidden: xdx2ixbrl0157">&#8212;</span></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0158">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0160">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzwJp_zjFhZzaYQo73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development incentive income</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">564,842</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,432</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,048,113</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,328,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--InterestIncomeExpenseNet_i01_maCzwJp_zazyTTGbL0Pl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest
    income, net</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,945</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,560,784</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,405</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--OtherFinancingExpense_i01_maCzwJp_zDX3qrIOuOBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    financing expense</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="-sec-ix-hidden: xdx2ixbrl0172">&#8212;</span></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">964,344</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0175">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzwJp_zRigtNhFgq28" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Foreign
    exchange (loss) gain</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,066</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">732,549</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,239</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,541</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzwJp_maCzKXa_zAV9bebLY2uh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    other income, net</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,291,721</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,800</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,815,792</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,162,539</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzKXa_maCzmDz_zLmNlaJ3zfR" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss before provision for income taxes</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,238,976</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,278,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,288,019</ix:nonFraction></b></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,539,318</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzmDz_zILIXHZ6eDSg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Income
    tax expense, current</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,421</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,954</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,201</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_mtCzmDz_z4xlEbflb8sf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,279,976</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,367,341</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,358,973</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareAbstract_iB_zSo4zIcPItaa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    Loss per share</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--NetLossPerShareBasicAndDiluted_i01_zfdMYqRfAemk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.47</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:NetLossPerShareBasicAndDiluted" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zlDJyzA7QYG4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of shares outstanding</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">80,875,235</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">77,442,236</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79,051,038</ix:nonFraction></b></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76,561,940</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Interim Consolidated
Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed
Interim Consolidated Statements of Changes in Stockholders' Equity</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the three months ended June 30, 2023 and 2022</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_zgatTGGvVQ55" summary="xdx: Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 9pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zkRxZVBdyNTl" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6j6H310Dvp9" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_custom--ShareProceedsReceivableMember_zYVAQtZyF4kf" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zvbxo4XgRqsh" style="font-size: 11pt; text-align: center">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_z9gH25bIWS2e" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock</b></span></td><td style="padding-bottom: 1pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Par
    Value</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid-in</b></span></p> <p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
                                            proceeds</b></span></p> <p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Receivable</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td></tr>
  <tr id="xdx_43E_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zDSuFHBvmvb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    April 1, 2023</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zliH8RussI3h" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,235,398</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,236</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,727,598</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,642,780</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,165,054</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--SharesIssuedUnder2023PurchaseAgreement_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued under 2023 purchase agreement</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockRepurchasedDuringPeriodValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Purchase
    shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--StockRepurchasedDuringPeriodShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbFvy1KLq9w" title="Purchase shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,050,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,050</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,533,467</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,534,517</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--CommitmentShares_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Commitment
    shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--CommitmentSharesShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zureE1IzdQka" title="Commitment shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,268</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zEGHgP57yFZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued pursuant to exercise of stock options</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmiY8MPgCa0c" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,119</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,220</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,866,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,866,781</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,279,976</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,279,976</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43F_c20230401__20230630_eus-gaap--StockholdersEquity_iE_zg9MrX8bxWae" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zekyXC3V37xh" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,390,916</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,391</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,595,961</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">282,922,756</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,754,596</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_434_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zrAwY71XyM0l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    April 1, 2022</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNyDYQrbBLFa" title="Beginning balance, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,161,688</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,163</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,437,616</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">403,696</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">218,906,042</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,205,041</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueOther_iP3us-gaap--SharesOutstanding_z0J1s1D9Zzf2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued under Sales Agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--SharesIssuedUnderSalesAgreementInShares_iP3us-gaap--StockIssuedDuringPeriodValueOther_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDva7gsw31q3" title="Shares issued under Sales Agreement, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">557,177</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,178,127</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,696</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,582,380</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--LessShareIssueCosts_iP3custom--SharesIssuedUnderSalesAgreementInShares_zb0WWAJFPHR7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Less:
    share issue costs</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,361</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">185,361</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_iP3custom--LessShareIssueCosts_zFbW26Toszr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued pursuant to exercise of stock options</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zazwqPjLTKLj" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">223,703</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,043</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,267</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zRGrt6ey3G04" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988,614</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988,614</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zRhnC59GD3pk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,367,341</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,367,341</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_432_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zksfjd4Qcyw8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxCw2JbVIMRi" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,568</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,932,039</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">231,273,383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,736,600</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;See Accompanying Notes to Condensed Interim Consolidated Financial
Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed
Interim Consolidated Statements of Changes in Stockholders' Equity</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the nine months ended June 30, 2023 and 2022</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z0ks7JdHxkD7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z54EeXyaIpIh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zAjb5QDCZc0f" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_zdBfklgegYH8" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></td>
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Par
    Value</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
    Paid-in Capital</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated
    Deficit</b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td></tr>
  <tr id="xdx_43B_c20221001__20230630_eus-gaap--StockholdersEquity_iS_zOaq17hVThga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 50%; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    October 1, 2022</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20221001__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCiquFvevXsb" style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,815</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,976,881</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">245,563,783</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,491,042</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--SharesIssuedUnder2023PurchaseAgreement_zzKOr5sQH1U7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued under 2023 purchase agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--InitialCommitmentShares_zAWTox8RGaga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Initial
    Commitment shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--InitialCommitmentSharesShares_iP3custom--InitialCommitmentShares_c20221001__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdsys65AkzFa" title="Initial commitment shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,425</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockRepurchasedDuringPeriodValue_zcQePZk8hzA8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Purchase
    shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockRepurchasedDuringPeriodShares_c20221001__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm9hg3MXq342" title="Purchase shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,125,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,125</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,683,892</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,687,017</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--CommitmentShares_zwKUVw8o9Qyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Commitment
    shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--CommitmentSharesShares_c20221001__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Commitment shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,348</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentShares" contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zIE72zHeEH6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued pursuant to exercise of stock options</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_c20221001__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z34gDREsaOI2" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,753</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,423</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,657</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zPDR6bIbeub1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,183,353</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,183,353</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zkMdu2lX3li8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,358,973</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,358,973</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43F_c20221001__20230630_eus-gaap--StockholdersEquity_iE_zJnWkbKZREAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20221001__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6MKaOR3zx7g" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,390,916</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,391</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,595,961</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">282,922,756</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,754,596</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43E_c20211001__20220630_eus-gaap--StockholdersEquity_iS_zQ6IErRDLIxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    October 1, 2021</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt74Z4pxv9Nh" title="Beginning balance, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,918,465</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,328,048</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">197,585,864</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,818,104</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zicnWvKMTYki" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued under Sales Agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--SharesIssuedUnderSalesAgreementInShares_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp53JPOoxtUg" title="Shares issued under Sales Agreement, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedUnderSalesAgreementInShares" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,623,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,623</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,980,525</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,982,148</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--LessShareIssueCosts_zgKZLbMiy8n9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Less:
    share issue costs</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:LessShareIssueCosts" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--SharesIssuedUponExerciseOfStockOptions_iP3custom--LessShareIssueCosts_zqMEGAxX6753" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued upon exercise of stock options</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--SharesIssuedUponExerciseOfStockOptionsShares_iP3custom--SharesIssuedUponExerciseOfStockOptions_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zONbkcfTCYJe" title="Shares issued upon exercise of stock options, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptionsShares" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptions" contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptions" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedUponExerciseOfStockOptions" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,190</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zTxiMoFWFhog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,336,844</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,336,844</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zsKKrVqCp0sd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43A_c20211001__20220630_eus-gaap--StockholdersEquity_iE_zW9g87eYomSi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    June 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20211001__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHD9CGGGdDi2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,942,568</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,944</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,932,039</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">231,273,383</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,736,600</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Interim Consolidated
Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed
Interim Consolidated Statements of Cash Flows</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the nine months ended June 30, 2023 and 2022</b></span></td></tr>
<tr style="vertical-align: top">
<td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zLmh3jVewoC5" summary="xdx: Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20221001__20230630_zDYWYq8uqqvj" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20211001__20220630_z6S5Y0dNr2ja" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zrY2lhxyw509" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    Flows used in Operating Activities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCz7a7_zk5QqLcmV1t7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 8%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,358,973</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 8%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,687,519</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zt0tZVAewjPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operations:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--NoncashFinancingRelatedCharges_i02_maCz7a7_zwjlqYEiVjZc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-cash
    financing related charges</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,500</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_pp0p0_maCz7a7_zvNvUjfzNXll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    based compensation</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,183,353</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,336,844</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zgGO8foYb8ya" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Changes
    in working capital balances related to operations:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCz7a7_ztcFsYYSYQwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Incentive
    and tax receivables</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,027,453</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,577,002</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCz7a7_zE2MAcQxl2U2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and deposits</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,410</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,414</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCz7a7_zPzGEO3Zt2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,069</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,612,889</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCz7a7_zbI4MqPWuLmg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    liabilities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,705</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,047</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInDeferredGrantIncome_i02_maCz7a7_zUv6lQLKYdVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 20pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
    grant income</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">472,932</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCz7a7_maCzewm_zpmlKLeycFBe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,935,371</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,193,929</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zsgetBehHmy6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    Flows provided by Financing Activities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzLof_ze7WEJIq3rpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Issuance
    of common shares</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,687,017</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,982,148</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCzLof_z0hHHjooN8He" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
    issue costs</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,802</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzLof_z2uYIc8cXuAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from exercise of stock options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,657</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,190</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzLof_maCzewm_zLdzbHAqSxf3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,594,674</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,285,536</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzewm_zNQFMeZgSg6c" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Increase
    in cash and cash equivalents during the period</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,659,303</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,091,607</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zzZQE6W07aUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents, beginning of period</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,157,861</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,107,745</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zGj6ZUkuapah" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents, end of period</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,817,164</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,199,352</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z2ApHJvq5OTd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Supplemental
    Cash Flow Information</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zTTuw40oLno3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    paid for state and local minimum income taxes</span></td><td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,577</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,374</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">See Accompanying Notes to Condensed Interim Consolidated
Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zftMYpa4fEH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 &#9;<span id="xdx_828_z6oEcvUOpLx">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:BasisOfAccounting"><p id="xdx_804_eus-gaap--BasisOfAccounting_zDr0DvYj0Kp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#9;<span id="xdx_824_z8Y8eG1yBZ48">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9FpFqvR7NNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i><span id="xdx_865_zqPQCWR9m2L">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three and nine months ended
June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="avxl:LliquidityPolicyTextBlock"><p id="xdx_840_ecustom--LliquidityPolicyTextBlock_z57odifUfOa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zBRPPeYZVXAk">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zO4x8xoFyuZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_23A_zpv7kZMFJJ3b" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zQn6XciBxQR4" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23A_zrYOePFLGHz4" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_239_z3KUthsCgM26" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_230_zxcPvUE1ZdDf" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_235_zSy9J3DgWpie" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zxhZVBvFkv82" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zsqhPD6nlj8b" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zUMXKXK8XvL8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zHLMuxjKuUI3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zTIruAIncJU3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_236_zb2wIAJ0wm7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zXbaWVysJdna">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zDjEre6jsve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zPStfmhlKJvl">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zdX4uGpSoWo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_235_zciNn8yJHjj8" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_zEpKQcQp8Aig" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_239_zDgj8SpIYf72" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_z2E0EF4BN9L2" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zE0ZopkvfJHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zg1TSdsmafj4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zkUDPzGLYptj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zYWsm6Khg1Ta" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zuUdpOcCzUdk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_239_zb5EYsBMtl5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrXksW990vL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zTuH7iC2OJle">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - &#9;quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - &#9;assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJkea6vlQS2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zLqs1Er9a9M2">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023 loss per share excludes <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230630_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,858,863</ix:nonFraction></span>
(June 30, 2022: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,194,616</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHQ8H7PzXKgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_868_zmuFYFUkU751">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_800_ecustom--OtherIncomeDisclosureTextBlock_z8oliW7QC1Gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3&#9;<span id="xdx_826_z7jjif1GjEZ2">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of June 30, 2023, the
Company had received $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-06-30_custom_MichaelJFoxMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">995,862</ix:nonFraction> </span>in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant will
be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-06-30_custom_AnavexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> was received during the nine months ended June 30, 2023, and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_AnavexMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">497,931</ix:nonFraction></span> was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_230_zM2EUbdlmUq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_238_zHf2xVgkk0g" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zOiZSbkac68f" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23E_zgBJgjXZDis5" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23C_zWOcEHIPG9lk" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zGswVMlHhjD9" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_234_zouGIh0jpBGi" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zdcaQOVbRHji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zHil1OPeEfd3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_ze4CUXoMA3Bg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zoH1yyD7o8kg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zyXx0f5tVeC7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_236_z0S8KNJXQwki" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was recorded
to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are
incurred. During the three and nine months ended June 30, 2023, the Company recognized $<span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230401__20230630_zAJqrmqdOncd" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20221001__20230630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>, respectively (2022: $<span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_c20220401__20220630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_c20211001__20220630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>,
respectively) of this grant on its statements of operations as grant income. At June 30, 2023, an amount of $<span id="xdx_908_ecustom--DeferredGrantIncome_iI_pp0p0_c20230630_ziJzV6sLxSoj" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">916,763</ix:nonFraction></span> (September 30, 2022:
$<span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,831</ix:nonFraction></span>) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to
other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset
the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#8220;Tax Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and nine
months ended June 30, 2023, the Company recorded research and development incentive income of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">564,842</ix:nonFraction></span> (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-04-012023-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">852,862</ix:nonFraction></span>) and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,048,113</ix:nonFraction></span> (AUD
<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,068,615</ix:nonFraction></span>), respectively (2022: $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">682,432</ix:nonFraction></span> (AUD <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-04-012022-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">954,986</ix:nonFraction></span>) and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,328,675</ix:nonFraction></span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2021-10-012022-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,218,303</ix:nonFraction></span>), respectively) in respect of the Tax Incentive Credit
for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO and the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2019 to 2022 are open to potential review or audit by the ATO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcOvQSgd919i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4&#9; &#9; <span id="xdx_825_zfLKr8lWoveb">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span style="font-size: 10pt">The principal components of accrued liabilities consist of:</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfB922u73kUc" summary="xdx: Disclosure - Accrued liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_zzOlms1Jk7xl" style="display: none">Schedule of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220930_zaPdbmPzgLH" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br />
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2022</td></tr>
<tr id="xdx_40A_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0_zqew2dFZIC9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,301,928</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,031,105</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">952,323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,297,337</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--FixedContractAccruals_iI_pp0p0_zxG7LGumKkuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">417,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zuJA5YbLRMNd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Milestone based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">570,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">137,337</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_zgHdOtfhy577" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,149,241</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,061,760</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_z8DYWwVzedwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,985,658</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,944,953</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="avxl:EquityOfferingTextBlock"><p id="xdx_80D_ecustom--EquityOfferingTextBlock_zWZwwBjRr5R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5&#9;&#9;<span id="xdx_827_zEvK0tLnX1n1">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_z7R5zY51HTji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_23F_zsunhTBMg8I2" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zvSZD6yI9Tp8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23A_zWFThV5hEjGk" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23E_zJQhjK6ooon" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zmGiYyvFrWFg" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23D_zarzft942vgk" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zu3zm1Z9ziug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zDejHbfhOPSi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_z7PV3gHV4GIe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z9AaPDgSRcnb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zaT1jP34wjmf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_235_zdG4LxyjoZPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_90E_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zMECYFFxh5d5" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the nine months ended June 30, 2023, <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zdgEZ5c2FtYk" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares
were sold pursuant to the Offering. During the nine months ended June 30, 2022, <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,623,566</ix:nonFraction></span> shares were sold for gross proceeds of $<span id="xdx_90E_ecustom--SoldForGrossProceedsAmount_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zprTr0hskgZ9" title="Sold for gross proceeds amount"><ix:nonFraction name="avxl:SoldForGrossProceedsAmount" contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,982,148</ix:nonFraction></span>
(net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,258,981</ix:nonFraction></span>). At June 30, 2023, an amount of $<span id="xdx_90F_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20230630_znVSWGiQsxj7" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span> (September 30, 2022: $<span id="xdx_90C_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20220930_zNHzHj4vUxCb" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,407,882</ix:nonFraction></span>) was registered pursuant
to an effective registration statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant
to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z2cVA74AsjIc" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction> </span>in
value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the Purchase Agreement,
the Company issued to Lincoln Park <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;) and
agreed to issue up to an additional <span id="xdx_902_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8vlLHayk2z5" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction> </span>shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction></span> aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_906_ecustom--FairValueOfInitialCommitment_iI_pp0p0_c20230630_zC5acRtRL89d" title="Fair value of the initial commitment"><ix:nonFraction name="avxl:FairValueOfInitialCommitment" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">844,500</ix:nonFraction></span> with reference
to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses
of $<span id="xdx_903_ecustom--IncurredExpenses_iI_pp0p0_c20230630__us-gaap--HealthCareOrganizationRevenueSourcesAxis__us-gaap--ThirdPartyPayorMember_zykhUbK1caub" title="Incurred expenses"><ix:nonFraction name="avxl:IncurredExpenses" contextRef="AsOf2023-06-30_us-gaap_ThirdPartyPayorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,844</ix:nonFraction></span> in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statement
of operations during the nine months ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended June 30, 2023, the Company
issued to Lincoln Park an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,138,348</ix:nonFraction> </span>(2022: <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuSoxJvGZGjd" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>) shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdYTaZl8Jn37" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,125,000</ix:nonFraction></span>
(2022: <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8dldQ5LwPD8" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>l) shares of common stock for aggregate proceeds of $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueNewIssues3_pip0_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zv7H6m337mae" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">26,687,017</ix:nonFraction></span>&#160;(2022: $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssues3_pip0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zO4M1UmEK94b" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">0</ix:nonFraction></span>) and&#160;<span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zFJGRylToDN6" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,348</ix:nonFraction></span>&#160;(2022:&#160;<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zNU3h12b1Lnk" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>) commitment
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2023, an amount of $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueNewIssues4_pip0_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_znlYwV6uSeFd" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">123,312,983</ix:nonFraction></span> (September
30, 2022: N/A) remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zDn2EykvajIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_232_z5FXOnBUWiEj" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_236_z9iJwEUUO4Ri" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_231_zYGYSix5Zx21" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23C_zIL9eXQ6p8eg" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_236_zaIbex4XBLT9" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_236_zKrxMrfC4nu1" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zbTXGIUk13a8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zUZMIAihZLK7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zj9ll9v90XGe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_za3RS2pYWrya" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zio1LdJMFjO2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_239_zVz12FzKt1i5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_z3tNEMpo5pRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Note 6 &#9;<span id="xdx_820_zOh3ZEBan8b3">Commitments and Contingencies</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Leases </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During the three
and nine months ended June 30, 2023, the Company incurred office lease expense of $<span id="xdx_90F_eus-gaap--CapitalLeaseObligationsIncurred_c20230401__20230630_pp0p0" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,103</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--CapitalLeaseObligationsIncurred_c20221001__20230630_pp0p0" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,243</ix:nonFraction></span>, (2022: $<span id="xdx_900_eus-gaap--CapitalLeaseObligationsIncurred_c20220401__20220630_pp0p0" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,015</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--CapitalLeaseObligationsIncurred_c20211001__20220630_pp0p0" title="Incurred office lease expense"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,348</ix:nonFraction></span>) respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three and nine months ended June 30, 2023, the Company made $<span id="xdx_902_eus-gaap--PensionContributions_c20230401__20230630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,313</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--PensionContributions_c20221001__20230630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">176,189</ix:nonFraction></span> (2022: $<span id="xdx_90F_eus-gaap--PensionContributions_c20220401__20220630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,358</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--PensionContributions_c20211001__20220630_pp0p0" title="Contribution amount"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,979</ix:nonFraction></span>), respectively,
in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray; text-align: justify"><span style="font-weight: normal"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023 and September 30, 2022, the Company
had <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230630_pdd" title="Warrants outstanding"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930_pdd" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></ix:nonFraction></span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_90C_ecustom--WarrantsOutstandingWeightedAverageExercise_c20230630_pdd" title="Warrants outstanding weighted average exercise"><span id="xdx_901_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_ztZ5rhQOhBT9" title="Warrants outstanding weighted average exercise"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></ix:nonFraction></span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zcwFmN4cEwI5" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"><span id="xdx_8B0_z9KJTV3Rm5cb" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number" style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price" style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 31%; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zO01AGksuY2d" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2023-06-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zwe7JPLVhNTj" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2023-06-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630_pdd" title="Number" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A6_zijDuhlNOS7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-10-012023-06-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zX3HWyUzZXUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_230_zTprzQ9Hql9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zUaEE5eUA8Ok" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_234_zyDSDrcbfit7" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_232_z8QcOwDM4QAa" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_238_z52EwwiyHIi9" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zHVpSQPbTDaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zGc5lAXVpdzi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zxcDASjG29H1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zmrLjNIn1Jl8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zTblD5RWyeLk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_231_zrtLlgY1Mkt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-10-012023-06-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at
June 30, 2023, <span id="xdx_905_ecustom--OptionIssued_c20221001__20230630_zImMkeK0W0qe" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,912,000</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option available issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-06-30_custom_StockOptionPlan2022Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,599,452</ix:nonFraction></span> options were available for issuance under the 2022
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z1cEAUlcROk" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zXMcIYcn2FOl" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Average</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Average</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Grant Date Fair</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate&#160;intrinsic</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise Price</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number
    of Options</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt">Outstanding,
                                                                                                                       September
                                                                                                                       30, 2021</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220903__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuOKwhlrEIHi" title="Options Outstanding at beginning" style="width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,330,903</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRXjDTOfh0J4" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.74</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXqPqZUSf1jc" title="Aggregate intrinsic value Outstanding at beginning" style="width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,132,451</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Options Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,358,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.13</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.07</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0nFtpnb5rhi" title="Options Forfeited" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">118,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.55pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z84Omxr3tGhb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.56</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXf9HG7RZXah" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.23</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw4cIMzFfJGg" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,537</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFJgcZP0geO3" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,201,015</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding,
                                                                                                                                 September
                                                                                                                                 30,
                                                                                                                                 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9smyxVbvwpk" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,169,616</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z70lrmLCk9fe" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.61</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIVWaTq564j8" title="Aggregate intrinsic value Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,267,309</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGSPhj8J3hi9" title="Options Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,914,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYrj2FLpdWna" title="Weighted Average Exercise Price Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.33</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOgJOO2Hrubg" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.62</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsjzMRyiQ0m4" title="Options Exercised" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,753</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm8jRU2pU12f" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.87</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfpnp2Q3NOD5" title="Weighted Average Grant Date Fair Value Exercised" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.7pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.91</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmdKH4i0Kuce" title="Aggregate intrinsic value Exercised" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,297,062</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIkQXJdc6bof" title="Options Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYA7SjU2JmX5" title="Weighted Average Exercise Price Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.69</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFcF30erOkEb" title="Weighted Average Grant Date Fair Value Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.64</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt">Outstanding,
                                                                                                                                 June
                                                                                                                                 30,
                                                                                                                                 2023</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWGgThYr0Wfc" title="Options Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,698,863</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeOwiNOAjPHa" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.95</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhx6slNvsosi" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,065,774</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
                                                                                                                                   June
                                                                                                                                   30,
                                                                                                                                   2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,027,446</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.91</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,730,916</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AF_zaYawBBRCe5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at June 30, 2023 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5wtJlWWQLtj" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_8BE_zDftxuPaeAdh" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> vested</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> average</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, lower range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of outstanding options" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,800,309</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5RXcE8N7274" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.34</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of vested options" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,800,309</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price options vested" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,022,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhyGhQNmDGI8" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.57</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,022,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,250,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z1TvEwHNJ6Zd" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.46</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,287,887</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.09</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,054,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z5vlPLOfouM1" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.64</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">432,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.47</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right; padding-top: 0; padding-right: 0"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,572,000</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zZRcO2XBdlH" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.74</ix:nonNumeric></span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.29</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,583</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.50</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right; padding-top: 0; padding-right: 0">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,698,863</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLdTpcGQmj1" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.09</ix:nonNumeric></span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.95</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,027,446</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.91</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A8_zX9iFzaRbbkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zzNC588Lczo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_239_z4fL77e2PDw1" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zD4SdUwHYTAk" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23F_zpNZUW3KNzZh" style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23D_ziMHhvhDmLi5" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zDEYV1qcPZz6" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zTqlt12DzQXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zTnNZTWs80l6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Anavex
Life Sciences Corp.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_z2TAp2JYho1e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to the Condensed Interim Consolidated Financial Statements</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zMQLIQu1zyml" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2023</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zGx4N1MKdjz4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p></ix:exclude>


<ix:exclude><p id="xdx_235_zeh1ApcY6Pd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested during the nine months ended June 30, 2023 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630_pdd" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.77</ix:nonFraction></span> (2022: $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630_pdd" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.83</ix:nonFraction></span>). At June 30, 2023, the weighted average contractual life of
options outstanding was <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630_zq6EMRiGi7b4" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.09</ix:nonNumeric></span> years (September 30, 2022: 6.40 years) and for options exercisable was <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630_zg98NUPgp2Uk" title="Options exercisable"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.72</ix:nonNumeric></span> years (September 30, 2022: 5.1
years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended June 30, 2023,
the Company recognized stock based compensation expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,866,781</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,183,353</ix:nonFraction></span> (2022: $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,988,614</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,336,844</ix:nonFraction></span>), respectively,
in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have been included
in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s statement of &#9;operations as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zgI3VlGVAPqb" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zv8vp7cNCaS1" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3EgG4dK9Elg" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,451,471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGsdIwacZSAi" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,490,267</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,450,841</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgFyrC2UU8Dg" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,739,021</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziqIJKCmfN2c" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,415,310</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyJPbWiK3XRj" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,498,347</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,732,512</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzWtjU5UUJrf" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,597,823</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630_zWpMxKskTG58" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,866,781</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630_zHpEy5npSAbk" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,988,614</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,183,353</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630_zZfYmmpUvYA2" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,336,844</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AF_zujBLwemshHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20230630_pp0p0" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,543,748</ix:nonFraction> </span>in stock based
compensation is expected to be recorded over the remaining term &#9;of such options through fiscal 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">The fair value of each option award
granted during the three and nine months ended June 30, 2023 and 2022 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-10-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zTjQCcbGHhT3" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zhE1fNGURUn" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230630_zRkYbWkXv0F5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.69</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zZKcEMuzyysg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.10</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230630_zOzHl7m225f5" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2022-10-01to2023-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.63</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zD85rXlAxpU3" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2021-10-012022-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.51</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230630_zl1b8e3R3k77" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.16</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_z0xQMxbfgOh8" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.12</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230630_zrEDyY9vZrC9" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_z1rNoyhBSlh5" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AF_zWcmbYsc6ZIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three and nine months ended June 30, 2023 and 2022 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

</ix:nonNumeric><p id="xdx_812_zv5XhTPKEcJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_003"></span>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes
forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form
10-Q, including statements regarding our anticipated future clinical and regulatory milestone events, future financial position,
business strategy and plans and objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221;
&#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221;
&#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;potential,&#8221; &#8220;predict&#8221;, &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;will,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify
forward-looking statements. Such forward-looking statements include, without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">volatility in our stock price and in the
markets in general;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to successfully conduct preclinical
studies and clinical trials for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to raise additional capital
on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of the COVID-19 outbreak and
its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to generate any revenue or
to continue as a going concern;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to execute our research and
development plan on time and on budget; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our products candidates&#8217; ability
to demonstrate efficacy or an acceptable safety profile; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain the support of qualified
scientific collaborators; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability, whether alone or with commercial
partners, to successfully commercialize any of our product candidates that may be approved for sale; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to identify and obtain additional
product candidates; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our reliance on third parties in non-clinical
studies and clinical trials; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend against product liability
claims; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to safeguard against security
breaches; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain and maintain sufficient
intellectual property protection for our product candidates; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply with our intellectual
property licensing agreements; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend against claims of
intellectual property infringement; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply with the maintenance
requirements of the government patent agencies; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to protect our intellectual
property rights throughout the world; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competition; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the anticipated start dates, durations
and completion dates of our ongoing and future clinical trials; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the anticipated designs of our future clinical
trials; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to attract and retain qualified
employees; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of Fast Track designation on
receipt of actual FDA approval; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our anticipated future regulatory submissions
and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast
Track designations; and </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our anticipated future cash position and
ability to obtain funding for our operations.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements
largely on our current expectations and projections about future events, including the responses we expect from the U.S. Food and
Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical studies and clinical trials, and financial needs. These
forward-looking statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks
described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange
Commission on November 28, 2022. These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional
factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly
changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to which any factor,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking
statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update or
supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q,
the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221;, and &#8220;Anavex&#8221; mean Anavex Life
Sciences Corp., unless the context clearly indicates otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Current Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage
biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous
system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers,
which we use in the analysis of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead product candidate, ANAVEX<sup>&#174;</sup>2-73,
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img src="image_001.jpg" alt="" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><i>* = Orphan Drug Designation by the FDA;
Dashed lines indicate planned clinical trials to-date</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone
protein with important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope
and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission
Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 target engagement or receptor
occupancy with SIGMAR1 in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt="Graphical user interface, diagram&#10;&#10;Description automatically generated" style="height: 416px; width: 624px" />&#160;<i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>Source: Reyes S et al.,
Sci Rep. 2021 Aug 25; 11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile
spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases,
such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup
of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic found in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking,
folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible to imbalances
that result in aggregation and degeneration in nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by
the presence of amyloid plaques, and neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are
a marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance (i.e. homeostasis). Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we
have incorporated a genomic analysis to better understand potential populations for whom our clinical programs might benefit. In
our clinical trials, a full genomic analysis of Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 has
helped us identify actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20%
of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73,
which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points, provides
support for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers identified
within the trial population itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment. We
may in the future utilize such an approach in Alzheimer&#8217;s disease as well as indications like Parkinson&#8217;s disease dementia
or Rett syndrome in which ANAVEX<sup>&#174;</sup>2-73 is currently being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the
safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic
receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis
and to reverse the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic
(&#8220;PK&#8221;) and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect
relationship between ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated
in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the clinical trial appeared to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144),
which also targets the SIGMAR1 receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase
2a trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing
these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian
Government Department of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
trial of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 trial enrolled 509 patients,
which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized 1:1:1 to
two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and Australia.
Primary and secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s
Disease Assessment Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study
&#8211; Activities of Daily Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and
function (&#8220;CDR-SB&#8221;). In addition to the primary endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated
pre-specified statistical analyses related to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a clinical trial. The trial was completed in mid-2022 and, in December 2022, the Company presented positive topline results
from the Phase 2b/3 clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 met the co-primary
endpoints ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB. ANAVEX<sup>&#174;</sup>2-73 treatment slowed decline of cognition
and function in patients with early Alzheimer&#8217;s disease over 48 weeks. Patients treated with ANAVEX<sup>&#174;</sup>2-73 had
1.84 times higher odds, or likelihood, to improve cognitively compared to placebo, with a ADAS-Cog score threshold change of -0.5
points or better [Odds Ratio = 1.84 (p = 0.015)]. At clinically significant levels of improvement in function (ADCS-ADL score threshold
change of +3.5 points or better), patients treated with ANAVEX<sup>&#174;</sup>2-73 had 2.67 times higher odds, or likelihood, to
improve function compared to placebo [Odds Ratio = 2.67 (p = 0.0255)]. <span style="color: black">Additionally, treatment with
ANAVEX<sup>&#174;</sup>2-73 reduced cognitive decline at end of treatment, measured with the ADAS-Cog, as compared to placebo, by
45%, representing a treatment difference in mean score change of -1.85 points (p=0.033). </span>Compared to placebo, ANAVEX<sup>&#174;</sup>2-73
reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by the
CDR-SB. <span style="color: black">ANAVEX<sup>&#174;</sup>2-73 was generally safe and well tolerated. All statistical analyses were
performed by outside consultancy companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term open
label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD trial, for patients who have completed the 48-week
Phase 2b/3 placebo-controlled trial referenced above. This trial extension for an additional two years, which is currently ongoing,
gives patients the opportunity to continue their treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related and
significant improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes
neurological symptoms that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;).
In January 2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs
of a multicenter Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received
in quarterly instalments which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The clinical
trials are being conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation
of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001),
which took place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled
safety, tolerability, PK and efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with
Rett syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers.
The primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated
dose-proportional PK. All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful
response in the Rett Syndrome Behaviour Questionnaire (&#8220;RSBQ&#8221;) response, when compared to placebo, in the intent to
treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically
significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants, p =
0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical Global Impression Improvement (CGI-I)
response throughout the 7-week clinical trial, when compared to placebo in the ITT cohort (all participants, p = 0.014). Consistent
with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73
experienced stronger improvements in the prespecified efficacy endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced
in June 2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2
trial for Rett syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and
efficacy of ANAVEX<sup>&#174;</sup>2-73 in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73
specific precision medicine biomarkers. Based upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001),
we updated the endpoints for the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful
outcome following International Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory
authorities in the U.K. and in Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released
in February 2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements
in primary efficacy endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I (p = 0.037)
response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms.
Convenient once daily oral liquid doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open
label extension protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third trial
of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE trial. This Phase 2/3 trial in pediatric
patients with Rett syndrome includes trial sites in Australia, the United Kingdom and Canada, and will evaluate the safety and
efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately 84 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating
ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. This trial completed enrollment in February 2023, exceeding
the original enrollment target. In June 2023, this trial completed dosing of all participants, and topline results are expected
in the second half of 2023. All patients who participate in the trial will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under
a voluntary open label extension protocol, which is currently ongoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements
on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional
data announced in October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism.
We believe the encouraging results we have gathered in this preclinical model, coupled with the favorable profile of this product
candidate in the Alzheimer&#8217;s disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat
Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia
in Spain and Australia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30 mg and 50 mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and
statistically significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis.
Treatment with ANAVEX<sup>&#174;</sup>2-73 also resulted in clinically meaningful improvements as measured by the global composite
score of Parkinson&#8217;s disease symptom severity, MDS-Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221;)
total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks of
treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability of slowing and reversing symptoms that progress in
Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker
in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 48-week Open Label Extension (&#8220;OLE&#8221;)
ANAVEX2-73-PDD-EP-001 Phase 2 trial was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001
Phase 2 trial discussed above. The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson&#8217;s
Disease Rating Scale Parts I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Clinical Global Impression
&#8211; Improvement (CGI-I), as well as cognitive efficacy endpoint Montreal Cognitive Assessment (MoCA) over a 48-week period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we reported the preliminary
ANAVEX2-73-PDD-EP-001 OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX<sup>&#174;</sup>2-73 on the prespecified
primary and secondary objectives. Preliminary analysis reveals that ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) was found to be generally
safe and well tolerated; and safety findings in this trial were consistent with the known safety profile of ANAVEX<sup>&#174;</sup>2-73.
In respect to efficacy, across all efficacy endpoints, patients performed better while on ANAVEX<sup>&#174;</sup>2-73. While all
patients were on drug holiday due to COVID-19 between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including
the MDS-UPDRS Part II + III and CGI-I, measured at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were
worsening, as expected in a progressive disease like Parkinson&#8217;s. However, when patients resumed daily oral ANAVEX<sup>&#174;</sup>2-73
treatment, a consistent improvement was observed during the extension phase from OLE Baseline through OLE Week 24, and OLE Week
48, respectively. These results are consistent with the pattern observed for all efficacy measures in the extension phase. The
two endpoints, MDS-UPDRS Part II + III and CGI-I measured in this study are the planned primary and key secondary endpoints in
our forthcoming pivotal 6-month Parkinson&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we were awarded a research
grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to develop ANAVEX<sup>&#174;</sup>2-73
for the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement
of target engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human
Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation
for the treatment of Frontotemporal Dementia (&#8220;FTD&#8221;) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered
small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.
In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying activity
against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and
tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase
1 clinical trial was a prospective double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male
and female subjects were included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate
the safety, tolerability, and PK of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial
met its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities
observed. ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging
from 5 mg to 200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71
exhibited linear PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of
the drug and food had no effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective
of characterizing the effect of ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically
significant ECG parameters throughout the trial. Participant QTcF measures were normal across all dose groups with no difference
between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based
on these results, and ANAVEX<sup>&#174;</sup>3-71&#8217;s pre-clinical profile, we intend to advance ANAVEX<sup>&#174;</sup>3-71
into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease,
evaluating longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of these clinical trials and
preclinical study could serve as a basis for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes
ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical trial indications, and several other compounds in different stages
of clinical and pre-clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple
viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular
processes, in order to ensure survival and replication. Hence, it is possible that SIGMAR1 could play a role in modulating the
cellular response to viral infection and ameliorate pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer
a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73
is being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily
capsule formulation for diseases such as Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
in liquid form resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET
Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was
evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.
Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73
for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic
oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett
syndrome disease mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths,
some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant
and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In
November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of
Rett syndrome. The RPD designation is intended to encourage the development of treatments for rare pediatric diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted
Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The
FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical
needs in the treatment of serious and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020,
we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
disease dementia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease.
The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results showed clinically meaningful, dose-dependent, and
statistically significant improvements in the CDR computerized assessment system analysis. We anticipate conducting further clinical
trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the trial to the FDA
to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease animal models,
ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,
anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type
muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73 has shown a potential dual mechanism which may impact amyloid, tau
pathology and inflammation. In a transgenic Alzheimer&#8217;s disease animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a
statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly
increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of Alzheimer&#8217;s disease. There were no significant changes in laboratory or ECG parameters.
ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed
to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s
disease. The Phase 2a trial met both primary and secondary objectives of the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were
analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients
treated with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73,
among them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with
the common SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved
cognitive (MMSE) and functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic
information in subsequent clinical trials, since these signatures can now be applied to neurological indications tested in future
clinical trials with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett
syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. On July 2, 2018, the Human Research
Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety
and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in
Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 trial design incorporates inclusion of
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial completed and, in December 2022,
the Company presented positive topline results from the Phase 2b/3 clinical trial. ANAVEX<sup>&#174;</sup>2-73 met the co-primary
endpoints ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB as further described above under <i>Clinical Trials Overview
&#8211; Alzheimer&#8217;s Disease.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies
also supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative
diseases beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms,
Fragile X syndrome, Angelman syndrome, multiple sclerosis, and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73
demonstrated significant improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The
results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In
a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive preclinical
data observed in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also
indicates that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease.
Further, our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons
in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data
of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
preclinical data demonstrated that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures
in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug
candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been shown
to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential
disease modifying treatment for cognitive impairments. We believe it is effective in very small doses against the major Alzheimer&#8217;s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects
on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation
and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of
ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX<sup>&#174;</sup>3-71. In April 2016, the FDA granted Orphan
Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment of FTD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if
impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase
1 clinical trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The trial took place in Australia and was a double-blind, randomized, placebo-controlled,
Phase 1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX<span style="background-color: white"><sup>&#174;</sup></span>3-71
including effects of food and gender in healthy volunteers. <span style="background-color: white">The trial met its primary and
secondary endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, </span>as
more fully described above under <i>Clinical Trials Overview &#8211; Frontotemporal Dementia</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based
on these results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71
into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease,
evaluating longitudinal effect of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of this clinical trial and
preclinical study could serve as a basis for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist.
Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through
the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition,
in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis
(programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.
These activities involve both muscarinic and SIGMAR1 systems through a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>&#174;</sup>1-41 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two
preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury
model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive
threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained
significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory
agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold
to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal
transit with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for
the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for
SIGMAR1 at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical
studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting
normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight
the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors
are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective
apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates
may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other
parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in
the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical
models will be shown in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further,
we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further
our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential
application to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Alzheimer&#8217;s disease &#8211; In 2023, an estimated 6.7 million Americans aged 65 and older are suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that the annual number of new cases of Alzheimer&#8217;s and other dementias is projected to double by 2050. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. We believe that there is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 28px">&#160;</td>
<td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease market is expected to reach $11.5 billion by 2029, according to GlobalData.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rett syndrome &#8211; Rett syndrome is a rare
        X-linked genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription,
        which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental
        disorder and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females,
        boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For
        females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s life;
        severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.
        Rett syndrome affects approximately 1 in every 10,000-15,000 females.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 22.5pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Fragile X &#8211; Fragile X syndrome (FXS) is the most prevalent genetic form of intellectual disability
and autism spectrum disorder, primarily affecting boys. As with most neurodevelopmental disorders, FXS is considered a condition
of synaptic development and function. The disease has a range of clinical presentations depending on the specific genetic changes
associated with an &#8220;expansion&#8221; of the FMR1 gene. The disease is characterized by deficits in long-term potentiation
and homeostatic plasticity. FXS has been detected in all populations and ethnic groups. Researchers do not know the exact number
for how many Americans could have full mutation FXS. Studies estimate that the disease affects approximately 1:4,000 males and
1:6,000-8,000 females. Worldwide, more than 1,400,000 people could be affected by FXS.&#160;</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 Billion by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands. However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Epilepsy &#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Prostate Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market Research Future.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.73 billion by 2027.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual
Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to twenty
one U.S. patents, twenty-one U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This
patent is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own one issued U.S. patent
entitled &#8220;A2-73 crystalline polymorph compositions of matter and methods of use thereof&#8221;. It claims crystals of A2-73
freebase or its fumarate salt, dosage forms and pharmaceutical formulations. This patent is expected to expire in July 2039, absent
any patent term extension for regulatory delays. We own four issued U.S. patents each with claims directed to crystalline forms
of ANAVEX<sup>&#174;</sup>2-73. The first of these four patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73, dosage forms
and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using
them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The second of these
four patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment
for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2036, absent any patent term extension
for regulatory delays. The third of these four patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2036,
absent any patent term extension for regulatory delays. The fourth of these four patents claims method of making certain crystalline
forms ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in October 2036, absent any patent term extension for regulatory
delays. We also own two issued U.S. patents for seizure treatment. The first of these two patents claims methods and dosage forms
for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73
and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. The second of these two patents further
claims a combination seizure treatment involving administration of an anti-epilepsy drug combined with (i) ANAVEX<sup>&#174;</sup>19-144,
or (ii) ANAVEX 19-144<sup>&#174;</sup> and ANAVEX 2-73<sup>&#174;</sup>. Both patents are expected to expire in October 2035, absent
any patent term extension for regulatory delays. We also own three issued U.S. patents with claims directed to treating neurodevelopmental
disorders. These patents claim methods for treating a neurodevelopmental disorder, multiple sclerosis, or their related biochemical
and functional abnormalities by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41
(another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All three patents are expected
to expire in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with
claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected
to expire in February 2030, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims
crystalline forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays. Further, we own one issued U.S. Patent with claims directed to methods of treating cardiac dysfunction
with ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2038, absent any patent term extension for regulatory
delays. Additionally, we own one issued U.S. Patent with claims directed to methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73,
ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038, absent any
patent term extension for regulatory delays. Further, we own one issued U.S. Patent with claims directed to a method of treating
systolic hypertension using ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2039, absent any patent term
extension for regulatory delays. Additionally, we own one issued U.S. Patent with claims directed to pharmaceutical dosage forms
of (-) enantiomer of ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents related
to ANAVEX<sup>&#174;</sup>1066. The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066
isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer. Both patents
are expected to expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada,
China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound
and methods of treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, which are expected to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications directed
to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more
of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made
with intellectual property authorities, we protect our intellectual property and confidential information by means of carefully
considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements
and provisions for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide
some form of recourse in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents,
see &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission
on November 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion should be read
in conjunction with our condensed interim consolidated financial statements and related notes thereto contained elsewhere in this
report. Past operating results are not necessarily indicative of results that may occur in future periods. The discussion contains
forward-looking statements, which involve a number of risks and uncertainties. See &#8220;Forward Looking Statements&#8221; included
elsewhere in this report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are in the development stage and have not
earned any revenue since our inception in 2004. We do not anticipate earning any revenues until we can establish an alliance with
other companies to develop, co-develop, license, acquire or market our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating costs consist primarily of research
and development activities including the cost of clinical trials and clinical supplies as well as clinical drug manufacturing and
formulation. Research and development expenses also include personnel related costs such as salaries and wages, and third-party
contract research organization (CRO) expenses in support of these clinical trials. Personnel costs include salaries and wages,
benefits, and non-cash stock-based compensation charges associated with options and other equity awards granted to employees and
consultants who are directly engaged in support of our research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist
of personnel costs, expenses for outside professional services and expenses associated with operating as a public company. Personnel
costs consist of salaries and wages, benefits and stock-based compensation for general and administrative personnel. Outside professional
services and public company expenses include expenses related to compliance and reporting, additional insurance expenses, audit
and SOX compliance, expenses associated with patent research, applications and filings, investor and stockholder relations activities
and other administrative expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of the three and nine months
ended June 30, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the quarter ended
June 30, 2023 were $13.5 million, compared to $12.5 million for the comparable quarter ended June 30, 2022. Total operating expenses
for the nine months ended June 30, 2023 were $43.1 million, compared to $35.7 million for the comparable nine-month period ended
June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the
three months ended June 30, 2023 were $10.3 million, as compared to $9.3 million for the three months ended June 30, 2022. The
increase in research and development expenses is primarily related to (i) an increase in personnel costs of $0.6 million as a result
of the expansion of our team engaged in research and development activities and (ii) an increase of approximately $0.4 million
over the comparable period relating to the manufacture and associated Phase 1 activities for ANAVEX<sup>&#174;</sup>3-71 tablets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the
nine months ended June 30, 2023 were $33.7 million, as compared to $26.5 million for the nine months ended June 30, 2022. The increase
in research and development expenses is primarily related to (i) an increase in personnel costs of $1.8 million and an increase
in stock-based compensation expense of $1.1 million as a result of the expansion of our team engaged in research and development
activities; (ii) an increase of approximately $2.9 million over the comparable period, relating to the manufacturing activities
for both our ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71 programs; (iii) an increase of approximately $0.4 million
in costs associated with new trial start up activities and (iv) an increase of approximately $1.6 million for our Rett syndrome
program, primarily associated with expanded enrollment in our EXCELLENCE trial. These increases were offset by a decrease in license
fees of $0.5 million over the comparable period, paid in connection with the completion of the Phase 1 clinical trial for ANAVEX<sup>&#174;</sup>3-71.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our research
and development expenses for the three and nine months ended June 30, 2023 and 2022 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended<br />
June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended<br />
June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Cost of external service providers</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,224</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,731</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,771</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,628</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,627</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,733</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,597</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other common costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">65</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,273</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,657</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,534</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended June
30, 2023 and 2022, external service providers cost by product candidate was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended<br />
June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended<br />
June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">15,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">11,139</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,402</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">26</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;Total external service provider costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,224</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,731</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,443</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,771</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $3.2
million for the three months ended June 30, 2023, as compared to $3.2 million for the same quarter of fiscal 2022. General and
administrative expenses were consistent between both periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $9.4
million for the nine months ended June 30, 2023, as compared to $9.2 million for the same nine-month period of fiscal 2022, an
increase of $0.2 million mostly relating to an increase in professional and IP related costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first nine months of fiscal 2023,
we utilized cash and cash equivalents of $21.9 million to fund our operations, compared to $20.2 million during the same period
of fiscal 2022. Our cash position was $154.8 million at June 30, 2023 compared to $149.2 million at our fiscal year ended September
30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to continue an increase in our research
and development expenditures as we advance our ANAVEX<sup>&#174;</sup>2-73 clinical trials, including planned advancement of ANAVEX<sup>&#174;</sup>2-73
for Parkinson&#8217;s disease program, planned initiation of a Fragile X clinical program, ongoing extension trials of our current
clinical programs, continued advancement of our other pipeline compounds such as ANAVEX<sup>&#174;</sup>3-71, and as we continue
to add additional staffing to manage and support these clinical initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income for the three
months ended June 30, 2023 was $2.3 million as compared to $0.2 million for the comparable three months ended June 30, 2022. The
increase in other income for the quarter is primarily related to an increase in return on excess cash invested in cash equivalents
and a reduction in foreign exchange fluctuation losses due to the stabilization of the Australian dollar against the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income for the nine
months ended June 30, 2023 was $5.8 million as compared to $2.2 million for the comparable nine months ended June 30, 2022. The
increase in other income for the nine-month period is primarily related to an increase in return on excess cash invested in cash
equivalents, partially offset by a financing charge of $1.0 million in connection with the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the three months ended June 30,
2023, was $11.3 million, or $0.14 per share, as compared to $12.4 million, or $0.16 per share in the comparative quarter of fiscal
2022. The decrease in net loss for the quarter is primarily related to an increase in other income as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the nine months ended June 30,
2023, was $37.4 million, or $0.47 per share, as compared to $33.7 million, or $0.44 per share in the comparative period of fiscal
2022. The increase in net loss for the nine-month period is primarily related to increased research and development fees as discussed
above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2023</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">157,809,863</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">152,704,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,055,267</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,213,561</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working Capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">146,754,596</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142,491,042</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023, we had current assets of
$157.8 million, an increase of $5.1 million from September 30, 2022. The increase in current assets primarily relates to an increase
in cash and cash equivalents of $5.7 million mainly due to $26.7 million in net proceeds received from issuance of common shares
under the 2023 Purchase Agreement, described below, offset by cash used in operations of $21.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023, we had current liabilities
of $11.1 million, an increase of $0.8 million from September 30, 2022. A portion of this increase relates to an increase in deferred
grant income of $0.5 million relating to amounts received during the quarter for a research grant awarded by The Michael J. Fox
Foundation for Parkinson&#8217;s Research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We intend
to continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71,
and to perform work necessary to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table summarizes cash flows during the nine months ended June 30, 2023 and 2022: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(21,935,371</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(20,193,929</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows from financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,594,674</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,285,536</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,659,303</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,091,607</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow used in operating activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the
nine months ended June 30, 2023 was $21.9 million, compared to $20.2 million during the comparable period ended June 30, 2022.
The principal reason for this increase in net cash used in operating activities in the current period is due to the increase in
net loss over the comparable quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow provided by financing activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the
nine months ended June 30, 2023 was $27.6 million, mainly attributable to the issuance of common shares under the 2023 Purchase
Agreement, described below, while <span style="background-color: white">cash provided by financing activities for the nine months
ended June 30, 2022 was </span>$21.3 million, primarily attributable to the sale of common shares at various market prices under
the Sales Agreement, described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: lightgrey">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into
a $150,000,000 purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln
Park&#8221;), pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase,
up to $150,000,000 in value of its shares of Common Stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to certain
customary conditions, the Company may direct Lincoln Park to purchase up to 200,000 shares of Common Stock (such purchases, &#8220;<span style="text-decoration: underline">Regular
Purchases</span>&#8221;). The amount of a Regular Purchase may increase under certain circumstances based on the market price of the
Common Stock; provided, however, that Lincoln Park &#8216;s committed obligation under any Regular Purchase shall not exceed $4,000,000.
The purchase price of shares of Common Stock will be based on the then prevailing market prices of such shares at the time of sales
as described in the Purchase Agreement. There are no limits on the price per share that Lincoln Park may pay to purchase Common
Stock under the Purchase Agreement. In addition, if the Company has directed Lincoln Park to purchase the full amount of Common
Stock available as a Regular Purchase on a given day, it may direct Lincoln Park to purchase additional amounts as &#8220;accelerated
purchases&#8221; and &#8220;additional accelerated purchases&#8221; as set forth in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement limits the Company&#8217;s
sale of shares of Common Stock to Lincoln Park to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common
Stock outstanding on the date of the Purchase Agreement unless (i)&#160;stockholder approval is obtained to issue more than such
amount or (ii)&#160;the average price of all applicable sales of Common Stock to Lincoln Park under the Purchase Agreement equals
or exceeds the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution
Date or (B) the average of the closing price of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately
preceding the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement also prohibits the Company
from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common
Stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial
ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated
pursuant to Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023
Purchase Agreement, the Company issued to Lincoln Park 75,000 shares of Common Stock as a commitment fee (the &#8220;initial commitment
shares&#8221;) during the nine months ended June 30, 2023 and agreed to issue up to 75,000 shares pro rata, when and if, Lincoln
Park purchased, at the Company&#8217;s discretion, the $150,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended June 30, 2023,
the Company issued to Lincoln Park an aggregate of 3,138,348 (2022: 0) shares of Common Stock under the 2023 Purchase Agreement,
including 3,125,000 (2022: 0) shares of Common Stock for aggregate proceeds of $26.7 million (2022: $0) and 13,348 (2022: 0) commitment
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of&#160;June 30, 2023, an amount of $123.3
million in shares of our common stock remain available for purchase by Lincoln Park under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended
and Restated Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales
Agents&#8221;), pursuant to which we may offer and sell shares of common stock registered under an effective registration statement
from time to time through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on
our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock
by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated
transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement.
We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices,
applicable state and federal law, and rules and regulations and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents&#8217;
commissions for their services of 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the Sales Agreement.
We have also agreed to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shares were sold during the nine months
ended June 30, 2023 under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended June 30, 2022,
1,623,566 shares were sold under the Sales Agreement for gross proceeds of $21.0 million (net proceeds of $20.3 million after deducting
commissions and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Off-Balance Sheet
Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have no off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are
material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We prepare our condensed
interim consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related
disclosures of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are
reasonable in the circumstances. Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no
significant changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year
ended September 30, 2022, as filed with the SEC on November 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>RECENT ACCOUNTING
PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Please refer to Note
2 &#8220;Recent Accounting Pronouncements&#8221; in notes to our Condensed Interim Consolidated Financial Statements included in
this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISKS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no
material changes in our exposure to market risk from that disclosed in Item 7A of our Annual Report on Form 10-K for the year ended
September 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>ITEM 4. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Disclosure Controls
and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We maintain disclosure
controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in
our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified
in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to
our management, our chief executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We carried out an
evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal
financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule
13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation,
our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective
as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Changes in Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the quarter
ended June 30, 2023, there were no changes to our internal control over financial reporting identified in management&#8217;s evaluation
pursuant to Rules 13a 15(d) or 15d 15 (d) of the Exchange Act that materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_014"></span>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiaries are a party or of which any of their property is subject. There are no proceedings in which any of
our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the
risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, filed with the SEC on November 28, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period covered by this Quarterly
Report on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were
not previously reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 5. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>ITEM 6. EXHIBIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border: black 1pt solid; width: 11%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Exhibit </b></span><br /> <span style="font-size: 10pt"><b>Number </b></span></td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 89%; padding-right: 5.75pt; padding-left: 5.75pt"><br /><span style="font-size: 10pt"><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(3) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-size: 10pt">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.2</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-size: 10pt">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on April 14, 2023)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(4)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Instruments Defining the Rights of Security Holders</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">4.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex4-1.htm"><span style="font-size: 10pt">Registration Rights Agreement, dated February 3, 2023, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the period ended December 31, 2022 filed on February 7, 2023)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(10)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Material Contracts</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">10.1</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112223000152/e4385_ex10-1.htm"><span style="font-size: 10pt">Purchase Agreement dated February 3, 2023 by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the period ended December 31, 2022 filed on February 7, 2023)</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(31) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Rule 13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.1*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4887_ex31-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.2*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4887_ex31-2.htm"><span style="font-size: 10pt">Certification of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(32) </b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Section 1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">32.1**</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e4887_ex32-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD and Sandra Boenisch.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(101)</b></span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.INS*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.SCH*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.CAL*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.DEF*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.LAB*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.PRE*</span></td>
<td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 100%; font-weight: normal; text-align: center; font-family: Calibri Light; color: #2F5496"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext"><b><span id="a_013"></span>SIGNATURES</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: center; text-indent: -36pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">/s/Christopher Missling, PhD</span></td>
<td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">Date: August 8, 2023</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">/s/Sandra Boenisch</span></td>
    <td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Date: August 8, 2023</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">40</span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e4887_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three months ended June 30, 2023 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 8, 2023</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Christopher Missling,
    PhD</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President and Secretary</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e4887_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right; text-indent: 0.5in">&nbsp;<B>Exhibit
31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on
Form 10-Q for the three months ended June 30, 2023 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f)
and 15d&ndash;15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 8, 2023</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Sandra Boenisch</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer, Treasurer</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e4887_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended June 30, 2023 as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the
date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: August 8, 2023</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Christopher
    Missling, PhD </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President,
    Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Sandra
    Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting
    Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished
solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before
or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement
required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed
form within the electronic version of this written statement required by Section 906, has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U G$# 2(  A$! Q$!_\0
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MLJOC@L,@?AD57\N__P"?FW_[\-_\70!:HJKY=_\ \_-O_P!^&_\ BZ/+O_\
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M_P"?FW_[\-_\71Y=_P#\_-O_ -^&_P#BZ +5%5?+O_\ GYM_^_#?_%T>7?\
M_/S;_P#?AO\ XN@"U157R[__ )^;?_OPW_Q='EW_ /S\V_\ WX;_ .+H M45
M5\N__P"?FW_[\-_\71Y=_P#\_-O_ -^&_P#BZ +5%5?+O_\ GYM_^_#?_%T>
M7?\ _/S;_P#?AO\ XN@"U157R[__ )^;?_OPW_Q='EW_ /S\V_\ WX;_ .+H
M SKO7I;74Y;8:?++#&T:&6,\[FQQC'/7L>WTJE'XRCD&[[+L4-'EG<C*L/F(
MX^;:WRG&>N>!6[Y5]_S\6W_?@_\ Q=(8+P[<S6IVG(_T<\?^/T 4[77#/:Z7
M.\42?;I-F/.Y3Y2PQQ\QXQVZUL52%M=@ "6T 4Y'^C'@_P#?=/\ +O\ _GYM
M_P#OPW_Q= %JBJOEW_\ S\V__?AO_BZ/+O\ _GYM_P#OPW_Q= %JBJOEW_\
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M_P"^Z ,Z/Q S:?I]VUN@%W.L102Y*!C@'ISC(S6[5(6UV,8EM!@Y'^C'@_\
M?=/\N_\ ^?FW_P"_#?\ Q= %JBJOEW__ #\V_P#WX;_XNCR[_P#Y^;?_ +\-
M_P#%T 6J*J^7?_\ /S;_ /?AO_BZLC.!D@GOB@!:*** "BBB@ K%\3;C8VT8
M=T$EU&C%&P<'-;58OB3_ (]K+_K\B_F:Y<;_ +O(WPO\:(G_  B]E_S\7O\
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MI<L/?1P_ I1Q%M5/\2*#Q!XMG(QKCA6565O+4[LJ6P %ZC!!]ZDMM=\4W,D
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MQ@@[@<\GVK+$3I>QE[-QYNFQIAX5?:Q]HI<O7<ZHZ.4^_P"*M6!/0>>A)_\
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MT;1FW!5U56S<(<A3E<G/8T]O!GC1F<_9(AO)+[98EWD@@YQUZGKZTN:AWC^
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M:!E3M/!X/7TJ!=7 D9_^$2UUMR;<&$\=<]_?]*0ZK&49/^$1UXAQALQGD
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M:]_T!K__ ,!V_P */^$:U[_H#7__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\
M/6U_[\?_ %Z/^%F^)?\ GK:_]^/_ *]8?_"-:]_T!K__ ,!V_P */^$:U[_H
M#7__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\ /6U_[\?_ %Z/^%F^)?\ GK:_
M]^/_ *]8?_"-:]_T!K__ ,!V_P */^$:U[_H#7__ (#M_A1['"]H_@'ML5WE
M^)N?\+-\2_\ /6U_[\?_ %Z/^%F^)?\ GK:_]^/_ *]8?_"-:]_T!K__ ,!V
M_P */^$:U[_H#7__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\ /6U_[\?_ %Z/
M^%F^)?\ GK:_]^/_ *]8?_"-:]_T!K__ ,!V_P */^$:U[_H#7__ (#M_A1[
M'"]H_@'ML5WE^)N?\+-\2_\ /6U_[\?_ %Z/^%F^)?\ GK:_]^/_ *]8?_"-
M:]_T!;__ ,!V_P */^$:U[_H"W__ (#M_A1['"]H_@'ML5WE^)N?\+-\2_\
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M\+VWAC3C#&WF7,N&GF_O$=@.P':MZOFZJ@IM4]CZ2DYN"=3<****S- HHHH
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M^A% "Z)?W,\8@OUG%X5,CAX-BIT!4$<$9)P>X!K8HHH **** "BBB@ HHHH
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MH^YY)Z] >G89_.FCQ3X24-C4;LLRA2QA.0 ",].3SU]A6?LJ_P#SX_\ 2O\
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M7&2ZQ#Y;FV9X6D@D#HHP!*S9&/;&3[9Q4@U&P-W'<"<)M25-OEL#ELX.1_\
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MY/Q_X(?6:G\_X?\  .@F\=WMNNZ;PQI:+N*Y,?<=?Y'\JA_X6/+_ -"]I/\
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M-_SQE_[X-='U2AV_%F'UNOW_  1V7_"QY?\ H7M)_P"^#1_PL>7_ *%[2?\
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MUC"/YB[85&UO[PXX/O5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#.UW4SHVAWFHK$)3;Q[]A;&[\:\_'Q:NB<
M#0@3[3G_ .)KL?''_(E:M_UP/\Q7C4&M0VSI/'Y@GVH#TPI2-D!'/.20:];
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M6+5X)D9Y6EDC56E*#D@G'RAN..X_*L3</4?G51P&'>\/Q9$L?B%M/\$>E_\
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M)D;0+S@COD[./RI__"U7W18T,;2!YA^U\KSSCY.>/7%>;[U$K1%@)5!+)_$
M!DY'7I0+B'RO-\U/+W;=^X;<^F?6E_9^%_IA_:&*_I'I ^*DA,F=#&!_J_\
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M]SP1D<=/6E]1_O\ X?\ !']>_N?C_P  ^@/LL_\ U#_^_!_^*H^RS_\ 4/\
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M&YO[[?\ ?1I_V<_Y_P /^"']H+^3\?\ @'TU]EG_ .H?_P!^#_\ %4?99_\
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MMG% T&T\J&0S2D&$R2 ,.#M1L$[3M^]TP>!FCEJ_S_@'-2_D_$ZO_A4^I_\
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M_P""#VE'^3\6>C_\*@O?^@Y9?]^S_C1_PJ"]_P"@Y9?]^S_C7G%%/V=;^?\
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M! &2.A /3K7JE>7BJ<X5'SN[/5PM2$Z:Y%9=@HHHKG.@**** "BBB@ HHHH
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M_P#G^MO^_P O^-17.IV!M9@+ZVR4;_EJOI]::B[["<E;<P_AK_R3_2O]U_\
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MJ\SWO_??_OHT;W_OO_WT:/9U_P#GY^"#VE#^3\6>F?\ "F[O_H.6_P#WX/\
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MX5:I5?Y_P,95:7\GXGJ@^%D220#_ (2:VV.!N!@&7.>=OS_EUJ5/AHJ^>/\
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M (1/6?\ H<=2_P"_:47_ .GO_I7^06_Z=?D1?\(;X)_Z :_]^9:/^$-\$_\
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MA_S[?WEU/AMJD;[TU]E8Y^86LX/;_ ?D*9_PK'4,@_VWT((_T2;@CH?PK/\
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M\7_@%-_A7MM%'UZOW_ /J-'M^)XE_P *LNO^@O%_X!3?X4?\*LNO^@O%_P"
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M!ST_Y?Q-_P#X19O^@[H/_@</\*/^$6;_ *#N@_\ @</\*P**.2I_-^ <]/\
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M1X4_Z".L?^ L?_Q5+$MEL7SEL/.RGV@ C:%RV[9@_>QM^[WQ2%;#='Y8MO\
M4+LWE.6^7=GG[V,XW<9HU[O\/\@T[+\?\P\CPI_T$=8_\!8__BJ/(\*?]!'6
M/_ 6/_XJGD:9$\!VVLT2O*9,%5WXW;1UW#^'';I37CTQ( L#02#=%EV*AMN!
MNSGG/7..]+7N_P /\@T[+\?\Q/(\*?\ 01UC_P !8_\ XJCR/"G_ $$=8_\
M 6/_ .*ITB:/*\SAX8Q-'Y<0Q]QQDEB!PO(4>A!-1)+82J!-%:KNCB4E%"E6
M8$,>/3@_A3U[O\/\@NNR_'_,?Y'A3_H(ZQ_X"Q__ !5'D>%/^@CK'_@+'_\
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M_'/\:/MGB+_GQ;_QS_&NDHH]I#^1?C_F'LY_SO\ #_(YO[9XB_Y\6_\ '/\
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M<FG)?JLJ_-)Y8E0X]5"X/'ZUMROS^\QYEY?<.SI&<?9[W/IN%)OT;_GC>?\
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M=/E:E<[L)4YDXV+%%%%<9V!1110 4444 %%%% !1110 4444 %%%% !1110
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MZ;_OH?X4?\(W8_WIO^^A_A113]O4_F%["G_*'_"-V/\ >F_[Z'^%'_"-V/\
M>F_[Z'^%%%'MZG\P>PI_RA_PC=C_ 'IO^^A_A1_PC=C_ 'IO^^A_A111[>I_
M,'L*?\H?\(W8_P!Z;_OH?X4?\(W8_P!Z;_OH?X444>WJ?S!["G_*'_"-V/\
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@ G # 2(  A$! Q$!_\0
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MMO'&8(8@Q"AU929"0,GD=<#&*[2>[,]M<0:=>6;:@(V\L.VY5?IEE!SC/44
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M/NYE)7!#,#DLP '2@#U&BF0EV@C:3;O*@MM.1G'.*?0 4444 %%%% !1110
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MV=+:%(59SDD*H )]^*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )^;'_P%%>844 >G_P#"_?'7_/S8_P#@**/^%^^.O^?FQ_\  45YA10!Z?\
M\+]\=?\ /S8_^ HH_P"%^^.O^?FQ_P# 45YA10!Z?_POWQU_S\V/_@**/^%^
M^.O^?FQ_\!17F%% 'I__  OWQU_S\V/_ ("BC_A?OCK_ )^;'_P%%>844 >G
M_P#"_?'7_/S8_P#@**/^%^^.O^?FQ_\  45YA10!Z?\ \+]\=?\ /S8_^ HH
M_P"%^^.O^?FQ_P# 45YA10!Z?_POWQU_S\V/_@**/^%^^.O^?FQ_\!17F%%
M'I__  OWQU_S\V/_ ("BC_A?OCK_ )^;'_P%%>844 >G_P#"_?'7_/S8_P#@
M**/^%^^.O^?FQ_\  45YA10!Z?\ \+]\=?\ /S8_^ HH_P"%^^.O^?FQ_P#
M45YA10!Z?_POWQU_S\V/_@**/^%^^.O^?FQ_\!17F%% 'I__  OWQU_S\V/_
M ("BC_A?OCK_ )^;'_P%%>844 >G_P#"_?'7_/S8_P#@**/^%^^.O^?FQ_\
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M/$7@72=7ORANKF$M(8UVJ2&(X'X5\25]E_"3_DE7A_\ Z]S_ .AM0!VE%%%
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MDXI*DB&9!]:TI1YII";LCT#X?^#QJLWVN[C)MU/R@CJ:]L6QTO18[>*8&,R
M;1&O ^M8_@#['%H-H,J!LY^M=+JL>F7\D4DTS$1=$4=:^9XGS/%O%_4:2E&$
M>W5GCY<L#B:T\1F4ERJZ2;VMY&5KF;%)&4Y7;E2/2L/0IY+R9F.< UM:U(+U
M&"KM7 51Z 5G:-"MF64$;LYKZ;*(U:&124H_O+/U\CY+%2P[JU'2^%RT]#9O
MM+1[/]^ RN,%37@OCC0$TS4W: ?NR<X':O?+F[:=53.*\X\<:8!9RSRN.>>:
MPX4>(JX>I3QDKM[)]#OPF*H4<:HX;X6E\V>+L,&DJ6;&\XJ*NBM!0FTC[9.Z
M"BBBLAA1110 4444 % &:*<OWA515VD!Z/\ #3P[#?71N[F/<L?W01QFO=_[
M+M! L&PB4Q[L]OI7 _#MK-= @,/7^/US7>7>MQ+#A JMMV[CUQ7A<42S"KC:
M>&P:E:/:Z5WU/F*6)P<ZM>IC=>D4]_D<9J82RN"5  -/T^=;Q@K*,>]9NMWJ
MW,QV]!3M)N?)()%?HT*-5X-1G\=M_.Q\\Z;]E?J=]:V\$ M8_LWFF<\L.B"O
M.OB5H*ZA;M)#%F2(GY@.U=I8:[Y8\M9/E_NFJ>NZA:QV,\LA4 H>,]:_.LFP
MV98#-G]8A*2G=-]-7N_0]>MC\,Z%#ZM#EG#==6?,LT9C<J>".*BJ[J,BR7\S
MJ/E9B15.OI,5!1J-1/KH-N*;$K[+^$G_ "2KP_\ ]>Y_]#:OC2OLOX2?\DJ\
M/_\ 7N?_ $-JY2SM**** /@_7/\ D8-2_P"OJ7_T,U0J_KG_ ",&I?\ 7U+_
M .AFJ% !1110 5Z=X8ODTWX:6\PUV+1GDU:=3*;#[090(HB!T. ,G\Z\QJTV
MI7;Z5'IC3$V<4S3I%@8#L "<]>0J_E0!W%OX=TS7XM+FNKR[FU?7]2EMH[E
MB0H$= 9"FW))#G"@BET;PCX;\1R03V;:I:6D=\UG<+,Z2.RF&21'4A0 ?W1!
M4YZC!KB1J^H+;V4"W4B1V,C2VVW@Q.Q4E@1SG*K^5:<_C?Q#/<03F_"/"[R+
MY4$<8+NI5W954!F()&X@F@#K-#T3PU]E35TLKR6UNM*U+-M<3(S1R0H#O5MF
M.0W''RGGFJEKX)TZ?P[+-*MU;WJZ4^HH\UW$&<JN[:+< OL*]')&>N,5RMAX
MFUC3%M%M+PHEKYHB0QJR@2@"0$$$,&  (.:L_P#";>(!9&T%\!&UL;-V\B/>
M\!&WRV?;N*@< $\<8Z"@#H=6TRQU#XU6^FW2K%97%Y:12JGR#:R1Y''3.>OO
M5:\\1Z[JMSK.COI=M<6D<<N+-;556P5#]]-H!78!C)//.<UR5_J5YJ>H/?WD
M[2W3[=TN #\H '3V K5O_&WB'4[&:TNK_<EP MPZPHDDX'02.JAGZ#J30!O7
M_A#1([K6=)MGOQJ&BHCSW$C+Y5Q^\2.0*N,I@R J23D#GK6M+X<\,I;^)]#T
MVUO'NK;4+73TO+N5"1(TKIN "<+QR,Y.!TKA[KQAKUY8BTGOBT?[O>PB0/*(
M_N!W W.%P,!B>@]*A7Q-K"RZI)]L);5&W7A**?-;<6W=/E())!&",\4 =9KG
MA+PWI(F<7<KBQODMYH8[Z&:6YC)(9E51^Z<$?=;/7KD&LGQSX6M/"%W:Z='-
M<W%U(K3O,Z;(_++$(H!&=P .[T/R]B:JS>.O$<\D,DE^N^*=;G<+>,&29?NR
M287]XPSP6S67=ZSJ-_8Q6=W=//#%+)-&),,5=\%SNZ\D9(SC//6@"C4UK;27
M=RD$10.YP/,D5%_%F( _&H:44UN!MKX7U'^_I_\ X,8/_BZTM-\,:F)AM>Q'
MTOX#_P"SURBUT7AJ,3:C&G&*]C+XOFW.7%2Y:;9[5X,\#WE[8SS3S0!X=N$\
MQ7# YSRI..E;'V2.W<H$7*G!((/ZU7TH-;Z:(8W*HV-R@X#8]:MYP*XLQQE2
M55PYM$?G./Q4*TER1::WUW^0T]3@TDD8<#-/$>8R>]5YIS&RKMR#7C9?4]M5
ME['XD<LJ52-O,Y;QAI!ETUY$)X':O#KE2DK*>H.*^DM8C6729@W0K7SMJ\0B
MU"91T#&OI?:3KX-2GNM#Z_ANNYPE"70SC12T5Y+/JQ****D HHHH *<M-IZ]
M*UI*\A,U-%LY;S4(8D[L,U] Z18+I^GQQC ;:"37B7@Q]NM1=.37O<?S0+GJ
M5KT,<W'"PA%Z2>I\3Q+6E[2,.@),)&PIZ=33]U,B@"$JG4]:M&#$?-?+YAF5
M##U53AL>#2PDJR<H+1%;<22".:XOX@Z<]SIOFQCD#FNV'0UA>*PW]B2E<=#7
MM97.+Q:E'1216!J2IXF+7<^>YE(<@]J@-6[L_OGSZFJAK?&)*3L?J$'="444
M5PEA1110 4444 %2Q#YJC%3P]:Z\+"\T3)Z'=>$-9OUFCMHI"$%>KK,PMPTC
M_-BO-_!%A&S"7@-7>W#A8]I!KWZM%5.6+W/@\V4)XBT420W(D8@&JMU*UL^]
M34EE;^824%2W=KE,/5)TJ=;D_ X$XQG8GL[\RP[GYP*\P^(.L7-Q<&W.1&.U
M>C60104 K@/B!9X_>A:RCAZ=.I4<%9L[\JC3CBU='F3CDTRI'X8U'7SU9+F9
M]Z@HHHK$84444 %%%% !2KUI*<M7!7D#.H\.^(;_ $\K! YV,>E>HZ5%<74(
MGN)&.1G!->4>&$1]00, :]HCA,>GJ5X&*^IHR<:2;>KT/C\[<(5$HJS?4H7U
MM&W*_>JI9W36TPC=.#WQ5N#=,[+UQ4K6K!N4'Y5VZ+23/+YDERR+IMTN8=R9
M!Q7G/BYKJWDDC,C%,>M>EVR2)'D8Q7(^,(8GMG=@-V*Y*4I-RA>Z-,NJ<M=)
MZH\>F^^:BJ>X'[PXJ'%?-XJ+51GWT=A*^R_A)_R2KP__ ->Y_P#0VKXTK[+^
M$G_)*O#_ /U[G_T-JY2CM**** /@_7/^1@U+_KZE_P#0S5"K^N?\C!J7_7U+
M_P"AFJ% !1110 5K:?X6U_5K/[7IVBW]W;;BOFP6[.N1U&0.M9->J:%:K/\
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M#]YO#^8-WSYV\ ].U<-XXT^VTKQOJ]E90^3;17!$<0)(0'G SV&: .?HHHH
M*44E36D<,URD<]P+>)C\TI0MM_ <FG'<!JUJ:1*T%]$ZG&#4PTK1?^ACC_\
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M][*H>TQ*E;8X.3EC4=2/]ZHS7SE=>\V?=QV TE%%<S*"BBBD 4444 %**2G
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M25>'_P#KW/\ Z&U8,9VE%%%(#X/ULYU_43ZW4O\ Z$:H5>UK_D/:C_U\R?\
MH1JC0 4444 %%%% !1110 4444 %%%% !1110 4444 %&<444 +N-.\QJ915
MJI-;,5D/\UQWIWGR>H_*HJ*I5ZB^TPY42_:)/4?E2&=SU/Z5'11[>K_,PY5V
M'^:WK^E(78]:;12=6;W8609HHHK,84444 %%%% !3E<KTQ3:*J,G%W0%H7TH
M39M3'TJ(SN3G _*HJ*U>)K/>3)4(KH3I=21D%<9^E32:I<RIM8KCV%4J*:Q5
M9*RDQ.G!N[1,EU(CA@%)'J*U?^$IU#R/)VP!<8X3G^=8E%$<77CM)DSH4Y_$
MKD\EW)*Q9@N3Z"HF8MUIM%1.M4G\3N:**6P4445D,**** "BBB@!0Q%.$C#I
MBF45<:DX[,5D3?:' Z+^5)]H?/:HJ*T^LU?YA<J+(O90N %'X4PW4AZ[?RJ&
MBG]:K?S,.2/8D,S'TH\UO05'14>WJ=Q\J'%R?2DS245+G)[L=@S1114 %%%%
M !1110 4N3244TVM@'"1AT-.\^3U_2HZ*M5JBVDQ61-]JE_O?I3A>3C^(?E5
M>BK^LUOYG]XN2/8F-U*>K#\J:9G/4C\JCHI/$57O)_>'*NPI8FDHHK)R;W*"
MOLGX1'/PJT _],&'_C[5\;5]D_"'_DE.@?\ 7%__ $8U(#MJ*** /@[6O^0]
MJ/\ U\R?^A&J-7M:_P"0]J/_ %\R?^A&J- !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7V3\(?\ DE.@
M?]<7_P#1C5\;5]D_"'_DE.@?]<7_ /1C4 =M1110!\':U_R'M1_Z^9/_ $(U
MTX\!V9DT^Q/B:TCU:_MX9X+26WD5295#(ADP5!.0,],US&M?\A[4?^OF3_T(
MUW$UYX5N]8T+7+KQ!A;"RLUEL8K24S.\,:@H&("<E<9SWH XM/#VLR17<L>E
M7DD5F[)<.D+,L3+]X,0,#'>F'1-572AJATV[&GDX%R86\OKC[V,=>*[^R\7Z
M9?7^AZY>:L]A-I=W<7-S8I$[&X+S-+^[(&W+!A&=Q'"]QQ4+^)-#F\,8N[N*
M>=+%8((HHI8;E6$@80R$'RI(!ZGYNG&10!PMWHVJ6%G#>7>G75O;3_ZJ:6%E
M5^,\$C!XYHL-%U358YI-/TZ[NTA&9&@A9PGUP.*[[QCXLTG4M-UV2PNK)CJ\
M\<BP1VDPF 5MW[UG;8I7[HV YR>@K+T'5M-?0='M)]:?2)M+U&2\DQ&[>>K>
M7ADV _O%V$ -@?-UZT 8]WX5N+#P=9>(;J1XUOIF2WA\AL,J]6+]!GG ZG!-
M+;^$;NX\&S^(UFC"12$"V(/F/&"JM*/]D,Z*?K[5=\8^(K#7=/L/L>Z-EN[Z
M=[<J0(EEEWH,]#QZ5T%OXYT"PU73])73X+C0X+(:;-?XE65HI!F=PF<??=F&
M5SP* .6U+P7?:;HNB:N98Y;355&&3K Y)PKCW )![X/I5G3_  %=ZAXMU70$
MO8(SITCQ/<R A'<2"-%'H7<J!]?:M>+Q=I-M?Z3I\TSW>AMIL5CJ.Q&4JR2R
M,LJ C.Y<JP]B5[FI-3\:Z/9G6)M/MH-3GU76I;R0SB6,1Q(Q,&-I4Y)9VQGC
MCO0!QM_H$]CH5AJID#I<S36\D84AH)8R,HWN0RD?7VK>E\!6VGP7DVL:_#9+
M:306TF+9Y2)I(C(4^7^[@@GU%;J^+?"]UKE]<WK,+&[:#6?LRPL1'?H#YD/3
M[KDL-W3!7TJEX<\6C^P-72?Q'%I6JWNII>/--:-.LJ['W=$;!W,#0!ST'A>V
MU.?48-%U>._FM;?[1%'Y#QM<J.9 @/\ $HYQW ..E2OX.6TNQ;ZGK%I9216@
MNKU7!9K?<0%BVCEY"&4E1]W/)&#C2@UNPTGQ!=^))M:CUC5K=$.G^5;/$C3$
M8WN"J_+&!G&/F)';-2QS>"]8\3?V[J-Z+5+B!KF?3Y(I63[9NY4L@)\ICE^.
M<';QUH Y37]#?0KV&(W$=S!<6Z7-O/&"!)$XX.#R#P00?2M<^$-.E\.W>KV?
MB6WG6V\M&C:UECW2/]V,,P )X8_12>E.UK7[4ZG?23IIGB![J-1'=^5/"MJ
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MU?&U?9/PA_Y)3H'_ %Q?_P!&-0!VU%%% 'P=K7_(>U'_ *^9/_0C5&KVM?\
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ME.@?]<7_ /1C5\;5]D_"'_DE.@?]<7_]&-0!VU%%% 'P=K7_ "'M1_Z^9/\
MT(U1KN-7^&OC236K^2/PUJ#HUQ(598L@@L>0:I?\*R\;_P#0L:E_WY- '*45
MU?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\
M*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=
M7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_
MPK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45
MU?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\
M*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=
M7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_
MPK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45
MU?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\
M*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=
M7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_
MPK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45
MU?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\
M*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=
M7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_
MPK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45
MU?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\
M*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=
M7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_
MPK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45
MU?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\
M*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_PK+QO_T+&I?]^30!RE%=
M7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*45U?\ PK+QO_T+&I?]^31_
MPK+QO_T+&I?]^30!RE%=7_PK+QO_ -"QJ7_?DT?\*R\;_P#0L:E_WY- '*5]
MD_"'_DE.@?\ 7%__ $8U?,/_  K+QO\ ]"QJ7_?DU]3_  RTV\TCX<:+8ZA;
MO;W44+"2)QAE)=B,_@10!UM%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !17/^);O4K.ZT9K.YBBM9;^*&X4Q[GD#'&T$\*/7C/TKE;WQ-
MK5I:)?)>DM?O=Q>2\:%+3RYA&KKQGY1G=N)!)[4 >E45A^'KFZ:XU>PN;E[H
M6-T(HYY H9E:)'PVT $@N1G'3%;+R;750N2P)Z^E #Z*9ND_YY_^/4;I/^>?
M_CU #Z*9ND_YY_\ CU&Z3_GG_P"/4 /HIFZ3_GG_ ./4AD=1DQ\?[U $E%,W
M2?\ //\ \>HW2?\ //\ \>H ?13-TG_//_QZC=)_SS_\>H ?13-TG_//_P >
MHW2?\\__ !Z@!]%1K([#(CX_WJ7=)_SS_P#'J 'T4S=)_P \_P#QZC=)_P \
M_P#QZ@!]%,W2?\\__'J-TG_//_QZ@!]%1B1R2!'T_P!JEW2?\\__ !Z@!]%,
MW2?\\_\ QZC=)_SS_P#'J 'T4S=)_P \_P#QZC=)_P \_P#QZ@!]%1F1P0/+
MY/\ M4NZ3_GG_P"/4 /HIFZ3_GG_ ./4;I/^>?\ X]0 ^BF;I/\ GG_X]1ND
M_P">?_CU #Z*C:1U&3'_ ./4NZ3_ )Y_^/4 /HIFZ3_GG_X]1ND_YY_^/4 /
MHIFZ3_GG_P"/4;I/^>?_ (]0 ^BF;I/^>?\ X]2+([ $1\'_ &J )**122.1
MC\:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KE_$'B>Z\/:Q&L]G%+IT\(\I_M4,+B8,=R
M_O77<,;>G3\:ZBO.?$>J0?\ "5W?V01R7*6BV]PE]H]Q<(J[G(,;(O.<G(Z-
MA>>#0!Z%;R--;QRO$T+NH8QL02A(Z$@D?D:DK,\.PBW\-Z9"HN $M8U N$V2
M8"C[R]C[=JTZ (I[6"Z$8GB23RY!(FX9VL.A'N*IC0-)%S=W']G6WFW:E+AC
M&#YBG[P/UP,^N.:T:* *MAIUGI=J+:QMXX(0Q;:@QDGJ3ZGWJ5_^/F+_ '6_
MI4M1/_Q\Q?[K?TH EHHHH **** "F2_ZL_4?SI],E_U9^H_G0 ^BBB@ HHHH
M **** &0_P"J%/ID/^J%/H **** "BBB@!B?ZR3ZC^5/IB?ZR3ZC^5/H ***
M* "BBB@!C?ZQ/QI],;_6)^-/H **** "BBB@!DO^K/U'\Z?3)?\ 5GZC^=/H
M **** "BBB@ ID7^J6GTR+_5+0 ^BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@O&DC0
MZ]%]JA-S;26O^C1?VP++9*I8LP&X%OEV_-SMQ[FN]K@O%6F7NH^*2VCO']MM
M;..XE6XMUD1@K2"-%)=2&8F3.?E^49QW .C\+3ZI-H5L-7MFBNHXT1I#.DOG
M?*,N"O')S6U63X8%JOA72ELGD>U%I&(FE&&*[1C(['V%:U !6.?%.B">ZB;4
M(U:U61Y2RL% 0@/AB,-M) ."<$XK8KS2?P9K-Q<WA$*+(6N)#*]SF*<M*LB+
M''_RRSL 8X&><[LYH ] T[4[35;=I[.7S$5S&X*E61AU#*P!!Y'!'<5,_P#Q
M\Q?[K?TK)\/V=Y%/JE_>P"VDO[D2K;^8',:K&B#)'&3LSQZBM610UQ$#_=;O
M]* )J*9Y2^__ 'T:/*7W_P"^C0 ^BF>4OO\ ]]&CRE]_^^C0 ^F2_P"K/U'\
MZ/*7W_[Z-,EC41GKU'<^M $U%,\I??\ [Z-'E+[_ /?1H ?13/*7W_[Z-'E+
M[_\ ?1H ?13/*7W_ .^C4<[06T1EF;8@ZDDT 21?ZH4^J5C<6E[#NMY1*HX)
M5CBK7E+[_P#?1H ?13/*7W_[Z-'E+[_]]&@!]%,\I??_ +Z-'E+[_P#?1H $
M_P!9)]1_*GU"L:[WZ]1W/I3_ "E]_P#OHT /HIGE+[_]]&CRE]_^^C0 ^BF>
M4OO_ -]&CRE]_P#OHT #?ZQ/QI]0M&OF)U[]S3_*7W_[Z- #Z*9Y2^__ 'T:
M/*7W_P"^C0 ^BF>4OO\ ]]&CRE]_^^C0 2_ZL_4?SI]0R1J$/7J.Y]:?Y2^_
M_?1H ?13/*7W_P"^C1Y2^_\ WT: 'T4SRE]_^^C1Y2^__?1H ?3(O]4M-D@W
MQLJ2/&QZ.IR1^?%4=&2633UEN+AYF<GJ N,$CMB@#3HI H48'\Z6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KS;XB7-FNNZ?#J4=C#;% JSW-N[F7=OW*&5API5"4YW;A7
MI->07/B!AK*Q3>*-2LFN;F[BU%1$[""-)"(A$-I6-BH W#.<D\G! !ZAH<LT
M^@Z?+<6BVDSV\9>W5=HB.T?*!V ].U7ZJZ8+<:7:"T=Y+;R5\IW9F9EQP26Y
M)QW/-<3:WGB5;]CI-Q"UF6E\NSUBZ22:=D/S+$8^5P>#O+8SR!0!Z!14<#O)
M;QO+$8I&4%HR02AQR,C@XJ2@ J)_^/F+_=;^E2U$_P#Q\Q?[K?TH EHHHH *
M*** "F2_ZL_4?SI],E_U9^H_G0 ^BBB@ HHHH **BEN883AY &[*.2?P'-4-
M4N+QM.E-G!*K8^\>#CO@=:PK5XTXN6[71:LTA3<FEM<ET7_D$0?\"_\ 0C5^
MN:\-"_DMI%:5D@!^0E<\\YQFMW[)DY>>=O\ @>W^6*SPV*>(I*I&#5^_]?H5
M5HJG-Q<KV+%1M/$GWI47ZL!48L;;.3$&/^T2W\Z>MM OW88Q]%%;WJ=E_7R,
M_=&F]M1UN(O^^Q3?M]K_ ,]0?H":L  = !]*6BU3NON_X(7CV_K[BHE[;[W.
M]CDCHC>GTI_VV'UD_P"_3?X5*O\ K)/J/Y4^BU3NON_X(7CV_'_@%?[9#_TT
M_P"_3?X4?;8?^FG_ 'Z;_"K%%%JG=?=_P0O'M_7W%?[=;_WF_%&_PI/M]M_S
MT_\ '3_A5FBBU3NON_X(7CV_'_@%0WUJ9$_?(.O7BI/MMJ?^7B+_ +[%2-_K
M$_&GX![46J=U]W_!"\>W]?<0_:[8]+B+_OL4X7$)Z31G_@0IQCC/5%/X4TV\
M!ZPQG_@(H_>>0>Z.#H>C+^=.ZU#]DMC_ ,N\7_? IIL;4_\ +O'^"T7J=E]_
M_ #W>Y++_JS]1_.GU4DL;8(2(5'(Z9'>G_8;?^ZP^CM_C1>IV7W_ / "T>_X
M?\$L457^Q0CIY@^DK?XT?9$_YZ3_ /?YO\:+U.R^_P#X 6CW+%%5_L:_\]9_
M^_K4?8U_Y[3_ /?PT<T_Y?Q"T>Y,[K&A=V"JHR23@"L_0I8Y-*C".K%2P8 ]
M/F)HU#2C=V4D*3RAFQC>Y(X/>J7AC3WMK9[AW!\W@*.V"17-*MB%B(TU3]QK
M5WV-E3I>R<N;WNQOT445VG.%%%%  2 "2< 5D6GB73;Z.62V-S)'''YH<6DN
M)$]8SM^?_@.<UJRE1$Y<$H%.X 9R/IWKS9[TPZ/JFFZ!?W-]I2:7,\8,3B2Q
M=<!(U? )!!;"G++LZXH ]+ZT5YA>/%>^,[@7KF)+?5HMEY*\VU4")B$;5\O#
M,3U;JW(SBK,NDM.5NG?4!/-XAE@=EGD!^SEW!08/$9 '3ZYH ]&HKSF\DCL+
M6XTR>U+6(U:2*![J27R8$\I7 .WE@69@HZ9[\ 5M>$7UJ;PSI#F2'8 RS_:D
MD\TJ)& QDY'R@?>R?6@#<L];T[4-0NK"TNEFN+0*9E0$A<D@<]"<J0<'C'-:
M%<G8ZKI\GQ"O8(;A2S644*J%(!=9)BR@XQD9!/UJ6^T]=0\>VXN!.]O#I_FH
M@=EC\T2C!('!([9]30!T]%>8>'AJ4EQ'+]OB37$BG-S;%9O-EDV-A7W'8%#[
M2"!C  '!J3S+4^$F;1I+S^TBEM_:AD\\N%\Q?.+@<[\;\[?FQG':@#TNHYKB
M&W"&:5(P[B-2QQEB< #W->9S-%;:*)?[4\S39-6M@T>G^<%B7^,*22Q!X)"]
M.?4TM[9V=SI]Q,L4LOA^WUBUDMV;S"J)A!*RYYV;B?8'=CB@#T^BO-=5>!CK
M 9[P:R&7^PQ$9/\ 5^6GE&/'RD;]V[/ONXQ72Z-IRR>)]<U"X\]YXKI8X-\C
M;$3R(\[%Z8))R?\ "@#H5N(7N)(%D4S1A6= >5#9P2/?!_*I*X6^2QTOQ;XA
MO9+&::\DTZ.6WCB9U:?:LH<*1WQ@<<C(Q6);F:XT_6[>SE9+20Z>4.GM,%5F
MG(D*,_.=H&XK^/.: /5:*\L\46UM%J]WI(5H;*"S@\J=I)RECEW9W^0$$D 9
MW$=/[M6+Q;F;Q-=)+J,%E.+J'^SY&69F\C:FWRMIV,I.\'@]3GM0!Z-#<0W'
MF>3*DGEN8WVG.UAU!]ZEKD?!]I8V.JZ_!'"8;S[?([*=V3&V"K<\$')Y%==0
M 4444 %%%% !1110 4444 %<TWC:R%]>6<6FZS/-:2^5-Y-@[!6QD<^A!!![
M@UTM<KXJ\3V'AV[M$^UV]O=331M<!H6=FMP3N/RJ3G@XSZ''>@#IK>87%M%,
M$DC$BAMDB[67(Z$'H?:O.O#T$EW?:5!#%J$NAV=P\UE,=/2('AP"TGF;BOS'
MD("V03WSZ':W,5[:0W4#%H9D$D;$$94C(.#STKR;PW<SVWBW34\R*WAN9V=+
M)+FZ9P&\W<-KR;#L="&^7 R",<4 >OUYN_C;55CN;L'8D[3PV<4UJ!'N281
MAPV21RS @ \[>G/I%8Y\*Z*TUS(]DK?:5D616=BG[PY?:N<*6(!)4 DT -T"
M]O)IM3L+Z9;B:PN1$)UCV>8K1HXR!P"-^./05J2'%Q%P3\K=/PJ'3M,M-*@>
M&TC95=S([.[.SL>K,S$DG@#D] *G?_CYB_W6_I0 [>?^>;?I1O/_ #S;]*?1
M0 S>?^>;?I1O/_/-OTI]% #-Y_YYM^E-E<E/N-U'IZU+3)?]6?J/YT &\_\
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MC>?^>;?I3Z* (I7/EGY&ZCT]:=O/_/-OTHE_U9^H_G3Z &;S_P \V_2C>?\
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MD;S)C_$>WL!V%3T45<8J*LB6V]PHHHJA!1110 R'_5"GTR'_ %0I] !1110
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M=/\ +_VW_.B'_5"GT ,\O_;?\Z/+_P!M_P Z?10 SR_]M_SH\O\ VW_.GT4
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MC^=/H **** "BBB@ ID7^J6GTR+_ %2T /HHHH **** "BBB@ HHHH ****
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M\@_\]I?S'^% $U%0^0?^>TOYC_"CR#_SVE_,?X4 345#Y!_Y[2_F/\*/(/\
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8Kk5s7xRiXgOn8uCbX9cOa6KaaOdyJV+WYkxt25xbamq/ygv6/X+4CeoAUf2cfcJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:avxl="http://anavex.com/20230630" elementFormDefault="qualified" targetNamespace="http://anavex.com/20230630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" id="InterimConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" id="InterimConsolidatedStatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BusinessDescription" id="BusinessDescription">
          <link:definition>00000007 - Disclosure - Business Description</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>00000008 - Disclosure - Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
          <link:definition>00000009 - Disclosure - Other Income</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>00000010 - Disclosure - Accrued Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
          <link:definition>00000011 - Disclosure - Equity Offerings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000012 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentationPolicies" id="BasisOfPresentationPolicies">
          <link:definition>00000013 - Disclosure - Basis of Presentation (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>00000014 - Disclosure - Accrued Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>00000015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>00000016 - Disclosure - Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
          <link:definition>00000017 - Disclosure - Other Income (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
          <link:definition>00000018 - Disclosure - Accrued liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
          <link:definition>00000019 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
          <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
          <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
          <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
          <link:definition>00000023 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
          <link:definition>00000024 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000025 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="avxl_ShareProceedsReceivableMember" name="ShareProceedsReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MichaelJFoxMember" name="MichaelJFoxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AnavexMember" name="AnavexMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherFinancingExpense" name="OtherFinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NetLossPerShareBasicAndDiluted" name="NetLossPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnderSalesAgreementInShares" name="SharesIssuedUnderSalesAgreementInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LessShareIssueCosts" name="LessShareIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfStockOptions" name="SharesIssuedUponExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUponExerciseOfStockOptionsShares" name="SharesIssuedUponExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentShares" name="InitialCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentSharesShares" name="InitialCommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnder2023PurchaseAgreement" name="SharesIssuedUnder2023PurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentShares" name="CommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" name="SharesIssuedPursuantToExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NoncashFinancingRelatedCharges" name="NoncashFinancingRelatedCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncreaseDecreaseInDeferredGrantIncome" name="IncreaseDecreaseInDeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LliquidityPolicyTextBlock" name="LliquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedClinicalSiteAndPatientVisitsCosts" name="AccruedClinicalSiteAndPatientVisitsCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MilestoneBasedContractAccruals" name="MilestoneBasedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SoldForGrossProceedsAmount" name="SoldForGrossProceedsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FairValueOfInitialCommitment" name="FairValueOfInitialCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncurredExpenses" name="IncurredExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheets" xlink:href="avxl-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheetsParenthetical" xlink:href="avxl-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20230630.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20230630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20230630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20230630.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20230630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20230630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20230630.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20230630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20230630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20230630.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20230630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000013 - Disclosure - Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheets" xlink:href="avxl-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheetsParenthetical" xlink:href="avxl-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20230630.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20230630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20230630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20230630.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20230630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20230630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20230630.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20230630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20230630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20230630.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20230630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlShareProceedsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementInShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUponExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedUponExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfStockOptions_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000013 - Disclosure - Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD" xlink:label="loc_currencyAUD_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome_140" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaapThirdPartyPayorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_us-gaapThirdPartyPayorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SoldForGrossProceedsAmount" xlink:label="loc_avxlSoldForGrossProceedsAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSoldForGrossProceedsAmount_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_100" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareProceedsReceivableMember" xlink:label="avxl_ShareProceedsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareProceedsReceivableMember" xlink:to="avxl_ShareProceedsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareProceedsReceivableMember_lbl" xml:lang="en-US">Share Proceeds Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_MichaelJFoxMember" xlink:label="avxl_MichaelJFoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxMember" xlink:to="avxl_MichaelJFoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxMember_lbl" xml:lang="en-US">Michael J Fox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_AnavexMember" xlink:label="avxl_AnavexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AnavexMember" xlink:to="avxl_AnavexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AnavexMember_lbl" xml:lang="en-US">Anavex [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">Purchase Agreement 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xml:lang="en-US">Third-Party Payor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 81,390,916 common shares (September 30, 2022 - 77,942,815)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OtherFinancingExpense" xlink:label="avxl_OtherFinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherFinancingExpense_lbl" xml:lang="en-US">Other financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="avxl_NetLossPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NetLossPerShareBasicAndDiluted" xlink:to="avxl_NetLossPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="avxl_SharesIssuedUnderSalesAgreementInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnderSalesAgreementInShares" xlink:to="avxl_SharesIssuedUnderSalesAgreementInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnderSalesAgreementInShares_lbl" xml:lang="en-US">Shares issued under Sales Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LessShareIssueCosts" xlink:label="avxl_LessShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LessShareIssueCosts" xlink:to="avxl_LessShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LessShareIssueCosts_lbl" xml:lang="en-US">Less: share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUponExerciseOfStockOptions" xlink:label="avxl_SharesIssuedUponExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfStockOptions" xlink:to="avxl_SharesIssuedUponExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedUponExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedUponExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUponExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_InitialCommitmentShares" xlink:label="avxl_InitialCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentShares" xlink:to="avxl_InitialCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentShares_lbl" xml:lang="en-US">Initial Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_InitialCommitmentSharesShares" xlink:label="avxl_InitialCommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentSharesShares" xlink:to="avxl_InitialCommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentSharesShares_lbl" xml:lang="en-US">Initial commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:to="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xml:lang="en-US">Shares issued under 2023 purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CommitmentShares" xlink:label="avxl_CommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentShares" xlink:to="avxl_CommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentShares_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="avxl_NoncashFinancingRelatedCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NoncashFinancingRelatedCharges" xlink:to="avxl_NoncashFinancingRelatedCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NoncashFinancingRelatedCharges_lbl" xml:lang="en-US">Non-cash financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="avxl_LliquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LliquidityPolicyTextBlock" xlink:to="avxl_LliquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LliquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share-based Payment Arrangement, Option, Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:to="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xml:lang="en-US">Accrued clinical site and patient visits costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="avxl_MilestoneBasedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MilestoneBasedContractAccruals" xlink:to="avxl_MilestoneBasedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MilestoneBasedContractAccruals_lbl" xml:lang="en-US">Milestone based contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SoldForGrossProceedsAmount" xlink:label="avxl_SoldForGrossProceedsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SoldForGrossProceedsAmount" xlink:to="avxl_SoldForGrossProceedsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SoldForGrossProceedsAmount_lbl" xml:lang="en-US">Sold for gross proceeds amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_FairValueOfInitialCommitment" xlink:label="avxl_FairValueOfInitialCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FairValueOfInitialCommitment" xlink:to="avxl_FairValueOfInitialCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FairValueOfInitialCommitment_lbl" xml:lang="en-US">Fair value of the initial commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_IncurredExpenses" xlink:label="avxl_IncurredExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncurredExpenses" xlink:to="avxl_IncurredExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncurredExpenses_lbl" xml:lang="en-US">Incurred expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Incurred office lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheets" xlink:href="avxl-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BalanceSheetsParenthetical" xlink:href="avxl-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:href="avxl-20230630.xsd#InterimConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20230630.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20230630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20230630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20230630.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20230630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20230630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20230630.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20230630.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20230630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20230630.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20230630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NetLossPerShareBasicAndDiluted" xlink:label="loc_avxlNetLossPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_avxlNetLossPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_avxlWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlShareProceedsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUnderSalesAgreementInShares" xlink:label="loc_avxlSharesIssuedUnderSalesAgreementInShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnderSalesAgreementInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LessShareIssueCosts" xlink:label="loc_avxlLessShareIssueCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlLessShareIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUponExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedUponExerciseOfStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUponExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUponExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="00000007 - Disclosure - Business Description">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="00000010 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="00000011 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="00000013 - Disclosure - Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="loc_avxlLliquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlLliquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="00000014 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000015 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000016 - Disclosure - Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="00000018 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="loc_avxlMilestoneBasedContractAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlMilestoneBasedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000019 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaapThirdPartyPayorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_us-gaapThirdPartyPayorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SoldForGrossProceedsAmount" xlink:label="loc_avxlSoldForGrossProceedsAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSoldForGrossProceedsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000023 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000024 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20230630.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334759084320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,951,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760316064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 154,817,164<span></span>
</td>
<td class="nump">$ 149,157,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">2,165,127<span></span>
</td>
<td class="nump">3,192,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">827,572<span></span>
</td>
<td class="nump">354,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">157,809,863<span></span>
</td>
<td class="nump">152,704,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,152,846<span></span>
</td>
<td class="nump">3,824,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 4</a></td>
<td class="nump">5,985,658<span></span>
</td>
<td class="nump">5,944,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income - Note 3</a></td>
<td class="nump">916,763<span></span>
</td>
<td class="nump">443,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">11,055,267<span></span>
</td>
<td class="nump">10,213,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 81,390,916 common shares (September 30, 2022 - 77,942,815)</a></td>
<td class="nump">81,391<span></span>
</td>
<td class="nump">77,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">429,595,961<span></span>
</td>
<td class="nump">387,976,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(282,922,756)<span></span>
</td>
<td class="num">(245,563,783)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">146,754,596<span></span>
</td>
<td class="nump">142,491,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 157,809,863<span></span>
</td>
<td class="nump">$ 152,704,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334758808976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">81,390,916<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">81,390,916<span></span>
</td>
<td class="nump">77,942,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334758845104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 3,247,843<span></span>
</td>
<td class="nump">$ 3,185,451<span></span>
</td>
<td class="nump">$ 9,447,447<span></span>
</td>
<td class="nump">$ 9,167,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,282,854<span></span>
</td>
<td class="nump">9,273,269<span></span>
</td>
<td class="nump">33,656,364<span></span>
</td>
<td class="nump">26,534,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,530,697<span></span>
</td>
<td class="nump">12,458,720<span></span>
</td>
<td class="nump">43,103,811<span></span>
</td>
<td class="nump">35,701,857<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(13,530,697)<span></span>
</td>
<td class="num">(12,458,720)<span></span>
</td>
<td class="num">(43,103,811)<span></span>
</td>
<td class="num">(35,701,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">564,842<span></span>
</td>
<td class="nump">682,432<span></span>
</td>
<td class="nump">2,048,113<span></span>
</td>
<td class="nump">2,328,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,827,945<span></span>
</td>
<td class="nump">229,917<span></span>
</td>
<td class="nump">4,560,784<span></span>
</td>
<td class="nump">242,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherFinancingExpense', window );">Other financing expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(964,344)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss) gain</a></td>
<td class="num">(101,066)<span></span>
</td>
<td class="num">(732,549)<span></span>
</td>
<td class="nump">146,239<span></span>
</td>
<td class="num">(408,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,291,721<span></span>
</td>
<td class="nump">179,800<span></span>
</td>
<td class="nump">5,815,792<span></span>
</td>
<td class="nump">2,162,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(11,238,976)<span></span>
</td>
<td class="num">(12,278,920)<span></span>
</td>
<td class="num">(37,288,019)<span></span>
</td>
<td class="num">(33,539,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(41,000)<span></span>
</td>
<td class="num">(88,421)<span></span>
</td>
<td class="num">(70,954)<span></span>
</td>
<td class="num">(148,201)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (11,279,976)<span></span>
</td>
<td class="num">$ (12,367,341)<span></span>
</td>
<td class="num">$ (37,358,973)<span></span>
</td>
<td class="num">$ (33,687,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NetLossPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">$ 80,875,235<span></span>
</td>
<td class="nump">$ 77,442,236<span></span>
</td>
<td class="nump">$ 79,051,038<span></span>
</td>
<td class="nump">$ 76,561,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334756953456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Share Proceeds Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="nump">$ 348,328,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (197,585,864)<span></span>
</td>
<td class="nump">$ 150,818,104<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2021</a></td>
<td class="nump">75,918,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">20,980,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,982,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">1,623,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(723,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(723,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfStockOptions', window );">Shares issued upon exercise of stock options</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">1,009,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,010,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares', window );">Shares issued upon exercise of stock options, shares</a></td>
<td class="nump">400,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,336,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,336,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,687,519)<span></span>
</td>
<td class="num">(33,687,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">381,932,039<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(231,273,383)<span></span>
</td>
<td class="nump">150,736,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">77,942,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 77,163<span></span>
</td>
<td class="nump">371,437,616<span></span>
</td>
<td class="num">(403,696)<span></span>
</td>
<td class="num">(218,906,042)<span></span>
</td>
<td class="nump">152,205,041<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">77,161,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">6,178,127<span></span>
</td>
<td class="nump">403,696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,582,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnderSalesAgreementInShares', window );">Shares issued under Sales Agreement, shares</a></td>
<td class="nump">557,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LessShareIssueCosts', window );">Less: share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(185,361)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(185,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">513,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">513,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">223,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,988,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,988,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,367,341)<span></span>
</td>
<td class="num">(12,367,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">381,932,039<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(231,273,383)<span></span>
</td>
<td class="nump">150,736,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">77,942,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 77,944<span></span>
</td>
<td class="nump">387,976,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,563,783)<span></span>
</td>
<td class="nump">142,491,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">Initial Commitment shares</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">844,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">844,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase shares</a></td>
<td class="nump">$ 3,125<span></span>
</td>
<td class="nump">26,683,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,687,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">Commitment shares</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">13,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">907,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">907,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">234,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,183,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,183,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,358,973)<span></span>
</td>
<td class="num">(37,358,973)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 81,391<span></span>
</td>
<td class="nump">429,595,961<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(282,922,756)<span></span>
</td>
<td class="nump">146,754,596<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">81,390,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 80,236<span></span>
</td>
<td class="nump">416,727,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(271,642,780)<span></span>
</td>
<td class="nump">145,165,054<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedUnder2023PurchaseAgreement', window );">Shares issued under 2023 purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase shares</a></td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">8,533,467<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,534,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares, shares</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">Commitment shares</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">4,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">468,119<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">468,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">101,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,866,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,866,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,279,976)<span></span>
</td>
<td class="num">(11,279,976)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 81,391<span></span>
</td>
<td class="nump">$ 429,595,961<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (282,922,756)<span></span>
</td>
<td class="nump">$ 146,754,596<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">81,390,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LessShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LessShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnder2023PurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnder2023PurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUnderSalesAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUnderSalesAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedUponExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedUponExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334756935200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (37,358,973)<span></span>
</td>
<td class="num">$ (33,687,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NoncashFinancingRelatedCharges', window );">Non-cash financing related charges</a></td>
<td class="nump">844,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">13,183,353<span></span>
</td>
<td class="nump">12,336,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">1,027,453<span></span>
</td>
<td class="nump">2,577,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(473,410)<span></span>
</td>
<td class="num">(106,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">328,069<span></span>
</td>
<td class="num">(1,612,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">40,705<span></span>
</td>
<td class="nump">299,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncreaseDecreaseInDeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">472,932<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,935,371)<span></span>
</td>
<td class="num">(20,193,929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">26,687,017<span></span>
</td>
<td class="nump">20,982,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(706,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">907,657<span></span>
</td>
<td class="nump">1,010,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">27,594,674<span></span>
</td>
<td class="nump">21,285,536<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash and cash equivalents during the period</a></td>
<td class="nump">5,659,303<span></span>
</td>
<td class="nump">1,091,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">149,157,861<span></span>
</td>
<td class="nump">152,107,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">154,817,164<span></span>
</td>
<td class="nump">153,199,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="nump">$ 208,577<span></span>
</td>
<td class="nump">$ 141,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncreaseDecreaseInDeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncreaseDecreaseInDeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NoncashFinancingRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NoncashFinancingRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760634192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zftMYpa4fEH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_828_z6oEcvUOpLx">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760755856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_804_eus-gaap--BasisOfAccounting_zDr0DvYj0Kp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 	<span id="xdx_824_z8Y8eG1yBZ48">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9FpFqvR7NNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i><span id="xdx_865_zqPQCWR9m2L">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three and nine months ended
June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_840_ecustom--LliquidityPolicyTextBlock_z57odifUfOa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zBRPPeYZVXAk">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zXbaWVysJdna">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zDjEre6jsve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zPStfmhlKJvl">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrXksW990vL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zTuH7iC2OJle">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJkea6vlQS2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zLqs1Er9a9M2">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023 loss per share excludes <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230630_pdd" title="Loss per share for potentially dilutive common shares">14,858,863</span>
(June 30, 2022: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares">13,194,616</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHQ8H7PzXKgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_868_zmuFYFUkU751">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334868970592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_800_ecustom--OtherIncomeDisclosureTextBlock_z8oliW7QC1Gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3	<span id="xdx_826_z7jjif1GjEZ2">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of June 30, 2023, the
Company had received $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income">995,862 </span>in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant will
be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income">497,931</span> was received during the nine months ended June 30, 2023, and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income">497,931</span> was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was recorded
to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are
incurred. During the three and nine months ended June 30, 2023, the Company recognized $<span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230401__20230630_zAJqrmqdOncd" title="Grant income">0</span> and $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20221001__20230630_pp0p0" title="Grant income">25,000</span>, respectively (2022: $<span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_c20220401__20220630_pp0p0" title="Grant income">0</span> and $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_c20211001__20220630_pp0p0" title="Grant income">0</span>,
respectively) of this grant on its statements of operations as grant income. At June 30, 2023, an amount of $<span id="xdx_908_ecustom--DeferredGrantIncome_iI_pp0p0_c20230630_ziJzV6sLxSoj" title="Deferred grant income">916,763</span> (September 30, 2022:
$<span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income">443,831</span>) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to
other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset
the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#8220;Tax Incentive Credit&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and nine
months ended June 30, 2023, the Company recorded research and development incentive income of $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630_pp0p0" title="Research and development incentive income">564,842</span> (AUD <span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">852,862</span>) and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630_pp0p0" title="Research and development incentive income">2,048,113</span> (AUD
<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">3,068,615</span>), respectively (2022: $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630_pp0p0" title="Research and development incentive income">682,432</span> (AUD <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">954,986</span>) and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630_pp0p0" title="Research and development incentive income">2,328,675</span> (AUD <span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">3,218,303</span>), respectively) in respect of the Tax Incentive Credit
for eligible research and development expenses incurred during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO and the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#8217;s tax incentive claims from 2019 to 2022 are open to potential review or audit by the ATO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334759081056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcOvQSgd919i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4	 	 <span id="xdx_825_zfLKr8lWoveb">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span style="font-size: 10pt">The principal components of accrued liabilities consist of:</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfB922u73kUc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_zzOlms1Jk7xl" style="display: none">Schedule of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220930_zaPdbmPzgLH" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2022</td></tr>
<tr id="xdx_40A_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0_zqew2dFZIC9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,301,928</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,031,105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297,337</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--FixedContractAccruals_iI_pp0p0_zxG7LGumKkuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,414</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zuJA5YbLRMNd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Milestone based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,337</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_zgHdOtfhy577" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,149,241</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,061,760</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_z8DYWwVzedwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,985,658</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,944,953</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760801744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80D_ecustom--EquityOfferingTextBlock_zWZwwBjRr5R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5		<span id="xdx_827_zEvK0tLnX1n1">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market offering&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_90E_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zMECYFFxh5d5" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the nine months ended June 30, 2023, <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zdgEZ5c2FtYk" title="Number of common stock sold">no</span> shares
were sold pursuant to the Offering. During the nine months ended June 30, 2022, <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold">1,623,566</span> shares were sold for gross proceeds of $<span id="xdx_90E_ecustom--SoldForGrossProceedsAmount_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zprTr0hskgZ9" title="Sold for gross proceeds amount">20,982,148</span>
(net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering">20,258,981</span>). At June 30, 2023, an amount of $<span id="xdx_90F_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20230630_znVSWGiQsxj7" title="Sales of agreement amount">142,407,882</span> (September 30, 2022: $<span id="xdx_90C_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20220930_zNHzHj4vUxCb" title="Sales of agreement amount">142,407,882</span>) was registered pursuant
to an effective registration statement and remained available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant
to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z2cVA74AsjIc" title="Value of shares obligated to purchase">150,000,000 </span>in
value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the Purchase Agreement,
the Company issued to Lincoln Park <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares">75,000</span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;) and
agreed to issue up to an additional <span id="xdx_902_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8vlLHayk2z5" title="Pro rata basic number of shares obligated to purchase">75,000 </span>shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the
$<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">150,000,000</span> aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_906_ecustom--FairValueOfInitialCommitment_iI_pp0p0_c20230630_zC5acRtRL89d" title="Fair value of the initial commitment">844,500</span> with reference
to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses
of $<span id="xdx_903_ecustom--IncurredExpenses_iI_pp0p0_c20230630__us-gaap--HealthCareOrganizationRevenueSourcesAxis__us-gaap--ThirdPartyPayorMember_zykhUbK1caub" title="Incurred expenses">119,844</span> in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statement
of operations during the nine months ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended June 30, 2023, the Company
issued to Lincoln Park an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares">3,138,348 </span>(2022: <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuSoxJvGZGjd" title="Share issued for offering, shares">0</span>) shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdYTaZl8Jn37" title="Number of shares issued for aggregate purchase price">3,125,000</span>
(2022: <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8dldQ5LwPD8" title="Number of shares issued for aggregate purchase price">0</span>l) shares of common stock for aggregate proceeds of $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueNewIssues3_pip0_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zv7H6m337mae" title="Number of shares issued for aggregate purchase price, value">26,687,017</span>&#160;(2022: $<span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssues3_pip0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zO4M1UmEK94b" title="Number of shares issued for aggregate purchase price, value">0</span>) and&#160;<span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zFJGRylToDN6" title="Number of shares issued for commitment">13,348</span>&#160;(2022:&#160;<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zNU3h12b1Lnk" title="Number of shares issued for commitment">0</span>) commitment
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2023, an amount of $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueNewIssues4_pip0_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_znlYwV6uSeFd" title="Amount of shares remain available">123,312,983</span> (September
30, 2022: N/A) remained available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334761029904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_z3tNEMpo5pRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Note 6 	<span id="xdx_820_zOh3ZEBan8b3">Commitments and Contingencies</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Leases </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During the three
and nine months ended June 30, 2023, the Company incurred office lease expense of $<span id="xdx_90F_eus-gaap--CapitalLeaseObligationsIncurred_c20230401__20230630_pp0p0" title="Incurred office lease expense">25,103</span> and $<span id="xdx_902_eus-gaap--CapitalLeaseObligationsIncurred_c20221001__20230630_pp0p0" title="Incurred office lease expense">85,243</span>, (2022: $<span id="xdx_900_eus-gaap--CapitalLeaseObligationsIncurred_c20220401__20220630_pp0p0" title="Incurred office lease expense">21,015</span> and $<span id="xdx_904_eus-gaap--CapitalLeaseObligationsIncurred_c20211001__20220630_pp0p0" title="Incurred office lease expense">42,348</span>) respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three and nine months ended June 30, 2023, the Company made $<span id="xdx_902_eus-gaap--PensionContributions_c20230401__20230630_pp0p0" title="Contribution amount">76,313</span> and $<span id="xdx_90D_eus-gaap--PensionContributions_c20221001__20230630_pp0p0" title="Contribution amount">176,189</span> (2022: $<span id="xdx_90F_eus-gaap--PensionContributions_c20220401__20220630_pp0p0" title="Contribution amount">27,358</span> and $<span id="xdx_90B_eus-gaap--PensionContributions_c20211001__20220630_pp0p0" title="Contribution amount">120,979</span>), respectively,
in matching contributions under the 401(k) plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray; text-align: justify"><span style="font-weight: normal"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023 and September 30, 2022, the Company
had <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230630_pdd" title="Warrants outstanding"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930_pdd" title="Warrants outstanding">160,000</span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_90C_ecustom--WarrantsOutstandingWeightedAverageExercise_c20230630_pdd" title="Warrants outstanding weighted average exercise"><span id="xdx_901_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_ztZ5rhQOhBT9" title="Warrants outstanding weighted average exercise">3.72</span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zcwFmN4cEwI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"><span id="xdx_8B0_z9KJTV3Rm5cb" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: right; text-indent: -10pt" title="Number">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 30%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 31%; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zO01AGksuY2d" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zwe7JPLVhNTj" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  </table>



<p id="xdx_8A6_zijDuhlNOS7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at
June 30, 2023, <span id="xdx_905_ecustom--OptionIssued_c20221001__20230630_zImMkeK0W0qe" title="Option issued">3,912,000</span> options had been issued under the 2022 Plan and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option available issue">6,599,452</span> options were available for issuance under the 2022
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the status of Company&#8217;s outstanding
stock options is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z1cEAUlcROk" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zXMcIYcn2FOl" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Average</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Average</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Grant Date Fair</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate&#160;intrinsic</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise Price</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number
    of Options</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt">Outstanding,
                                                                                                                       September
                                                                                                                       30, 2021</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220903__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuOKwhlrEIHi" style="width: 15%; text-align: right" title="Options Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">11,330,903</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRXjDTOfh0J4" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">5.74</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXqPqZUSf1jc" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">140,132,451</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">2,358,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">10.13</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">7.07</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0nFtpnb5rhi" style="text-align: right" title="Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(118,750</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.55pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z84Omxr3tGhb">6.56</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXf9HG7RZXah" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">5.23</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw4cIMzFfJGg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(400,537</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font: 10pt Times New Roman, Times, Serif">2.52</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFJgcZP0geO3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font: 10pt Times New Roman, Times, Serif">1.88</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"><span style="font: 10pt Times New Roman, Times, Serif">4,201,015</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding,
                                                                                                                                 September
                                                                                                                                 30,
                                                                                                                                 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9smyxVbvwpk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">13,169,616</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z70lrmLCk9fe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">6.61</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIVWaTq564j8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">62,267,309</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGSPhj8J3hi9" style="text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">1,914,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYrj2FLpdWna" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">9.33</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOgJOO2Hrubg" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">6.62</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsjzMRyiQ0m4" style="text-align: right" title="Options Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(234,753</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm8jRU2pU12f" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font: 10pt Times New Roman, Times, Serif">3.87</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfpnp2Q3NOD5" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.7pt">2.91</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmdKH4i0Kuce" style="text-align: right" title="Aggregate intrinsic value Exercised"><span style="font: 10pt Times New Roman, Times, Serif">1,297,062</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIkQXJdc6bof" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYA7SjU2JmX5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">12.69</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFcF30erOkEb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">5.64</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt">Outstanding,
                                                                                                                                 June
                                                                                                                                 30,
                                                                                                                                 2023</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWGgThYr0Wfc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">14,698,863</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeOwiNOAjPHa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">6.95</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhx6slNvsosi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">39,065,774</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
                                                                                                                                   June
                                                                                                                                   30,
                                                                                                                                   2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"><span style="font: 10pt Times New Roman, Times, Serif">10,027,446</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"><span style="font: 10pt Times New Roman, Times, Serif">4.91</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"><span style="font: 10pt Times New Roman, Times, Serif">38,730,916</span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p id="xdx_8AF_zaYawBBRCe5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at June 30, 2023 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5wtJlWWQLtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_8BE_zDftxuPaeAdh" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> vested</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> average</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">3.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options">3,800,309</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5RXcE8N7274" title="Weighted average remaining contractual life (in years)">4.34</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options">3,800,309</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options">2,022,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhyGhQNmDGI8" title="Weighted average remaining contractual life (in years)">4.57</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options">2,022,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">3.28</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">5.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">9.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options">5,250,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z1TvEwHNJ6Zd" title="Weighted average remaining contractual life (in years)">6.46</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options">3,287,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">6.09</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">9.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">13.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options">2,054,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z5vlPLOfouM1" title="Weighted average remaining contractual life (in years)">8.64</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">10.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options">432,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">11.47</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right; padding-top: 0; padding-right: 0" title="Range of exercise prices, lower range limit">13.01</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">25.00</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,572,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zZRcO2XBdlH" title="Weighted average remaining contractual life (in years)">7.74</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.29</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">484,583</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.50</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right; padding-top: 0; padding-right: 0">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">14,698,863</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLdTpcGQmj1" title="Weighted average remaining contractual life (in years)">6.09</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">6.95</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">10,027,446</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">4.91</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>
<p id="xdx_8A8_zX9iFzaRbbkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested during the nine months ended June 30, 2023 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630_pdd" title="Weighted average grant date fair value of options vested">3.77</span> (2022: $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630_pdd" title="Weighted average grant date fair value of options vested">3.83</span>). At June 30, 2023, the weighted average contractual life of
options outstanding was <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630_zq6EMRiGi7b4" title="Weighted average contractual life of options outstanding">6.09</span> years (September 30, 2022: 6.40 years) and for options exercisable was <span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630_zg98NUPgp2Uk" title="Options exercisable">4.72</span> years (September 30, 2022: 5.1
years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and nine months ended June 30, 2023,
the Company recognized stock based compensation expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_pp0p0" title="Share based compensation">3,866,781</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" title="Share based compensation">13,183,353</span> (2022: $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Share based compensation">3,988,614</span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Share based compensation">12,336,844</span>), respectively,
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been included
in general and 	administrative expenses and research and development expenses on the Company&#8217;s statement of 	operations as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zgI3VlGVAPqb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zv8vp7cNCaS1" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3EgG4dK9Elg" style="width: 10%; text-align: right" title="Total share based compensation">1,451,471</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGsdIwacZSAi" style="width: 10%; text-align: right" title="Total share based compensation">1,490,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">4,450,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgFyrC2UU8Dg" style="width: 10%; text-align: right" title="Total share based compensation">4,739,021</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziqIJKCmfN2c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,415,310</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyJPbWiK3XRj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,498,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">8,732,512</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzWtjU5UUJrf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">7,597,823</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630_zWpMxKskTG58" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,866,781</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630_zHpEy5npSAbk" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,988,614</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">13,183,353</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630_zZfYmmpUvYA2" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">12,336,844</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AF_zujBLwemshHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20230630_pp0p0" title="Remaining stock based compensation">17,543,748 </span>in stock based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">The fair value of each option award
granted during the three and nine months ended June 30, 2023 and 2022 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zTjQCcbGHhT3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zhE1fNGURUn" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230630_zRkYbWkXv0F5" title="Risk-free interest rate">3.69</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zZKcEMuzyysg" title="Risk-free interest rate">3.10</span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230630_zOzHl7m225f5" title="Expected life of options (years)">5.63</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zD85rXlAxpU3" title="Expected life of options (years)">5.51</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230630_zl1b8e3R3k77" title="Annualized volatility">85.16</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_z0xQMxbfgOh8" title="Annualized volatility">84.12</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230630_zrEDyY9vZrC9" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_z1rNoyhBSlh5" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
</table>
<p id="xdx_8AF_zWcmbYsc6ZIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three and nine months ended June 30, 2023 and 2022 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334758812960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9FpFqvR7NNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i><span id="xdx_865_zqPQCWR9m2L">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three and nine months ended
June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LliquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_840_ecustom--LliquidityPolicyTextBlock_z57odifUfOa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zBRPPeYZVXAk">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zXbaWVysJdna">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zDjEre6jsve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zPStfmhlKJvl">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


















<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrXksW990vL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zTuH7iC2OJle">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJkea6vlQS2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zLqs1Er9a9M2">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023 loss per share excludes <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230630_pdd" title="Loss per share for potentially dilutive common shares">14,858,863</span>
(June 30, 2022: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares">13,194,616</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHQ8H7PzXKgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_868_zmuFYFUkU751">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB
issued ASU 2021-10, &#8220;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#8221; (&#8220;ASU&#160;2021-10&#8221;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#8217;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#8220;ATO&#8221;) for its clinical trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LliquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LliquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334759913440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfB922u73kUc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_zzOlms1Jk7xl" style="display: none">Schedule of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220930_zaPdbmPzgLH" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br/>
2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2022</td></tr>
<tr id="xdx_40A_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0_zqew2dFZIC9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,301,928</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,031,105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,297,337</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--FixedContractAccruals_iI_pp0p0_zxG7LGumKkuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,414</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zuJA5YbLRMNd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Milestone based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,337</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_zgHdOtfhy577" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,149,241</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,061,760</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_z8DYWwVzedwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,985,658</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,944,953</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760371792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zcwFmN4cEwI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"><span id="xdx_8B0_z9KJTV3Rm5cb" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: right; text-indent: -10pt" title="Number">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 30%; text-align: right" title="Exercise Price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 31%; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zO01AGksuY2d" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zwe7JPLVhNTj" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z1cEAUlcROk" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zXMcIYcn2FOl" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Average</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Weighted Average</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Grant Date Fair</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate&#160;intrinsic</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise Price</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Value</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number
    of Options</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt">Outstanding,
                                                                                                                       September
                                                                                                                       30, 2021</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220903__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuOKwhlrEIHi" style="width: 15%; text-align: right" title="Options Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">11,330,903</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRXjDTOfh0J4" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">5.74</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXqPqZUSf1jc" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">140,132,451</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">2,358,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">10.13</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">7.07</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0nFtpnb5rhi" style="text-align: right" title="Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(118,750</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.55pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z84Omxr3tGhb">6.56</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXf9HG7RZXah" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">5.23</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw4cIMzFfJGg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(400,537</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font: 10pt Times New Roman, Times, Serif">2.52</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFJgcZP0geO3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font: 10pt Times New Roman, Times, Serif">1.88</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"><span style="font: 10pt Times New Roman, Times, Serif">4,201,015</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt">Outstanding,
                                                                                                                                 September
                                                                                                                                 30,
                                                                                                                                 2022</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9smyxVbvwpk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">13,169,616</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z70lrmLCk9fe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">6.61</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIVWaTq564j8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">62,267,309</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGSPhj8J3hi9" style="text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">1,914,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYrj2FLpdWna" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">9.33</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOgJOO2Hrubg" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">6.62</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsjzMRyiQ0m4" style="text-align: right" title="Options Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(234,753</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm8jRU2pU12f" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font: 10pt Times New Roman, Times, Serif">3.87</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfpnp2Q3NOD5" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.7pt">2.91</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmdKH4i0Kuce" style="text-align: right" title="Aggregate intrinsic value Exercised"><span style="font: 10pt Times New Roman, Times, Serif">1,297,062</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIkQXJdc6bof" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYA7SjU2JmX5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">12.69</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFcF30erOkEb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">5.64</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt">Outstanding,
                                                                                                                                 June
                                                                                                                                 30,
                                                                                                                                 2023</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWGgThYr0Wfc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">14,698,863</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeOwiNOAjPHa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">6.95</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhx6slNvsosi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">39,065,774</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
                                                                                                                                   June
                                                                                                                                   30,
                                                                                                                                   2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"><span style="font: 10pt Times New Roman, Times, Serif">10,027,446</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"><span style="font: 10pt Times New Roman, Times, Serif">4.91</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"><span style="font: 10pt Times New Roman, Times, Serif">38,730,916</span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5wtJlWWQLtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_8BE_zDftxuPaeAdh" style="display: none">Schedule Of Share-based Payment Arrangement, Option, Activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">remaining</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> vested</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"> average</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">3.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options">3,800,309</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5RXcE8N7274" title="Weighted average remaining contractual life (in years)">4.34</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price">2.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options">3,800,309</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options">2,022,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhyGhQNmDGI8" title="Weighted average remaining contractual life (in years)">4.57</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options">2,022,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">3.28</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">5.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">9.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options">5,250,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z1TvEwHNJ6Zd" title="Weighted average remaining contractual life (in years)">6.46</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price">6.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options">3,287,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">6.09</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit">9.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">13.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options">2,054,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z5vlPLOfouM1" title="Weighted average remaining contractual life (in years)">8.64</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price">10.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options">432,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested">11.47</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right; padding-top: 0; padding-right: 0" title="Range of exercise prices, lower range limit">13.01</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit">25.00</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,572,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zZRcO2XBdlH" title="Weighted average remaining contractual life (in years)">7.74</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.29</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">484,583</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.50</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right; padding-top: 0; padding-right: 0">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">14,698,863</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLdTpcGQmj1" title="Weighted average remaining contractual life (in years)">6.09</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">6.95</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">10,027,446</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">4.91</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zgI3VlGVAPqb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zv8vp7cNCaS1" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3EgG4dK9Elg" style="width: 10%; text-align: right" title="Total share based compensation">1,451,471</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGsdIwacZSAi" style="width: 10%; text-align: right" title="Total share based compensation">1,490,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation">4,450,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgFyrC2UU8Dg" style="width: 10%; text-align: right" title="Total share based compensation">4,739,021</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziqIJKCmfN2c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,415,310</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyJPbWiK3XRj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,498,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">8,732,512</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzWtjU5UUJrf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">7,597,823</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630_zWpMxKskTG58" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,866,781</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630_zHpEy5npSAbk" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,988,614</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">13,183,353</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630_zZfYmmpUvYA2" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">12,336,844</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zTjQCcbGHhT3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_zhE1fNGURUn" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2022</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230630_zRkYbWkXv0F5" title="Risk-free interest rate">3.69</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zZKcEMuzyysg" title="Risk-free interest rate">3.10</span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230630_zOzHl7m225f5" title="Expected life of options (years)">5.63</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zD85rXlAxpU3" title="Expected life of options (years)">5.51</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230630_zl1b8e3R3k77" title="Annualized volatility">85.16</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_z0xQMxbfgOh8" title="Annualized volatility">84.12</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230630_zrEDyY9vZrC9" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_z1rNoyhBSlh5" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760801744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">14,858,863<span></span>
</td>
<td class="nump">13,194,616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334756882624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 564,842<span></span>
</td>
<td class="nump">$ 682,432<span></span>
</td>
<td class="nump">$ 2,048,113<span></span>
</td>
<td class="nump">$ 2,328,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">916,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 852,862<span></span>
</td>
<td class="nump">$ 954,986<span></span>
</td>
<td class="nump">3,068,615<span></span>
</td>
<td class="nump">$ 3,218,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_AnavexMember', window );">Anavex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember', window );">Michael J Fox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 995,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_AnavexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_AnavexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334756899600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts', window );">Accrued clinical site and patient visits costs</a></td>
<td class="nump">$ 2,301,928<span></span>
</td>
<td class="nump">$ 2,031,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">952,323<span></span>
</td>
<td class="nump">1,297,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">11,170<span></span>
</td>
<td class="nump">417,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MilestoneBasedContractAccruals', window );">Milestone based contract accruals</a></td>
<td class="nump">570,996<span></span>
</td>
<td class="nump">137,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">2,149,241<span></span>
</td>
<td class="nump">2,061,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 5,985,658<span></span>
</td>
<td class="nump">$ 5,944,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedClinicalSiteAndPatientVisitsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MilestoneBasedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MilestoneBasedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760065056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,407,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,407,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FairValueOfInitialCommitment', window );">Fair value of the initial commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,623,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SoldForGrossProceedsAmount', window );">Sold for gross proceeds amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,982,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,258,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">Purchase Agreement 1 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">3,138,348<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,687,017<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,348<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,312,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FairValueOfInitialCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FairValueOfInitialCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SoldForGrossProceedsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SoldForGrossProceedsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760383920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334758956832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - Equity Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 62,267,309<span></span>
</td>
<td class="nump">$ 140,132,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,914,000<span></span>
</td>
<td class="nump">2,358,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 9.33<span></span>
</td>
<td class="nump">$ 10.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 6.62<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(118,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 12.69<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(234,753)<span></span>
</td>
<td class="num">(400,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value Exercised</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value Exercised</a></td>
<td class="nump">$ 1,297,062<span></span>
</td>
<td class="nump">$ 4,201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">14,698,863<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 39,065,774<span></span>
</td>
<td class="nump">$ 62,267,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending</a></td>
<td class="nump">10,027,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending</a></td>
<td class="nump">$ 38,730,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334754790288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">14,698,863<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
<td class="nump">11,330,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">10,027,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,800,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,800,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,022,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,022,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">5,250,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,287,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">432,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 11.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">484,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334754773936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 3,866,781<span></span>
</td>
<td class="nump">$ 3,988,614<span></span>
</td>
<td class="nump">$ 13,183,353<span></span>
</td>
<td class="nump">$ 12,336,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,451,471<span></span>
</td>
<td class="nump">1,490,267<span></span>
</td>
<td class="nump">4,450,841<span></span>
</td>
<td class="nump">4,739,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,415,310<span></span>
</td>
<td class="nump">$ 2,498,347<span></span>
</td>
<td class="nump">$ 8,732,512<span></span>
</td>
<td class="nump">$ 7,597,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334760985840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">85.16%<span></span>
</td>
<td class="nump">84.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140334762548128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Incurred office lease expense</a></td>
<td class="nump">$ 25,103<span></span>
</td>
<td class="nump">$ 21,015<span></span>
</td>
<td class="nump">$ 85,243<span></span>
</td>
<td class="nump">$ 42,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution amount</a></td>
<td class="nump">$ 76,313<span></span>
</td>
<td class="nump">27,358<span></span>
</td>
<td class="nump">$ 176,189<span></span>
</td>
<td class="nump">$ 120,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 3,866,781<span></span>
</td>
<td class="nump">$ 3,988,614<span></span>
</td>
<td class="nump">$ 13,183,353<span></span>
</td>
<td class="nump">$ 12,336,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 17,543,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,543,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issue</a></td>
<td class="nump">6,599,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,599,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>e4887_10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20230630"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20230630.xsd" xlink:type="simple"/>
    <context id="From2022-10-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_MichaelJFoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_ThirdPartyPayorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-01to2023-06-30">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-01to2023-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-10-01to2023-06-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-10-01to2023-06-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-10-01to2023-06-30">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2021-10-012022-06-30"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:OtherFinancingExpense
      contextRef="From2021-10-012022-06-30"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUnder2023PurchaseAgreement
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2022-10-01to2023-06-30"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedUponExerciseOfStockOptions
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2021-10-012022-06-30"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2021-10-012022-06-30"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-10-01to2023-06-30"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-10-01to2023-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-10-01to2023-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-01to2023-06-30">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-10-01to2023-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-10-01to2023-06-30">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-10-01to2023-06-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-01to2023-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-01to2023-06-30">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-01to2023-06-30">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-10-01to2023-06-30">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-01to2023-06-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-10-01to2023-06-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2022-10-01to2023-06-30">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-01to2023-06-30">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-10-01to2023-06-30">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-01to2023-06-30">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-10-01to2023-06-30">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-01to2023-06-30">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-01to2023-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-10-01to2023-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-10-01to2023-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-10-01to2023-06-30">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-10-01to2023-06-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-01to2023-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-10-01to2023-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-08-08" decimals="INF" unitRef="Shares">81951115</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">154817164</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">2165127</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3192580</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">827572</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">354162</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">157809863</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">4152846</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3824777</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">5985658</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">916763</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</us-gaap:DeferredIncomeCurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">11055267</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">10213561</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">81390916</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">81390916</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">77942815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">81391</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">77944</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">429595961</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">387976881</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">-282922756</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-245563783</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">146754596</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">157809863</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">152704603</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">3247843</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3185451</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">9447447</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">9167560</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">10282854</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">9273269</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">33656364</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">26534297</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">13530697</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">12458720</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">43103811</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">35701857</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-13530697</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12458720</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-43103811</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-35701857</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">564842</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">682432</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">2048113</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">2328675</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">1827945</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">229917</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">4560784</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">242405</us-gaap:InterestIncomeExpenseNet>
    <avxl:OtherFinancingExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-964344</avxl:OtherFinancingExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-101066</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-732549</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">146239</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-408541</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">2291721</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">179800</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">5815792</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">2162539</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-11238976</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12278920</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-37288019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-33539318</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">41000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">88421</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">70954</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">148201</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-11279976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12367341</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-37358973</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:NetIncomeLoss>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.14</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.16</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.47</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:NetLossPerShareBasicAndDiluted
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.44</avxl:NetLossPerShareBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">80875235</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">77442236</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">79051038</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">76561940</avxl:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">80235398</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">80236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">416727598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-271642780</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">145165054</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1050000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1050</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8533467</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">8534517</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4268</avxl:CommitmentSharesShares>
    <avxl:CommitmentShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4</avxl:CommitmentShares>
    <avxl:CommitmentShares
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-4</avxl:CommitmentShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">101250</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">101</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">468119</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">468220</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3866781</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">3866781</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-11279976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-11279976</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">81390916</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">81391</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">429595961</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-282922756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">146754596</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77161688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77163</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">371437616</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">-403696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-218906042</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">152205041</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">557177</avxl:SharesIssuedUnderSalesAgreementInShares>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">557</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6178127</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30_custom_ShareProceedsReceivableMember"
      decimals="0"
      unitRef="USD">403696</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">6582380</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-185361</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-185361</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">223703</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">224</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">513043</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">513267</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3988614</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3988614</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12367341</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-12367341</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942568</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">381932039</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-231273383</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">150736600</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">387976881</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-245563783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142491042</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">844425</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">844500</avxl:InitialCommitmentShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3125000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3125</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">26683892</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">26687017</us-gaap:StockRepurchasedDuringPeriodValue>
    <avxl:CommitmentSharesShares
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13348</avxl:CommitmentSharesShares>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">13</avxl:CommitmentShares>
    <avxl:CommitmentShares
      contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-13</avxl:CommitmentShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">234753</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">234</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">907423</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">907657</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13183353</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">13183353</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37358973</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-37358973</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">81390916</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">81391</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">429595961</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-282922756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">146754596</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75918465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">75920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">348328048</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197585864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">150818104</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedUnderSalesAgreementInShares
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1623566</avxl:SharesIssuedUnderSalesAgreementInShares>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1623</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">20980525</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">20982148</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-723167</avxl:LessShareIssueCosts>
    <avxl:LessShareIssueCosts
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-723167</avxl:LessShareIssueCosts>
    <avxl:SharesIssuedUponExerciseOfStockOptionsShares
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">400537</avxl:SharesIssuedUponExerciseOfStockOptionsShares>
    <avxl:SharesIssuedUponExerciseOfStockOptions
      contextRef="From2021-10-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">401</avxl:SharesIssuedUponExerciseOfStockOptions>
    <avxl:SharesIssuedUponExerciseOfStockOptions
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1009789</avxl:SharesIssuedUponExerciseOfStockOptions>
    <avxl:SharesIssuedUponExerciseOfStockOptions
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">1010190</avxl:SharesIssuedUponExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12336844</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77942568</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">381932039</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-231273383</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">150736600</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-37358973</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-33687519</us-gaap:NetIncomeLoss>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">844500</avxl:NoncashFinancingRelatedCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">13183353</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-1027453</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-2577002</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">473410</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">106414</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">328069</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-1612889</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">40705</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">299047</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">472932</avxl:IncreaseDecreaseInDeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">-21935371</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">-20193929</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">26687017</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">20982148</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">706802</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">907657</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">1010190</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">27594674</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">21285536</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">5659303</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">1091607</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">149157861</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">152107745</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">154817164</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">153199352</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">208577</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">141374</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zftMYpa4fEH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 	&lt;span id="xdx_828_z6oEcvUOpLx"&gt;Business Description&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73
is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_804_eus-gaap--BasisOfAccounting_zDr0DvYj0Kp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 	&lt;span id="xdx_824_z8Y8eG1yBZ48"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9FpFqvR7NNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zqPQCWR9m2L"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed interim consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the three and nine months ended
June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--LliquidityPolicyTextBlock_z57odifUfOa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zBRPPeYZVXAk"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zXbaWVysJdna"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zDjEre6jsve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zPStfmhlKJvl"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrXksW990vL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zTuH7iC2OJle"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At June 30, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJkea6vlQS2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zLqs1Er9a9M2"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2023 loss per share excludes &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230630_pdd" title="Loss per share for potentially dilutive common shares"&gt;14,858,863&lt;/span&gt;
(June 30, 2022: &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,194,616&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHQ8H7PzXKgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zmuFYFUkU751"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2021, the FASB
issued ASU 2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#x2019;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#x201c;ATO&#x201d;) for its clinical trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9FpFqvR7NNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zqPQCWR9m2L"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed interim consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary
for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the
audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included
in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company
follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the three and nine months ended
June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <avxl:LliquidityPolicyTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_840_ecustom--LliquidityPolicyTextBlock_z57odifUfOa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zBRPPeYZVXAk"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the Sales Agreement
and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:LliquidityPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zXbaWVysJdna"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zDjEre6jsve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zPStfmhlKJvl"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrXksW990vL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zTuH7iC2OJle"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At June 30, 2023 and September 30, 2022, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJkea6vlQS2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zLqs1Er9a9M2"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2023 loss per share excludes &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230630_pdd" title="Loss per share for potentially dilutive common shares"&gt;14,858,863&lt;/span&gt;
(June 30, 2022: &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares"&gt;13,194,616&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">14858863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="Shares">13194616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHQ8H7PzXKgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zmuFYFUkU751"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2021, the FASB
issued ASU 2021-10, &#x201c;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&#x201d; (&#x201c;ASU&#160;2021-10&#x201d;).
ASU&#160;2021-10&#160;increases the disclosure requirements for annual reporting periods relating to material government assistance transactions
on the entity&#x2019;s financial statements and any significant terms and conditions of the agreements including commitments and contingencies.
The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The
adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company
receives from the Australian Tax Office (&#x201c;ATO&#x201d;) for its clinical trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_800_ecustom--OtherIncomeDisclosureTextBlock_z8oliW7QC1Gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 3	&lt;span id="xdx_826_z7jjif1GjEZ2"&gt;Other Income&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of June 30, 2023, the
Company had received $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_pp0p0" title="Research and development incentive income"&gt;995,862 &lt;/span&gt;in a research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant will
be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Parkinson&#x2019;s disease.
Of the total, $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income"&gt;497,931&lt;/span&gt; was received during the nine months ended June 30, 2023, and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_pp0p0" title="Research and development incentive income"&gt;497,931&lt;/span&gt; was received during the year ended September
30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income was recorded
to deferred grant income when received and is being amortized to grant income as the related research and development expenditures are
incurred. During the three and nine months ended June 30, 2023, the Company recognized $&lt;span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230401__20230630_zAJqrmqdOncd" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_c20221001__20230630_pp0p0" title="Grant income"&gt;25,000&lt;/span&gt;, respectively (2022: $&lt;span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_c20220401__20220630_pp0p0" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_c20211001__20220630_pp0p0" title="Grant income"&gt;0&lt;/span&gt;,
respectively) of this grant on its statements of operations as grant income. At June 30, 2023, an amount of $&lt;span id="xdx_908_ecustom--DeferredGrantIncome_iI_pp0p0_c20230630_ziJzV6sLxSoj" title="Deferred grant income"&gt;916,763&lt;/span&gt; (September 30, 2022:
$&lt;span id="xdx_90F_ecustom--DeferredGrantIncome_c20220930_pp0p0" title="Deferred grant income"&gt;443,831&lt;/span&gt;) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to
other income. The Company will recognize this income on its statement of operations as the related expenditures are incurred to offset
the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia, of the Australian research and development tax incentive credit (the
&#x201c;Tax Incentive Credit&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the three and nine
months ended June 30, 2023, the Company recorded research and development incentive income of $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630_pp0p0" title="Research and development incentive income"&gt;564,842&lt;/span&gt; (AUD &lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20230401__20230630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;852,862&lt;/span&gt;) and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630_pp0p0" title="Research and development incentive income"&gt;2,048,113&lt;/span&gt; (AUD
&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20221001__20230630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;3,068,615&lt;/span&gt;), respectively (2022: $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630_pp0p0" title="Research and development incentive income"&gt;682,432&lt;/span&gt; (AUD &lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20220401__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;954,986&lt;/span&gt;) and $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630_pp0p0" title="Research and development incentive income"&gt;2,328,675&lt;/span&gt; (AUD &lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20211001__20220630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;3,218,303&lt;/span&gt;), respectively) in respect of the Tax Incentive Credit
for eligible research and development expenses incurred during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Although the Company believes that it complies with all the relevant conditions of the program, the Company may be subject
to pre-issue review or audit by the ATO and the ATO may have different interpretations of certain eligibility requirements. Currently,
the Company&#x2019;s tax incentive claims from 2019 to 2022 are open to potential review or audit by the ATO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-06-30_custom_MichaelJFoxMember"
      decimals="0"
      unitRef="USD">995862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-06-30_custom_AnavexMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_AnavexMember"
      decimals="0"
      unitRef="USD">497931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">916763</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">443831</avxl:DeferredGrantIncome>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">564842</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-04-012023-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">852862</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">2048113</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">3068615</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">682432</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-04-012022-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">954986</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">2328675</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-10-012022-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">3218303</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcOvQSgd919i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 4	 	 &lt;span id="xdx_825_zfLKr8lWoveb"&gt;Accrued Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="font-size: 10pt"&gt;The principal components of accrued liabilities consist of:&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfB922u73kUc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_zzOlms1Jk7xl" style="display: none"&gt;Schedule of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230630" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220930_zaPdbmPzgLH" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0_zqew2dFZIC9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,301,928&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,031,105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,297,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--FixedContractAccruals_iI_pp0p0_zxG7LGumKkuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;417,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zuJA5YbLRMNd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Milestone based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;570,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_zgHdOtfhy577" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,149,241&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,061,760&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_z8DYWwVzedwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,985,658&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,944,953&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2022-10-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfB922u73kUc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_zzOlms1Jk7xl" style="display: none"&gt;Schedule of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230630" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220930_zaPdbmPzgLH" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30,&lt;br/&gt;
2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_pp0p0_zqew2dFZIC9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,301,928&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,031,105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedBonusesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,297,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--FixedContractAccruals_iI_pp0p0_zxG7LGumKkuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;417,414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--MilestoneBasedContractAccruals_iI_pp0p0_zuJA5YbLRMNd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Milestone based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;570,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_zgHdOtfhy577" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,149,241&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,061,760&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_z8DYWwVzedwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,985,658&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,944,953&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">2301928</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2031105</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">952323</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1297337</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">11170</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">417414</avxl:FixedContractAccruals>
    <avxl:MilestoneBasedContractAccruals contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">570996</avxl:MilestoneBasedContractAccruals>
    <avxl:MilestoneBasedContractAccruals contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">137337</avxl:MilestoneBasedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">2149241</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2061760</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">5985658</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5944953</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:EquityOfferingTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_80D_ecustom--EquityOfferingTextBlock_zWZwwBjRr5R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 5		&lt;span id="xdx_827_zEvK0tLnX1n1"&gt;Equity Offerings&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#x201c;Board&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board has the authority to issue
preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series of the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer and sell shares of common stock
registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon delivery of a placement notice based on the Company&#x2019;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#x201c;at the market offering&#x201d; offering, in negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to
the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company
or Sales Agents may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales
Agents will act as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable
state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has agreed to pay the Sales Agents commissions
for their services of up to &lt;span id="xdx_90E_ecustom--PercentageOfGrossProceedsFromSales_dp_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zMECYFFxh5d5" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the nine months ended June 30, 2023, &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_do_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zdgEZ5c2FtYk" title="Number of common stock sold"&gt;no&lt;/span&gt; shares
were sold pursuant to the Offering. During the nine months ended June 30, 2022, &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Number of common stock sold"&gt;1,623,566&lt;/span&gt; shares were sold for gross proceeds of $&lt;span id="xdx_90E_ecustom--SoldForGrossProceedsAmount_pp0p0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zprTr0hskgZ9" title="Sold for gross proceeds amount"&gt;20,982,148&lt;/span&gt;
(net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceeds from Issuance Public Offering"&gt;20,258,981&lt;/span&gt;). At June 30, 2023, an amount of $&lt;span id="xdx_90F_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20230630_znVSWGiQsxj7" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt; (September 30, 2022: $&lt;span id="xdx_90C_ecustom--SalesOfAgreementAmount_iI_pp0p0_c20220930_zNHzHj4vUxCb" title="Sales of agreement amount"&gt;142,407,882&lt;/span&gt;) was registered pursuant
to an effective registration statement and remained available to be sold under the Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant
to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pp0p0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z2cVA74AsjIc" title="Value of shares obligated to purchase"&gt;150,000,000 &lt;/span&gt;in
value of its shares of common stock from time to time over a three-year period until February 3, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the Purchase Agreement,
the Company issued to Lincoln Park &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"&gt;75,000&lt;/span&gt; shares of common stock as a commitment fee (the &#x201c;initial commitment shares&#x201d;) and
agreed to issue up to an additional &lt;span id="xdx_902_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8vlLHayk2z5" title="Pro rata basic number of shares obligated to purchase"&gt;75,000 &lt;/span&gt;shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion, the
$&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"&gt;150,000,000&lt;/span&gt; aggregate commitment. The Company determined the fair value of the initial commitment shares was $&lt;span id="xdx_906_ecustom--FairValueOfInitialCommitment_iI_pp0p0_c20230630_zC5acRtRL89d" title="Fair value of the initial commitment"&gt;844,500&lt;/span&gt; with reference
to the closing price of the Company&#x2019;s shares on the Purchase Agreement date. In addition, the Company incurred third party expenses
of $&lt;span id="xdx_903_ecustom--IncurredExpenses_iI_pp0p0_c20230630__us-gaap--HealthCareOrganizationRevenueSourcesAxis__us-gaap--ThirdPartyPayorMember_zykhUbK1caub" title="Incurred expenses"&gt;119,844&lt;/span&gt; in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense on the statement
of operations during the nine months ended June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended June 30, 2023, the Company
issued to Lincoln Park an aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"&gt;3,138,348 &lt;/span&gt;(2022: &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zuSoxJvGZGjd" title="Share issued for offering, shares"&gt;0&lt;/span&gt;) shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zdYTaZl8Jn37" title="Number of shares issued for aggregate purchase price"&gt;3,125,000&lt;/span&gt;
(2022: &lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8dldQ5LwPD8" title="Number of shares issued for aggregate purchase price"&gt;0&lt;/span&gt;l) shares of common stock for aggregate proceeds of $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueNewIssues3_pip0_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zv7H6m337mae" title="Number of shares issued for aggregate purchase price, value"&gt;26,687,017&lt;/span&gt;&#160;(2022: $&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodValueNewIssues3_pip0_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zO4M1UmEK94b" title="Number of shares issued for aggregate purchase price, value"&gt;0&lt;/span&gt;) and&#160;&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zFJGRylToDN6" title="Number of shares issued for commitment"&gt;13,348&lt;/span&gt;&#160;(2022:&#160;&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20211001__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zNU3h12b1Lnk" title="Number of shares issued for commitment"&gt;0&lt;/span&gt;) commitment
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As at June 30, 2023, an amount of $&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodValueNewIssues4_pip0_c20221001__20230630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_znlYwV6uSeFd" title="Amount of shares remain available"&gt;123,312,983&lt;/span&gt; (September
30, 2022: N/A) remained available under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















</avxl:EquityOfferingTextBlock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1623566</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:SoldForGrossProceedsAmount
      contextRef="From2021-10-012022-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">20982148</avxl:SoldForGrossProceedsAmount>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-10-012023-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">20258981</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142407882</avxl:SalesOfAgreementAmount>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">150000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">75000</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">150000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:FairValueOfInitialCommitment contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">844500</avxl:FairValueOfInitialCommitment>
    <avxl:IncurredExpenses
      contextRef="AsOf2023-06-30_us-gaap_ThirdPartyPayorMember"
      decimals="0"
      unitRef="USD">119844</avxl:IncurredExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">3138348</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">3125000</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">26687017</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">13348</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2021-10-012022-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">0</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2022-10-012023-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">123312983</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2022-10-01to2023-06-30">&lt;p id="xdx_800_eus-gaap--CommitmentsDisclosureTextBlock_z3tNEMpo5pRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Note 6 	&lt;span id="xdx_820_zOh3ZEBan8b3"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Leases &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;During the three
and nine months ended June 30, 2023, the Company incurred office lease expense of $&lt;span id="xdx_90F_eus-gaap--CapitalLeaseObligationsIncurred_c20230401__20230630_pp0p0" title="Incurred office lease expense"&gt;25,103&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--CapitalLeaseObligationsIncurred_c20221001__20230630_pp0p0" title="Incurred office lease expense"&gt;85,243&lt;/span&gt;, (2022: $&lt;span id="xdx_900_eus-gaap--CapitalLeaseObligationsIncurred_c20220401__20220630_pp0p0" title="Incurred office lease expense"&gt;21,015&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--CapitalLeaseObligationsIncurred_c20211001__20220630_pp0p0" title="Incurred office lease expense"&gt;42,348&lt;/span&gt;) respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
During the three and nine months ended June 30, 2023, the Company made $&lt;span id="xdx_902_eus-gaap--PensionContributions_c20230401__20230630_pp0p0" title="Contribution amount"&gt;76,313&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--PensionContributions_c20221001__20230630_pp0p0" title="Contribution amount"&gt;176,189&lt;/span&gt; (2022: $&lt;span id="xdx_90F_eus-gaap--PensionContributions_c20220401__20220630_pp0p0" title="Contribution amount"&gt;27,358&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--PensionContributions_c20211001__20220630_pp0p0" title="Contribution amount"&gt;120,979&lt;/span&gt;), respectively,
in matching contributions under the 401(k) plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At June 30, 2023 and September 30, 2022, the Company
had &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230630_pdd" title="Warrants outstanding"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930_pdd" title="Warrants outstanding"&gt;160,000&lt;/span&gt;&lt;/span&gt; warrants outstanding at a weighted average exercise price of $&lt;span id="xdx_90C_ecustom--WarrantsOutstandingWeightedAverageExercise_c20230630_pdd" title="Warrants outstanding weighted average exercise"&gt;&lt;span id="xdx_901_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_c20220930_ztZ5rhQOhBT9" title="Warrants outstanding weighted average exercise"&gt;3.72&lt;/span&gt;&lt;/span&gt; as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zcwFmN4cEwI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"&gt;&lt;span id="xdx_8B0_z9KJTV3Rm5cb" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: right; text-indent: -10pt" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 30%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 31%; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zO01AGksuY2d" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zwe7JPLVhNTj" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A6_zijDuhlNOS7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;2015 Stock Option Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20221001__20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the plan. Any awards outstanding under a previous
stock option plan will remain subject to and be paid under such plan, and any shares subject to outstanding awards under a previous plan
that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become
available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant and shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date,
then the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date.
Stock options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such
lesser periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at
June 30, 2023, &lt;span id="xdx_905_ecustom--OptionIssued_c20221001__20230630_zImMkeK0W0qe" title="Option issued"&gt;3,912,000&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20230630__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_pdd" title="Option available issue"&gt;6,599,452&lt;/span&gt; options were available for issuance under the 2022
Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the status of Company&#x2019;s outstanding
stock options is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z1cEAUlcROk" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zXMcIYcn2FOl" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant Date Fair&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#160;intrinsic&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
    of Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt"&gt;Outstanding,
                                                                                                                       September
                                                                                                                       30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220903__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuOKwhlrEIHi" style="width: 15%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,330,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRXjDTOfh0J4" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXqPqZUSf1jc" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;140,132,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0nFtpnb5rhi" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(118,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.55pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z84Omxr3tGhb"&gt;6.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXf9HG7RZXah" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw4cIMzFfJGg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(400,537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFJgcZP0geO3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,201,015&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt"&gt;Outstanding,
                                                                                                                                 September
                                                                                                                                 30,
                                                                                                                                 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9smyxVbvwpk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13,169,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z70lrmLCk9fe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIVWaTq564j8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;62,267,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGSPhj8J3hi9" style="text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,914,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYrj2FLpdWna" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOgJOO2Hrubg" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsjzMRyiQ0m4" style="text-align: right" title="Options Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(234,753&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm8jRU2pU12f" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfpnp2Q3NOD5" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.7pt"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmdKH4i0Kuce" style="text-align: right" title="Aggregate intrinsic value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,297,062&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIkQXJdc6bof" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYA7SjU2JmX5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFcF30erOkEb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt"&gt;Outstanding,
                                                                                                                                 June
                                                                                                                                 30,
                                                                                                                                 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWGgThYr0Wfc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,698,863&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeOwiNOAjPHa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.95&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhx6slNvsosi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;39,065,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
                                                                                                                                   June
                                                                                                                                   30,
                                                                                                                                   2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,027,446&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;38,730,916&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AF_zaYawBBRCe5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at June 30, 2023 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5wtJlWWQLtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_8BE_zDftxuPaeAdh" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt; average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt; vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt; average&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,800,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5RXcE8N7274" title="Weighted average remaining contractual life (in years)"&gt;4.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,800,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,022,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhyGhQNmDGI8" title="Weighted average remaining contractual life (in years)"&gt;4.57&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;2,022,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;5,250,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z1TvEwHNJ6Zd" title="Weighted average remaining contractual life (in years)"&gt;6.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;3,287,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,054,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z5vlPLOfouM1" title="Weighted average remaining contractual life (in years)"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;10.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;432,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;11.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right; padding-top: 0; padding-right: 0" title="Range of exercise prices, lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,572,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zZRcO2XBdlH" title="Weighted average remaining contractual life (in years)"&gt;7.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.29&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;484,583&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-top: 0; padding-right: 0"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;14,698,863&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLdTpcGQmj1" title="Weighted average remaining contractual life (in years)"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;10,027,446&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;4.91&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A8_zX9iFzaRbbkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average grant date fair value of options
vested during the nine months ended June 30, 2023 was $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630_pdd" title="Weighted average grant date fair value of options vested"&gt;3.77&lt;/span&gt; (2022: $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211001__20220630_pdd" title="Weighted average grant date fair value of options vested"&gt;3.83&lt;/span&gt;). At June 30, 2023, the weighted average contractual life of
options outstanding was &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630_zq6EMRiGi7b4" title="Weighted average contractual life of options outstanding"&gt;6.09&lt;/span&gt; years (September 30, 2022: 6.40 years) and for options exercisable was &lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630_zg98NUPgp2Uk" title="Options exercisable"&gt;4.72&lt;/span&gt; years (September 30, 2022: 5.1
years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and nine months ended June 30, 2023,
the Company recognized stock based compensation expense of $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_pp0p0" title="Share based compensation"&gt;3,866,781&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" title="Share based compensation"&gt;13,183,353&lt;/span&gt; (2022: $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_pp0p0" title="Share based compensation"&gt;3,988,614&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20211001__20220630_pp0p0" title="Share based compensation"&gt;12,336,844&lt;/span&gt;), respectively,
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been included
in general and 	administrative expenses and research and development expenses on the Company&#x2019;s statement of 	operations as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zgI3VlGVAPqb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zv8vp7cNCaS1" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine months ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3EgG4dK9Elg" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,451,471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGsdIwacZSAi" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,490,267&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;4,450,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgFyrC2UU8Dg" style="width: 10%; text-align: right" title="Total share based compensation"&gt;4,739,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziqIJKCmfN2c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,415,310&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyJPbWiK3XRj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,498,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;8,732,512&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzWtjU5UUJrf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;7,597,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630_zWpMxKskTG58" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,866,781&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630_zHpEy5npSAbk" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,988,614&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;13,183,353&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630_zZfYmmpUvYA2" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;12,336,844&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AF_zujBLwemshHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20230630_pp0p0" title="Remaining stock based compensation"&gt;17,543,748 &lt;/span&gt;in stock based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"&gt;The fair value of each option award
granted during the three and nine months ended June 30, 2023 and 2022 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zTjQCcbGHhT3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zhE1fNGURUn" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230630_zRkYbWkXv0F5" title="Risk-free interest rate"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zZKcEMuzyysg" title="Risk-free interest rate"&gt;3.10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230630_zOzHl7m225f5" title="Expected life of options (years)"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zD85rXlAxpU3" title="Expected life of options (years)"&gt;5.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230630_zl1b8e3R3k77" title="Annualized volatility"&gt;85.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_z0xQMxbfgOh8" title="Annualized volatility"&gt;84.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230630_zrEDyY9vZrC9" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_z1rNoyhBSlh5" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AF_zWcmbYsc6ZIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the three and nine months ended June 30, 2023 and 2022 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">25103</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">85243</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">21015</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">42348</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:PensionContributions
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">76313</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">176189</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">27358</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">120979</us-gaap:PensionContributions>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2022-10-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zcwFmN4cEwI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center"&gt;&lt;span id="xdx_8B0_z9KJTV3Rm5cb" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="padding: 0pt 0pt 0pt 10pt; width: 31%; text-align: right; text-indent: -10pt" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" style="width: 30%; text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 31%; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zO01AGksuY2d" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zwe7JPLVhNTj" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20230630_pdd" style="border-bottom: Black 1pt solid; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: right; text-indent: -10pt" title="Number"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2023-06-30_custom_PurchaseWarrants1Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2023-06-30_custom_PurchaseWarrants2Member">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-10-012023-06-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-10-012023-06-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">3912000</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-06-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      unitRef="Shares">6599452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2022-10-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_z1cEAUlcROk" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zXMcIYcn2FOl" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant Date Fair&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate&#160;intrinsic&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number
    of Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt"&gt;Outstanding,
                                                                                                                       September
                                                                                                                       30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20211001__20220903__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuOKwhlrEIHi" style="width: 15%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,330,903&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRXjDTOfh0J4" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXqPqZUSf1jc" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;140,132,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,358,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0nFtpnb5rhi" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(118,750&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.55pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z84Omxr3tGhb"&gt;6.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXf9HG7RZXah" style="text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw4cIMzFfJGg" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(400,537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFJgcZP0geO3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20211001__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,201,015&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.3pt"&gt;Outstanding,
                                                                                                                                 September
                                                                                                                                 30,
                                                                                                                                 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9smyxVbvwpk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;13,169,616&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z70lrmLCk9fe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIVWaTq564j8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;62,267,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGSPhj8J3hi9" style="text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,914,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYrj2FLpdWna" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;9.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOgJOO2Hrubg" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsjzMRyiQ0m4" style="text-align: right" title="Options Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(234,753&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm8jRU2pU12f" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfpnp2Q3NOD5" style="text-align: right" title="Weighted Average Grant Date Fair Value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.7pt"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmdKH4i0Kuce" style="text-align: right" title="Aggregate intrinsic value Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,297,062&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIkQXJdc6bof" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYA7SjU2JmX5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;12.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFcF30erOkEb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; letter-spacing: -0.35pt"&gt;Outstanding,
                                                                                                                                 June
                                                                                                                                 30,
                                                                                                                                 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWGgThYr0Wfc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,698,863&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeOwiNOAjPHa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.95&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhx6slNvsosi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;39,065,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
                                                                                                                                   June
                                                                                                                                   30,
                                                                                                                                   2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,027,446&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.91&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;38,730,916&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11330903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">140132451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">118750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.23</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">400537</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.88</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2021-10-012022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">4201015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">62267309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1914000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">234753</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.91</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1297062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.64</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">14698863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">39065774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">10027446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">38730916</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-10-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5wtJlWWQLtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_8BE_zDftxuPaeAdh" style="display: none"&gt;Schedule Of Share-based Payment Arrangement, Option, Activity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;remaining&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt; average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt; vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt; average&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;(in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,800,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5RXcE8N7274" title="Weighted average remaining contractual life (in years)"&gt;4.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,800,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,022,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhyGhQNmDGI8" title="Weighted average remaining contractual life (in years)"&gt;4.57&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Number of vested options"&gt;2,022,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;5,250,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_z1TvEwHNJ6Zd" title="Weighted average remaining contractual life (in years)"&gt;6.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;6.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Number of vested options"&gt;3,287,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of outstanding options"&gt;2,054,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z5vlPLOfouM1" title="Weighted average remaining contractual life (in years)"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price"&gt;10.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Number of vested options"&gt;432,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" style="text-align: right" title="Weighted average exercise price options vested"&gt;11.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right; padding-top: 0; padding-right: 0" title="Range of exercise prices, lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,572,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zZRcO2XBdlH" title="Weighted average remaining contractual life (in years)"&gt;7.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.29&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;484,583&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-top: 0; padding-right: 0"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;14,698,863&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLdTpcGQmj1" title="Weighted average remaining contractual life (in years)"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;10,027,446&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20230630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;4.91&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3800309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">P4Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="Shares">3800309</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2022500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">P4Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="Shares">2022500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">5250054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">P6Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="Shares">3287887</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      unitRef="USDPShares">6.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">13.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">2054000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">10.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="Shares">432167</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      unitRef="USDPShares">11.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">1572000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">P7Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="Shares">484583</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      unitRef="USDPShares">18.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">14698863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">10027446</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">3.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-01to2023-06-30">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-10-01to2023-06-30">P4Y8M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">3866781</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">13183353</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3988614</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-10-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zgI3VlGVAPqb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zv8vp7cNCaS1" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine months ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3EgG4dK9Elg" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,451,471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zGsdIwacZSAi" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,490,267&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;4,450,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgFyrC2UU8Dg" style="width: 10%; text-align: right" title="Total share based compensation"&gt;4,739,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziqIJKCmfN2c" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,415,310&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyJPbWiK3XRj" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,498,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;8,732,512&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzWtjU5UUJrf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;7,597,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630_zWpMxKskTG58" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,866,781&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630_zHpEy5npSAbk" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,988,614&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20221001__20230630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;13,183,353&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20211001__20220630_zZfYmmpUvYA2" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;12,336,844&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1451471</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1490267</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">4450841</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">4739021</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2415310</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2498347</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">8732512</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">7597823</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">3866781</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3988614</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-06-30"
      decimals="0"
      unitRef="USD">13183353</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-10-012022-06-30"
      decimals="0"
      unitRef="USD">12336844</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">17543748</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-10-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zTjQCcbGHhT3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zhE1fNGURUn" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20221001__20230630_zRkYbWkXv0F5" title="Risk-free interest rate"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20220630_zZKcEMuzyysg" title="Risk-free interest rate"&gt;3.10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230630_zOzHl7m225f5" title="Expected life of options (years)"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20220630_zD85rXlAxpU3" title="Expected life of options (years)"&gt;5.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20221001__20230630_zl1b8e3R3k77" title="Annualized volatility"&gt;85.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20220630_z0xQMxbfgOh8" title="Annualized volatility"&gt;84.12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20221001__20230630_zrEDyY9vZrC9" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20211001__20220630_z1rNoyhBSlh5" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="Pure">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.0310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-10-01to2023-06-30">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-012022-06-30">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="Pure">0.8516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.8412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-01to2023-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -J#"%<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #:@PA7#37EN^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#,9?9?B>R$E@%)/FLK'3!H,5-G8SMMJ:Q7^P-9*^_1RO31G; PQTD?3I
MIT^@7@6A?,3GZ -&,IAN9CNZ)%38LB-1$ !)'='*5&>%R\V]CU923N,!@E0?
M\H#0<GX+%DEJ21(68!56(AMZK82**,G',UZK%1\^XUA@6@&.:-%1@J9N@ W+
MQG":QQZN@ 5&&&WZ+J!>B:7Z)[9T@)V5<S*K:IJF>NJ*+M_0P-O3XTLYMS(N
MD70*\U0R@DX!M^RR^;6[N]\]L*'E;5?Q38Y=RT678_.^>/WA[VK8>FWVYA\[
MOA@<>OCU%\,74$L#!!0    ( -J#"%>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MT^@W+4,+BE96!:4%*$5;-@Z5IUZ!T^=D&@<++K5X>(AAF$WKJFMTM8!H;57
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MWID*&E.F_A]GQ/<B$I+ FXP?#UVR2'HQ\<,H()WD$5ZOP^L-XOT,65>8RFY
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M8Q\^00^PA3%$81P&472NY/>L@0S3!F@ =5YGS2T!KDLB$58"3?JDX()&-*9
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M%<?7/L<#HW;5>XU'98S*JJ];*6)9E #X?:V4.1V4 S0OWV;_ U!+ P04
M" #:@PA7#P*2^W8*   ^4P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;+5<:V_;R!7]*X1:M+O *N*\^$AM XE$HBF:PH@WVP]%/S#2V"8BD5J2LK/_
MOD-)%L69X35'OD6 V))GSES=PSOD.;S4U7-9?:\?I6R\'YMU45]/'IMF^WXV
MJY>/<I/5[\JM+-1?[LMJDS7J9?4PJ[>5S%;[29OUC/I^,-MD>3&YN=J_=UO=
M7)6[9IT7\K;RZMUFDU5_?)3K\OEZ0B8O;WS)'QZ;]HW9S=4V>Y!WLOFZO:W4
MJ]D)995O9%'G9>%5\OYZ\H&\3X7?3MB/^"V7S_79[U[[4;Z5Y??VQ:?5]<1O
M(Y)KN6Q:B$S]>))SN5ZW2"J.WX^@D].:[<3SWU_0T_V'5Q_F6U;+>;G^=[YJ
M'J\GT<1;R?MLMVZ^E,]_E\</)%J\9;FN]_][S\>Q_L1;[NJFW!PGJP@V>7'X
MF?TX)N)L J4#$^AQ M4FL&!@ CM.8/H$,3"!'R=P/:1P8((X3A#:!,(')@3'
M"<$^]X=D[3.]R)KLYJHJG[VJ':W0VE_V=.UGJP3G17MDW365^FNNYC4W\[)8
MJ>-$KKQ/12.K?..I=^IRG:^R1KUYUZ@?ZD!J:J^\]^:/6?$@:R\OU!_*Y??'
M<KV25?U7+_E]ES=_>#]]+;+=*E<3?_:FWM>[A??3GW^^FC4JSG:UV?(8T\=#
M3'0PILVF/"[A_>>SW'R3U7\M,',8YL-*A:*.WFSMW6;Y:JJBGF?;O%&O = %
M#'KWF%72NZW*I92KVOLBES)_RKZM)829P)A?9*.V )7M)*N*O'BH(:P4QOJU
M5)^O/VVF#HG3<4%/QP7=X_ !G(_R(2_:8%3=KK-B*7_QGK+U3GI9X]W)[3N/
M^;]XU*?$1N\!.MA#MUO;TTTH8NI?S9[.V3-',1XQ&OD\ZH]<@*&V>^_[>ILM
MY?5$;:ZUK)[DY.8O?R*!_S<;%^:R4Q*'(A)1P/OKIN90(OR(1,3O1O:RRT[9
M9:[9K=L#JQZ5W@.VZ*>71#P06H;!(!SSML $2S#!4B2P'I/\Q"0'F;P[T);7
M]4X5\$YMII5WEZW56Q\>*KG?.FT4<O/("BC3Z.,&S]2/(U]0C><%&*(K-1>
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MR+\BG>PFK^AN=P[ S<Y4I92RT#<NJ# E]0(5+4%%2['0^K<B.RU/82WOXJO
M4 Z['365,8NC*""ZL8*U8H(%E(X(O<]$)^DI+.DA5P6>ZI)Y)* %%E!"+:*?
M4!:$C&OGOG34T'[VS^[)NVG^\88*M=R2MQ@JU'0&A@P5.%27W)IK#AHJEK&O
M&"JTD^ 4EN!O,%2HY8Z\W5"!8W ]9:"B):AH*19:G\W.$*#.AH"U?\7.IWE[
MWEHMIFW HC .@RC2KXCA:)V9,A>>4BY$P$*S9,RQA%,>DW.#II_D3J136*2/
M;F.Q9]D4N_NJB8C>QP*'X5PUJ'?C4=%2++0^H9U+0&&7X%.1-WFV]MH.O+QI
M30'@,OF(U6_STIDS?8.(<VYTL,!Q.7."=<?='KX8/-ET\IW"\OTET4L]T9 N
MH::(#54L1E\=YDWT!2I:@HJ68J'U2>RD/X6E_^VN6CXJ40)19LIZ=6EC5(DI
MC&D01"R*J5XGJ,K^$C1[G=@_0.B3 6U/.VU/86VO)1FL#U.WM\FV5 BJ<$=%
M2U#14BRT?I=K)]P9+-Q'G4>.&+UF2-UJ89;;U/J@!1R,<XLJEAI' .JGOU/K
M#%;K1OJAZF&6F]6,Z;W8<WA)YZ9B3+0$%2W%0NN3UXE]!HM])&.9F<J?,EW)
M,%-7QW[(]8[D!1RR,UU(%D)J#S\0 R<?=M:F#WL"R,8R,WT"Q44HC-T.MW$?
MMW,?MW7__^$2L,XE8+!+X&(LPU .]B:S*')&(L;TXV!QR9( <T@?(!WS ?J$
M=(X"@QT%R%^&I[H0@ 2TN 0(X,?T0Z8L9"**0]W4&36T3T'G 3#8 QAE,C,K
M0:8A$!$6Z[W@S!35G,9"_3-N),.A.IC,EC6G-*(QI:$(].2:8PD/0L'%6>-'
M/[F=[F>P[A]G,MNS:ZK_-KM^K'=OS>$8G$\?J 8 *EJ*A=9GLS, &&P C.W:
ML_-I6@.1&FJ0:6GO)T&HCMM8?TP2CM:E6LPUIS0D :=AY.O58HXE7)! ^&+H
M(<E.^S-8^X_NZK,GV+0#V@0+IB=N#H?A7#"H?@ J6HJ%UG]6LO,#^"LW\BU=
M:"U][:7UP>7)P*<F,07^'!5M@8J6H**EEZ!!#@3O' @..Q C+%)N]OH37^B6
M'3?=B4@PQHTG]^" '#9!+*#4'KK:(P?D*>\L @Y;! [>*+?<.?=;:]1(-&K+
M/RI:@HJ68J'UR>N\!0Y["Z.\46ZV]NO>#;?UZNM%<8',MA<%$E"* -3/^]D#
M^[#F=S)%N2EU.36Z.N 5G6L&5?6CHJ58:'WN.GN NSP5<+$GRLVG!(CQR#*W
M-/\'$=&?H%O (;O4%M93!/;(*1VX:\T[:X"[/$3P9CN46X2VW]ZPTYE ?:@
M%2U!14NQT/K\=NX$?^6; !SL4!C*P8WCIJ_!HB (C1XJK!43+*!T1.A])CIG
M@</. N2#PE-=,H\$M, "2KC%>""$AG$<ZB[=J*']['>^ X=]A\LMT"/P:Q:H
M9=B0!0J'ZI);<\U!"]0R]A4+5'0>@( ]@#=8H,+L ABP0.$87$\9J&@)*EJ*
MA79@<W;V38+M-TM^SJJ'O*B]M;Q7\/Z[4.6^.GQ9X^%%4V[W7R[XK6R:<K/_
M]5%F*UFU ]3?[\NR>7G1?E_AZ2LS;_X'4$L#!!0    ( -J#"%?5T"':NP4
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M60'XOI'2O+S8!;HKW=5_4$L#!!0    ( -J#"%=<KFVM3@,  !H'   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULC55M;]LV$/Z>7W%0@6(# DN6W::-
M7P#;;;$-:QK46S>@Z >:.DE$)%+C47'<7[\C)2MIX1K]8I/'NX?/O?#1?&_L
M'96(#A[J2M,B*IUKKN.89(FUH)%I4/-);FPM'&]M$5-C460AJ*[B-$E>QK50
M.EK.@^W6+N>F=972>&N!VKH6]K#&RNP7T3@Z&CZJHG3>$"_GC2APB^[OYM;R
M+AY0,E6C)F4T6,P7T6I\O9YZ_^#P2>&>GJS!9[(SYLYO?L\64>()8872>03!
M?_>XP:KR0$SCOQXS&J[T@4_71_1W(7?.92<(-Z;Z1V6N7$2O(L@P%VWE/IK]
M;]CG\\+C25-1^(5][YM$(%MRINZ#F4&M=/<O'OHZ_$Q V@>D@7=W46#Y1CBQ
MG%NS!^N]&<TO0JHAFLDI[9NR=99/%<>YY;HEMA#!&R1I5>-+-8\=(_OS6/8H
MZPXE_0'*:WAOM"L)WNH,LV_C8V8TT$J/M-;I6< _6CV"27():9).SN!-AC0G
M 6_R [P/MA!:?14^O4O8&$VF4IGH!D-G<&N14+O.8')XI[304HD*MFQ$GD)'
M\'FU(V=YCKZ<JE!'8'J:@'];U]0(B8NH\7?9>XR6SY^-7R:S,^E-A_2FY]!_
MNHMG44YSO#$.80RG;G@TKK2XQP?X4^4(6ZE02R2NLFU&\,OS9Z_2-)EU+F$S
MGH&Q%ZY$Z,\VIFZ$/O2'OX(B$""9GI+< 7*L#K!3IBD%OT.)K0MVV44!ZH(=
M,E :/&:&]RPUC6^9[V2F\APM;Q3W,?,>5C0!@F!WN!!-4QV4+H SEBI(38V9
MDIP7. .2 RW?I;D8IB6@ _$T#$EM;K8#Z4P1LCP0/V!70LEJ *VN658U8C8Z
MEDAH41V^LE>!VM1* @^AN,BMJ1\3=I8'C_SU*O/$\X//GC7S#BU=PKY4L@1A
M$5IZ3#L $U>.<U8\K-^CL7X'/\?2[8[%T=A:DR%SX:IX>;SPCZ&W#F5DD&-R
M(_B+,9[T:WPU(ZCX:Q#:85H.7]VL/KW]EWL[OIK.X-1TQT_TJD9;!%5FRASN
M.ND:K(/PKSJ]>W3OOAKOA2V4]A1R#DU&5R\BL)T2=QMGFJ!^.^-82\.R9+IH
MO0.?YX8'O-_X"X;/X?)_4$L#!!0    ( -J#"%?[1N+2IPT  '8D   8
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M=3_F7,+_HI'NLTJC ?!I8H>9< G/1K#T--&>@_9(EJB$!#5<W246)HF#(G'
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M]A_0LR4B6Z,=(;:Y_);>;CH"P4@I&^:<>$J(KLJ@S#U/0]IX$+#$=:+1KH'
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MG^0Y_[_D&8G3Z5F\$8-<A"XJ-%B]T[>5HO*46O'0#)JFRW[9&M6OI'1!H\1
MV5M&Y$UL'BKE5R;,H4ZO#IX5$+*;\Y:;?I'K;E3'=+5!MX"-<:I+X$6P2$:J
M+9.O!2L "/-X+3@:LBTZMFG5=TX-M;&E4C=><W;E\8 ^#P@/<S)7N43&HEW
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MT8J:+H5*H;3J&HK&/W7^=F-8%6$4X#SL]?W5=LJ.NB#".$C:NIT <1L@/B^
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M[I&0)2OSA&Y4PK(-5=U8(I*MC../<DLYDEN2(3/HZSO%1'>2IN+OCAMZ6U[
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M3A^C*HN6IIAHD>5MQ%QH;$KR88QM($BS =\OA=#W$].95(UE^ =02P,$%
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M>A.+67O^!-P"9[_&B!'"Q @!QPAG+-9ZUM,[8LZZ6 Q7[&S3&.E!F/0@X/2
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MSZ5#8QA'V M<;Z8=&L,H6$2QAV?B89],1PVP;3>6<IG:OA7]6_*X.XZ^5]W
M-]N_=B_7KF8_5:-R-XT]X_LY^X:P;=5R5,-&AG(N(BEUK!]=^X6@NVXV>Z!"
M3GK=82G'?6#*0)[?4"J>%BK ^ ="\A502P,$%     @ VH,(5^O6I,/0 @
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MP#55CWS["0[^# Q?QJFT_VCK; >1A[):*EX>P%I!29C[XMTA#B> :' %$!T
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M/VC-@M;Q@S8L:!,_:,N"MO&#,A:4Q0_:L:!=_* ]"]K'#SJPH$/\($BYC*F
MI 76 K0&SC4(\!HXV"! ;.!D@P"S@:,- M0&SC8(<!LXW"! ;N!T@P"[@>,-
M O1&KC<*T!NYWBA ;UQ\; O0&[G>*$!OY'JC +V1ZXWOU-N'1TM^[GFN^?GO
MI#J,S])\_+1\;BY>J EGS7[13[]02P,$%     @ VH,(5RO0<HYR 0  GQ
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M<' N>&UL4$L! A0#%     @ VH,(5PTUY;OM    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ VH,(5YE<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #:@PA7U3CMA_@%  "-(   &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ VH,(5QK/DB"^
M!   QA   !@              ("!.@X  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( -J#"%=43JQHS (  *,(   8              "
M@2X3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #:@PA7
M1A-&A@P&  "(&P  &               @($P%@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ VH,(5P\"DOMV"@  /E,  !@
M     ("!<AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M -J#"%?5T"':NP4  -X5   8              " @1XG  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #:@PA77*YMK4X#   :!P  &
M            @($/+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ VH,(5_M&XM*G#0  =B0  !@              ("!DS   'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -J#"%?Q-I[.1P0  ,X)
M   8              " @7 ^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #:@PA7(86.Z.<"  !R!@  &0              @('M0@
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -J#"%=&]UZY
M608  !$/   9              " @0M&  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ VH,(5P\^Z&?0"P  O1T  !D
M ("!FTP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #:
M@PA78] ;2"P.   Y*   &0              @(&B6   >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -J#"%?*<BF&SP(  # &   9
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M970Q."YX;6Q02P$"% ,4    " #:@PA7]T 6T$T&  !**P  &0
M    @(&$>@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M -J#"%<BQV1NZ@(  &0*   9              " @0B!  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ VH,(5YDZ[Z"9!   CQ,  !D
M             ("!*80  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #:@PA7V/KA< 8(  !11@  &0              @('YB   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -J#"%>D3P<OC0,
M $P0   9              " @3:1  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ VH,(5^O6I,/0 @  \0<  !D              ("!
M^I0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #:@PA7
M"/'6!W0&  !>+   &0              @($!F   >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( -J#"%=1#*BN, ,  .X2   -
M      "  :R>  !X;"]S='EL97,N>&UL4$L! A0#%     @ VH,(5Y>*NQS
M    $P(   L              ( !!Z(  %]R96QS+RYR96QS4$L! A0#%
M  @ VH,(5_I;6]6N @  <!$   \              ( !\*(  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( -J#"%=^V5 B/ $  +(/   :
M  "  <NE  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M -J#"%<KT'*.<@$  )\0   3              "  3^G  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     A "$ W@@  .*H      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>91</ContextCount>
  <ElementCount>182</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Interim Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescription</Role>
      <ShortName>Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BasisOfPresentationPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e4887_10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e4887_10-q.htm">e4887_10-q.htm</File>
    <File>avxl-20230630.xsd</File>
    <File>avxl-20230630_cal.xml</File>
    <File>avxl-20230630_def.xml</File>
    <File>avxl-20230630_lab.xml</File>
    <File>avxl-20230630_pre.xml</File>
    <File>e4887_ex31-1.htm</File>
    <File>e4887_ex31-2.htm</File>
    <File>e4887_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="370">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e4887_10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 370,
    "http://xbrl.sec.gov/dei/2023": 31
   },
   "contextCount": 91,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "e4887_10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 289,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20230630": 25,
    "http://fasb.org/us-gaap/2023": 33,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 63
   },
   "keyCustom": 43,
   "keyStandard": 139,
   "memberCustom": 17,
   "memberStandard": 8,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://anavex.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Equity Offerings",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://anavex.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "13",
     "role": "http://anavex.com/role/BasisOfPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "14",
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Basis of Presentation (Details Narrative)",
     "menuCat": "Details",
     "order": "16",
     "role": "http://anavex.com/role/BasisOfPresentationDetailsNarrative",
     "shortName": "Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Other Income (Details Narrative)",
     "menuCat": "Details",
     "order": "17",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Accrued liabilities (Details)",
     "menuCat": "Details",
     "order": "18",
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Equity Offerings (Details Narrative)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:SalesOfAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://anavex.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2022-09-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details 1)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_StockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details 2)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-012023-06-30_us-gaap_StockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments and Contingencies (Details 3)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments and Contingencies (Details 4)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeaseObligationsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeaseObligationsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://anavex.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Interim Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Interim Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": "0",
      "lang": null,
      "name": "avxl:NoncashFinancingRelatedCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://anavex.com/role/BusinessDescription",
     "shortName": "Business Description",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://anavex.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e4887_10-q.htm",
      "contextRef": "From2022-10-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 25,
   "tag": {
    "avxl_AccruedClinicalSiteAndPatientVisitsCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical site and patient visits costs"
       }
      }
     },
     "localname": "AccruedClinicalSiteAndPatientVisitsCosts",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_AnavexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anavex [Member]"
       }
      }
     },
     "localname": "AnavexMember",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "localname": "CommitmentSharesShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_DeferredGrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredGrantIncome",
        "verboseLabel": "Deferred grant income"
       }
      }
     },
     "localname": "DeferredGrantIncome",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://anavex.com/20230630",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20230630",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_EquityOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "EquityOfferingTextBlock",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_FairValueOfInitialCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the initial commitment"
       }
      }
     },
     "localname": "FairValueOfInitialCommitment",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_FixedContractAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "localname": "FixedContractAccruals",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncreaseDecreaseInDeferredGrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantIncome",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncurredExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred expenses"
       }
      }
     },
     "localname": "IncurredExpenses",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_InitialCommitmentShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Commitment shares"
       }
      }
     },
     "localname": "InitialCommitmentShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_InitialCommitmentSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares, shares"
       }
      }
     },
     "localname": "InitialCommitmentSharesShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_LessShareIssueCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: share issue costs"
       }
      }
     },
     "localname": "LessShareIssueCosts",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund L L C [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_LliquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "LliquidityPolicyTextBlock",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_MichaelJFoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox [Member]"
       }
      }
     },
     "localname": "MichaelJFoxMember",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_MilestoneBasedContractAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone based contract accruals"
       }
      }
     },
     "localname": "MilestoneBasedContractAccruals",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "NetLossPerShareBasicAndDiluted",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonOperatingIncomeFromGrant",
        "verboseLabel": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrants",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NoncashFinancingRelatedCharges": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing related charges"
       }
      }
     },
     "localname": "NoncashFinancingRelatedCharges",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "localname": "OptionIssued",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionPrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "localname": "OptionPrice1Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "localname": "OptionPrice2Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "localname": "OptionPrice3Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "localname": "OptionPrice4Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OptionPrice5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "localname": "OptionPrice5Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherFinancingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financing expense"
       }
      }
     },
     "localname": "OtherFinancingExpense",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 1 [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesOfAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "localname": "SalesOfAgreementAmount",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareProceedsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Proceeds Receivable [Member]"
       }
      }
     },
     "localname": "ShareProceedsReceivableMember",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options, shares"
       }
      }
     },
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUnder2023PurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2023 purchase agreement"
       }
      }
     },
     "localname": "SharesIssuedUnder2023PurchaseAgreement",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedUnderSalesAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, shares"
       }
      }
     },
     "localname": "SharesIssuedUnderSalesAgreementInShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedUponExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon exercise of stock options"
       }
      }
     },
     "localname": "SharesIssuedUponExerciseOfStockOptions",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedUponExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued upon exercise of stock options, shares"
       }
      }
     },
     "localname": "SharesIssuedUponExerciseOfStockOptionsShares",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SoldForGrossProceedsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sold for gross proceeds amount"
       }
      }
     },
     "localname": "SoldForGrossProceedsAmount",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2022Member",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise"
       }
      }
     },
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://anavex.com/20230630",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r318",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r295"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities - Note 4",
        "verboseLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r229",
      "r332",
      "r333",
      "r334",
      "r368",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r29",
      "r30",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r158",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r66",
      "r78",
      "r86",
      "r102",
      "r104",
      "r106",
      "r108",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r170",
      "r172",
      "r182",
      "r210",
      "r253",
      "r295",
      "r306",
      "r338",
      "r339",
      "r373"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r17",
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Incurred office lease expense"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r16",
      "r77",
      "r290"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r16",
      "r54",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r54"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r37",
      "r211",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r332",
      "r333",
      "r368",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r41",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r41",
      "r241",
      "r259",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r41",
      "r213",
      "r295"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 81,390,916 common shares (September 30, 2022 - 77,942,815)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r64",
      "r165",
      "r168",
      "r331"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred grant income - Note 3"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r284",
      "r285",
      "r286",
      "r287",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r231",
      "r232",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r284",
      "r285",
      "r286",
      "r287",
      "r291",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r19",
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r5",
      "r75",
      "r81",
      "r82",
      "r83",
      "r87",
      "r88",
      "r89",
      "r91",
      "r96",
      "r98",
      "r101",
      "r109",
      "r110",
      "r127",
      "r159",
      "r160",
      "r161",
      "r166",
      "r167",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r218",
      "r219",
      "r220",
      "r229",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r277"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.",
        "label": "Foreign exchange (loss) gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52",
      "r263"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r49",
      "r68",
      "r102",
      "r103",
      "r105",
      "r107",
      "r209",
      "r216",
      "r294"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r112",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r36",
      "r328"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r86",
      "r108",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r171",
      "r172",
      "r173",
      "r182",
      "r239",
      "r293",
      "r306",
      "r338",
      "r373",
      "r374"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r67",
      "r215",
      "r295",
      "r330",
      "r335",
      "r370"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r50",
      "r56",
      "r69",
      "r76",
      "r79",
      "r80",
      "r83",
      "r86",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r105",
      "r107",
      "r108",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r181",
      "r182",
      "r217",
      "r261",
      "r278",
      "r279",
      "r294",
      "r304",
      "r338"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r102",
      "r103",
      "r105",
      "r107",
      "r294"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r39",
      "r65",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BusinessDescription"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "All other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Contribution amount"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r40",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r40",
      "r212",
      "r295"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r2",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r8"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r128",
      "r194",
      "r195",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r258",
      "r260",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r128",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r258",
      "r260",
      "r283",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r38",
      "r163",
      "r375"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r60",
      "r214",
      "r221",
      "r222",
      "r228",
      "r242",
      "r295"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r75",
      "r87",
      "r88",
      "r89",
      "r91",
      "r96",
      "r98",
      "r109",
      "r110",
      "r159",
      "r160",
      "r161",
      "r166",
      "r167",
      "r174",
      "r176",
      "r177",
      "r179",
      "r180",
      "r218",
      "r220",
      "r229",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Number of common stock sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r6",
      "r7",
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value of options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Option available issue"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of outstanding options",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at beginning",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of exercise prices, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r5",
      "r14",
      "r75",
      "r81",
      "r82",
      "r83",
      "r87",
      "r88",
      "r89",
      "r91",
      "r96",
      "r98",
      "r101",
      "r109",
      "r110",
      "r127",
      "r159",
      "r160",
      "r161",
      "r166",
      "r167",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r218",
      "r219",
      "r220",
      "r229",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r101",
      "r196",
      "r225",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r280",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r101",
      "r196",
      "r225",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r280",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r40",
      "r41",
      "r60",
      "r226",
      "r280",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Share issued for offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r40",
      "r41",
      "r60",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r5",
      "r40",
      "r41",
      "r60",
      "r227",
      "r280",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Purchase shares, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r5",
      "r40",
      "r41",
      "r60",
      "r229",
      "r280",
      "r289",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r58",
      "r243",
      "r259",
      "r281",
      "r282",
      "r295",
      "r306",
      "r330",
      "r335",
      "r370",
      "r377"
     ],
     "calculation": {
      "http://anavex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BalanceSheets",
      "http://anavex.com/role/InterimConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r71",
      "r72",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://anavex.com/role/InterimConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r307": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r308": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r309": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r311": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r312": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r313": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r314": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r315": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r316": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r317": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r318": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r319": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r321": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r322": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r323": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r324": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r325": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r326": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001731122-23-001412-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-23-001412-xbrl.zip
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M!8P8K1I6^3]?GZH_ZKSR'9Y8^ISSF3I<>]&09+Z@ZE2R3IL)/+EHJ/.US?
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MDE>W\7 2!7%2D(IRZ^IY^IOZT1N),253M;M\X.$T' (SD*LK8ZFW+EG;P??
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M#,G@3*KMZL-_8.0&\PODXY$_0Y[S5YR,N<+>$M\3MBS )3?JR[?0X1FYLBQ
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M+=O6G:-7R@.%F)!.S=NZ"V,R\II3)C /KR$\C$^_BTAF'8ACYS:*&1 @UQ1
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MU*D&%'0>?\__X7:7??/_4$L#!!0    ( -J#"%=KH K/US8  - 9 P 5
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M( ?99T%?)B F2($IV-#*LB!-7AAQ0BP3ANE%%J.G?T//RG()<FXYH8#9)\5
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M]&CA=9!N552Q49['LGSGA#T1_X45H>@+.Z8:8O=X65&4/>9JR6>,A_S5F2J
M&5C0D6#%'.\#P#,XJ",M^E_A;ZOE;+U)\V=4/^HLKZ5%RF"P2S/5@\]_HIB'
M(V'AV>S[U>3Y^>EN,U6;O!=.G%F G7.>$NI&N17*$(8I6P*",;V,3 ^BL(=-
M>H]+T!U:4CT/U4L3CRC--ZR#UU(!]>6VVBHKM* .0-?$T=557I=%L5WSWW8>
M&%^2B>]!\N459!HP=\\AP/XY8;%TG?(K2E8/= T+/I+.N4( MHFQ( )+ND7
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M/O;W[-4@'CFW'ZR^ .J\"*;\@NI /WV 7W4G&T_3X>&Y96^1[4E<=3'O,1
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M9=6;&M0'>"'@CC(&H$Z-KH;+!=QB,+,KF+.3?Q6FIXGG:'_96<1'FA)4B?K
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M0N[JC6^-3XG"F2]LGQT$SA' .;L4SKFU%XK=SKN;JX8%Y=N[FTKU J.7 )4
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M6]!(9%,G5HDCO+PI)XN42]P5.5R.9AB__!41)#LL2/),"@1)8&6*:U3Y'QJ
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MHI_5A+I@<N __WO$YL;,WO!L2: MN\DZ;(5IS]M2FVL1VBM3MD-F_FB5629
MV U@2Z@9EIJA#TL0P;=%#*51[MEI$$+<6(A[*^CVG*U(_VI$3C]%?<DW$_59
M'NWPQ'PB7?#$EYM:=/^,2L\<L9<)HC.]$W0<X)D)$O3&3GA++-OK"_N?ON-V
MIQ=-DX   53BXE 4![V!(EC5N&D%R 5JRZ)LKHX.8I&$7,:]-BO. PO;^6I3
MQ.DK)LNPS:;U4YYG/*?/O-D/.ZC5E!O-T45C4/MR_M)[:?&)GR]S\B-9G%&.
MM*I=$501T?94RGU=5BC63NX%&'3.1+CU<\@A:LS<;- _?N&[2,O)7%"4BM[C
MAW,57)C_?I@)&P5=F+]0Y"_%NX%AU/GN$67*)E[7.0(YA..D@"2;1<ZYO]DB
M@_P_O@FA2(O=W-;E<V29KF0K&S=MNQ"3S_#C"'MS;L5K5;9Y"N<Y/D?S);_R
MS$6(30!,N[Y%@KJ+; -J<R(X5JS-7PS,K%+23B#V?B"V,)6Z_N7I>;K %>@<
M$6N[CCGOUS(&$C/R6Z8K2V"MG5!@:7#R6TM7&([+8GH4.9:;$(3P>7?XO.26
MES6%BW^2?./[7[@"2^>S'%TH!I\%2 !V0=W:".*2UF;KW\N=H]E\CF9\;Y3?
MIOSR/\)>FQQAMQV(NF$,D/0 SK..J7$[T,6N8*!R1T>6]]:4F_T^TV<2O#PA
MKA/K]H+MZ<C6LH&9L&Z[=+?OK)P2W*4'\&]YPCJR+1JB=B<.A1>FP#+Q<1-;
M+F$H82AA*&$H82AA*&$H:585=:"##QOH2-X[.)_-^=TAURR6+@8Z&.VW\$9-
MLHJ<-O ,UDW]>=I:1>,2N.Z./;SA5,CM"<(GJ;RY7&X 7VT/*;[$7JOV,F2_
M73V77L=Y/9<##O'GLGJ)A@L6DB5<(ZR8LGPLS>08FF%"AZN(V$]*[*\-*TN*
M)H2J^< 5!A0!T[L&4RR9NR*=XWDZF_>[)X6 :R<,U&(*#%3"N74X5R*<2QGG
MDA#HFXCJ+)UC4R&JE[9<QJ:/;&+'PW%3$LI,1>YT3A:RYVXG&\R\N#W-@8ZJ
M;'TD_7@2QJ[F9 [;<C:M)HG^I-BJ=YFEN7SH.BNB.[:J.WPQM"TO,G31 P%-
M0J!9=!WAAJB)R%T,*,E*'DJSU5<$12L['-D\<3AVE',%PKD=Y5P:PC/^WAKC
M7UUX.]"-@:":]UKU#>FB;*";MF5\W/2QH#>:H^KEE\YMKC"L_>&V<U-=@C6'
M?8<:N'\U<NAA76.'*4)I-DGV9IM,O,& TM-EX(C;4^S)C\7OMYV*P(AC3]$>
M<R6&;<>77)V0V\UB,BQL4))V2IWJB09A6\ME,BR!%(%4;&<1\T6:94L$8FF#
M6$B#.9>&@CO"N74XER.<2QGGDA3KFPALCDN%F>GO)Y<\]9AEZ2]X1=:= _=:
M@/ZR2-O"&6+LV2#5$/!#=PB<'4,V$0S_(HO(SAO?(5'KJ-9;-BW33=T!/HP@
M>S86,2C10PVR9X.'F9:@1'2F6NGE&:+T4L:YA44\<0OP-+A /%W,Y^E"D?C9
MJ<-F6*G"$:FRHYSC">=2QKD=T =[(>D#LXQC[^D:F745W !TI1F;5(2NDT)D
MD_%Z8(GV7!188@ 3$K[R>HN7>R=WS_5BMXG<;[ZW]YN'U<MA:Y\(5-X]5,(6
M6Q&HO'NHA*WN(E#95Z@LZ:0Y9?*N&!R*J9TFR])<H427"J$;1,>+WJ"^F@2X
M.P;</4>F_VT<M35NXZ@V1YW2=_UWL?7V2T!QYOJX3[EIOS>.BS>^#E1$\<S"
MBS=F&65-+$FOUQHPP0LYF,47<OA?XA))C2QZ&OZN\#_YPMOD0HZJ-6S@;1R^
M4L?&CJ0-6@I*X2T=,5:^%EF:+S%TB5U;#B6#MFWMK17A$DN3ZC1!-G3SZG@J
M:BVXA@X!$Z@2J*X*U7@J=;D2G2OEZ%*>8)=@=Y6P2R%LC3#!RU[C););3)((
MNW!%CBYQ'%W(I<:J#!MY(<A-LY9>_S:4/( Q"SHX-8!<4E602*' I#P:SWN^
M.W<T$132</T]-%PG#"4,)0PE#"4,W?9R"4,)0PE#4\!0_RQJUDJ'<>-T&!<B
MB]IHCO3RZV.!_3W\SB@)GIB,(X=:[NNR0K%6#I7;FV+^J7Y"B]*A#5_^1Y(.
MO1Y>//[06^=7M4ESV7/4D55U448T7>E.+J*+XOW3G84"S>99.E\D764WCB*E
M+$04%7#F@D<69GB"ESW'2SSG4PLLG>4+=#Y\?04!4/P BB:;XB+([A[8M'3,
MK:Z)"$G&'1*1_"*T%!15&V*&I_/AP]>Q)4X(@*('4-SI.+9(EY@\S60Y I]4
MP"=*]*R=$\MQ-,?D !4I/E);G'6,[39.<_?1W)A=<(#D6WZ!YS5BOK(&>U'Z
M,VKO?S-?F#C2J8:@P/?*'1U9'N4.[L5ESG;9OWGO UZ^M?KQXNNJ>SV/%R5+
M,16;LW[Q(A0ZQBO//O,!_7U]>;C]?KX+:.M[>((;'Y[@8BUESN7 42NDXLZH
M7=Y;VU!VBW9@0IB:TX\ )P*E=PVE6"(">9!119KE"+C>)[BB#1:D(T9 D+4$
M6=ZO+2CV+K&DHU;*.)>$3%A?E>2*',T74]Q0V..>72'#ONK#(EA%,TS+%5O5
M>QNUF%^_RE]KMU_N"@G>L!J7ZXZI<N*Y;M7V_0 V0!ZR+==K@46D8]KT&KF-
M+V6<6W0;IX^@WH[C%-0ZHYBC^? '*=]U*B-M@B -5P02SJW#N1+A7+HX%XL(
MWQ/A[.^,G*]Y"ZC'2_%S8D:UUB\N?Z\9(SV[]WG%]WI)*+?Q):&Q)!&%T>OS
M[=^K^V]7?]_M):%)Y1<YCJ<+#"D$39LBC//JKP3RC!R7)9 BD(HKWYAC>9K)
MID1J>5]##KCM_ $W(C-6]Z1YAMP=FC;.)2GM-Y'C7#X552.!J;[D[@X=W5WJ
M9AX-^4MF'9^;7""Z%QN7I %3P8:PFH\E%XBFC7/INS N8?>(ITO%(IUGB0^>
M.FR&E2KD M%=Y1RY0#1MG-L!?; 7DM[?A:H$7B ZNNNJE5SI\H+O/Y%;1,DM
MHG'[3N02MWV]"RNT<B:WB!*HA(0*N4640"4D5,@MHN\=*AM?QA@<(8KK%E&.
MYO,%F@_?*(7<(DJ FTBU;:J1Z=__EENC_VVU.7HRVG^E[ ]Q^%K<JUM$9SO@
M!C%J[V\1Y<+<(AI+$>U;Y97[VOI9_WXG[^TMHO&6QA8*="G+T;E\Z+:ZY+HR
M<NE3B 9W\93<6G -'0<F4"50716J\>2JBRQ=XCF:X4L$NP2[*X1=N.R:81>"
ME[W"2V1MBQ.Y191G::[ TWPQ].D%<HOHOB(W2N"NWS&9H0M\GLXSP1V79E>7
M:0L]61F>+%U?U( .._"BXH1C$_>D@Y_Q?S_W5^7:*=43](X,<V0FX_3/UGV9
M=]$B>/9(=P?(F%H?!AG_ZE)K/&P#(:HLXJ)J01UBO_Y:,V$H4Z,J&H[OX)+K
M.GZCW,-_L4*'@@E_K,DJ^/^RH!P>C ,,QB:+"*;(?S(9& XIT@EU*W1@\S30
M\P"I(CJA"J>452 #0U"9C"L-)/EE\5:<!$&]9&(YC* 92N4M<66Q&VBK* [N
MK$V ?P=TB.[O*Z_Y59;,+GZ4^0</H@<5V;A,G7[>0Q>7(J?4_; /U"CK0DL6
M3ZEK$ 8VU:XU3*""]TO'[K?P)Q. N^#^? QT]"%I']Z6:>E(>,JT$,@+&$!0
M7H6A,4W-O \Q,8532DT7<PNIX"4>)JJ-N:CQ/B&/EQRSY'(&]"SBE'+0+FJ*
M(O0-8(S[$P[P+K@\&1AF/R'-K .G"RKP4$N7:>H+4EX0_AZL05"-S +I,\V*
M-15;ZZRL"B_H[?#@2FXCJB'*&*P&R"&]_^GS<>O,1S8GM\A-UC66K8<'OL)U
M(E%Q0X)*5U [N&^!2GG5^?]1MD+?:4K4-/WPP.PB"NQC1/7@JUV#0D =:2H7
MP%."*CE)@1U>[8<'51A(,K#X8] ZHK<L J5+I,(W4/3,"(.UKW&/[62:5_+#
M/YY?0U0M3W_9[SG'NE_^H-\+-YO-.+5XG@V;#EJ4#6*>C,)7Z<O;TT7!MQV*
MNS^VN]3"RDM=&))LCG+9*OH]%.K]>C?%RZZMO&S_X$1S5/[;ROVXJ/P1F7:*
MUYMOCJ3S]I/209W'+\7()[I4J]B":OUR<==2"I5*#^>RGE+>'@?VFUKC5;7"
M>M)6X8/UIE>$91=>JR(E,JL),4'HXS__>\2RBU/+GH*6N3F'5-^;K,,6D[9=
M%KP:[V#+)^B[0\8$X8\6,B[V%:^#IVV!)Z6T\I;_$/&R5?'"IUJZV%4DA+BQ
M$/=6T.TY6Q%$0N18B#RQK>VI8PL;Y!'EV-B$ZO%0710'O8&"8TGVW"]06Q9E
MDY [%G+?:WY0]B_R/;>K-5G&J=;D0Q3Y-IJC&^&9+71_WG<[0N*==)WX30Y'
MF&.K_+T130W<3XI=6/OK3(5;/ZH<(H7LQJO^B;V\8U+CRRZN\6WXHB:2&M^*
M_#RHO:"7WT9K-JF0_R?!1'788MU2[,6Z1387MJPB.:CL^@8(JI78!M1"UT1$
M@K4-BVP)Q-X/Q&(JC@6\%?)TL1CZ+!3!7"HQ%UF18BF)(L5LCL[E>;H0OD@Q
M#@8%%282Q"4MY=8N+@23+%MB:2;+I4Q^^?<JJOE?B&%=W8A-]]N!+G8% XUO
M<&R.1M]N])SQXPO[$/O-C0DT+O*Y'&6 %V\7<O2=Y5."NW[2=6SC84CO-\(%
MP@7"!<(%PH7D+1YF8O'4<==*0<&Q$MEJB.E>3EW^=:^]%>\NA40#V)Y[JJ.Q
M;9SUV:-/5NET0=@;Q$X"T^6EO'4X[+D+, @$L<6P)6-HY'/EIU%-&/>I<":!
M+PR89M)VKG1;2+R IC@L8S?%X>-M49&CF07GMHB,WXZ,7QU+":%H/IX=.EU"
MP+,OX(DE4EW,9NDL1]"4.C1YO[:@F4*6M*U/&^<BE0.F-I$$F^SQ7#K,#7]G
M)CM;C'.'W)"E=#'0P<6P>_0[UVV)/]#MGZ=B=U2.M?M>+,Z,&XFVA]];%X8+
MR=&XO91>J=OAO_]^YK/<V$MQ6; MWV0JE;.0+EOU47B:Y8B;LCL:)@RL%MUL
M$KO/8@&*@.E=@RD6'X;+T_DB3Q=+H9/5!%TI<V-RY#;&M'$N/KD0A4]C[?D"
MS; IOH2X.HGCSR=G7K\]_'PM:J4?0V67DS.3A>VY1\,',S-F)Z8O26/?92[]
MM9W,2@I3*BQ/\]G0';^)&ME^-"PMN10V=+$L04U"J FHNHX"-A%Y($%WH"2/
MI=EJ:P*CU;V/L'?&$0&0-LZ%O<(M>>N_[%^3?CO0C8&@FO=:]0WIHFR@F[:E
MQ&[Z6%R 9U"O%KC1%U3]DM_/PO2^0P'<\18Y-, ]%PU,!4JSR; W6V/B0136
M T3<*1(^V[FXJQK"37V2(K''7(EAVW%$5B?D5IT4CL_2A1RQ-U.G;J)!V+8\
M&( 5@12!5%SYE1)3H+,<D5JI@UA((SF?38&13#B7K'"((LF"-WX^E^(,B[=P
MK"S]!>O:ZN!^KP7(08NX+9RPPA8R4@T!/W2'P&@VP&^"X5]D$=EIK#LD:AW5
M>HM3=W9[<9=OU5MHT&(3;P@5KY.&,67/QB(./L QI@[9Q<'#3,M4(DS3K09+
M1 VFC',+:PSB%NAI,*U9GF:+/,V3F$#ZP!E2K!18(E92QKG4BI4HC/)TB0Q_
MN[S@L<NOD5E7P:!$5YIA-$=/WZ4!I_SF%3G6PQO^+=HCMYQA<?9<%%A< /G#
M->>/;+<N;;L?WQ9>UB@X*=-[BR1(F-FK4'P?^!Y:*8<->1&HO'NHY A4WCE4
MEC3YG+)@5O0:8^KTR1?  "S2I<+:MY%'B]ZP=Y$3X*82N.OY)3N)3?\K(FIK
M7!%1;8Z^JK^>6M_^W%7+[80R O:5]A[/)HZ+(::N@0W),VMB2?HUX6^?CZ9\
MJ[KXNHAJ?!5:^>_?A)L[?O16Z(PKM*K6L  JFV^SQ5?^=[!;V)&T04M!:;ME
M(MZZJR)+\R6&+K'Y=452,FC;UMY:$2ZQ---.$V3#-=F.K9[+@FOHFP,(5 E4
M5X5J+,FL+%>B<Z4<7<H3[!+LAO!/U@1O7+=G%#FZQ'%T(9<:*R&L6TV0FV:I
MN_XM''D 8Q9D:FH N20#&%\^;Z82+AJOER32(QJ&E#,0+A N$"X0+A N)%YM
MQ-NA5W8<>N7"W>_\(U^OZG<75_4W>3OE_/'?Z<SN#88G<?A\F&N;9\$021S>
M+&3_9/MO+Z7K[C@.?XXZLJHN"L6G*\[.QGN;<XXNL44ZFR=]/C=V=U/FRT8%
M')^K+.@21YH,[SM>XKEG.5ND>:Y(,Z3S6YH %$W8=Q9!,85]V5*!SA5S=#&?
M?!.%7>S=M5OR9^W8:XZABV#*L$PJ6FOX'[/(SSHY]K'QN6:\-V87VZ^RJ/YZ
M^?;]_O%I'8=G!SI+V5<>-P0%OE?>NZN.ITJ1 J^[ME8_7GQ=];2/BL4IZN?X
MK[<WVIOYT EH'^7+E>VWBUI +=]2279<X\O%V\B6SG,\G<N'SOD0BR85YPJ7
M"N"$4#6ORC"@")C>-9CBN7>#H4M%ALZ16UW2AR[OUQ8<?BJ%/?Q$.+=/<F&C
M'<_1;#K"+?Y.46YB'%\AP^[Z:5&LHAFFT1QUOOVY:GV7AT6UM)V+-^)RB/!J
M3SRW<-CV-^ !EDWV&VGBE&HVA%18689<%)4RSBVZJ\%' &_'< V(_1; TV;S
MR3<XW,6X;]H$ 4<$0;HX%XL@V),M'M@FR3>.V]?4@,LAY%M^H7'[_+UZ67[[
MG2_D^ 1#_/$%]($2[^J."'951#CA?0\N0B(IMH3 S77K26S?5QZ_HJ"$P$*N
MIB SL(3:6TT/@ 5,Y_A4]&3>Y2V7/FQM*SV094*?UB1@VE,PQ=/;EF:8$ETH
ME@B\T@:OL#X6N1<O;9Q+1C!LL.59AF9+J2CG]?>Y^$2OC+A_D[]KM5^UKM8A
M5T:0_4NR#>E@0U@%R)(@8]HXE[[>[DF;U1S-\WFZF$U%83(!YSIB)6QW:L(Y
M(E8V-\I3)3#\K?*+X LCC&_?])_/E3YC2.3"B#CV*KDP@K1VW]L.V:%5<MA0
M%X'*NX=*D4#EG4-EX[[[P3YC7!=&\'2^6*!S;.AL#+DP@@ WB0*M="/3O^-4
M>8V.4]7FZ%>I4RR@1ZW72*KC5.+717 A>;;WUT5DPUP7$4L!UI>+4N7R\E*Z
MD+F]O2XBWAJK0H$N93DZEP]]S(GT,2?=H)=U)(FM@LN":^C@'H$J@>JJ4(VG
M>5>1I4L\1S/\VI8?P>Y>83>:OF$)>=0<S])<@:?YXMKWW)'K(O8%N5$"=Y.6
M904^3^>9X/*[V=5EVD)/5H8G2]<7-:###KPH@WAL"L!&^-G^[^?^JGP[I7J"
MWI%AELQDI/[9NB_S+EL$7PWI[@ 94^O#(.-?77K!L V$J+*(J^<$=8A]M&O-
MA$%,C:IHV%?'M75U_"ZYA_]B183 -90.#VJR"LZ<+"C4V%DT-IE^I+3PO&S\
MFO]D,E1-1HIT0MT*'=A_#?0\0."/GE#%4\K*A,/+J4S&%2B2_+)X-T]"9%XZ
MLQP&X0RI\Y;$LQ #S%$4![K6/L*_ \!$]_>55_LJ2V87/\K\@P?1@Y+I+BJF
MG_?0Q:7(*74_[ ,URKK0DL53ZAKDB4VU:PT3J.C]TK'[+?S)9(^X^^/S,=#1
MAZ1]>%NFI2/A*=-"(')@ $%Y%8;&-#7S/L3$%$XI-5WH+J2"EWB8J#;FHMXV
M$_)XR3%++F= SR).*0?MHJ8H0M\ QK@_X9C?@HMV@&'V$]+,.G PN0(/M729
MIKX@Y07A[\$:!-7(+!!?TZQ84S>VSLJJ\(+>#@^NY#:B&J*,P6J .-/[GSX?
MM\Y\Q'MRB]QD76,1?7C@)Z,]@AD?<ZP(1I>J*=JKL=.+KFGZX8'91118TXCJ
MP5>[!H6 $-+TQ<&4H$I.2'B'5_OA014&X/TBZ6/0.J;LD$A$2* @621GW=@S
MSU2:+,LU1U>]+O_W)WK5*CD0,X,>##.T'CF9 )/*++$S C%,>2BSAI /%'$S
M0B?QJ\665GYY-<PT0#.O"'L1>%:*-/7@W"SF'O>SFF=&&N>?2K6FSUW3HXO'
M7X_/Q<'S\\O?HY#CN/LCY)J63W+AHE=88;'IDQX9Y1NY1T:ZUKF_@N_Q\,7+
M63S\4J%D0VW]6D)7IT:8AUNU!N24\H%I#&$ V(+XS_\>\8M33)X<=TB@KCG9
M%2ZRCZOB8 V:1$L +C"QO3'@_45H4H!/B%L1<F-_E^%?WEV9+N_&1L2MKKW(
M8#.>#Q_ ]*BK-WVD"R:@JBR:\HMLRL@ ,P3^,("_.1^"65)N&28.:C7E\^9(
M?^24[MOP-<<DV<HQ@2IQ3"![,K:I-<#6F:Q28R)1$RJ10QT;#T..UNPC%Y:?
M_YX^:2*#K=D3*J."4&B.GG(_GJ_$WD_6+"332,MQ>G+Y?U)P L693/&?I S&
MF2"8W[@)I(S<X;GEXV^Y#).SRS!-;9U;QH,*,0LTGRO2I4+H?&9"[ I*:XY1
MFA D$\5?BL"6AIK?.-@0ID5CUK]=R+6FBF"CU4W4,^XU?)Y3%64%3='R7@MI
MYTYL6H8%J]9DS#\_R^CU[^W?_;)J/?2SYV1JE.Z2CE*1::DD_%?\,Z;OV/#5
MQ@[ ";&T4F=I$2ZD@0O^ JPTZ2CJ""VG;D#MW"$%1_@K74'OX!ZB##>Q?U__
M*L^/5?GGWS]BW/9O E<CP,HSXMBG;KL$ .EC48 2;1($,"U1$SA.0VHA-&,U
M>!?T+5N,RNBMWVE+I)C-TKD%!5/K9$2(8-UJ=Q6^E(+N*O["N#Q[*.A\MF&(
M)87[?:;/3&3QR_7+P]_VZ/JWHNS7C36K-)$CPCC) UASN(PA"@'H17YEK#S-
M%GF:SX4.0Q"AG-;&22M@:9,@0Q"2=J#Q4<FC$>JJJ",@U@6R_^T)%C@';F8B
M!9W+FV);>VP5AT*"MSW$EO3J"FIG? &$2KUJ^A,VTD5[[>[A56-LM9L:B0ND
MVB,E7$@#%_P%#[-0\-A1S'OA#1EW2$3R"ZY Q+;I=5.2FSW#L4Q-L68\/C8>
M?[RB_;),8?WP%OD%V3/"E:RF\(:CE0XM2*Q@2^9I2*PFEC5C:88KT%EBK>Z"
M#(X/6M'GR#@Z5RC0#,.EUWB]6*A#;G74%V2I^H8-?Q_E4>6^E\4?;PKWP.U!
MB-E9K3T?9*_9L!2'A/J:(<_=P4LT1E(9[F70C#O&G"WP=)9-18R97#R:*(BB
MZ^',Y %"R<<QPI1(E!=J 7RV>:":QJTP='V(263[=G19O>'_F)R4W2__P5VU
M/:&^O7:B -+B,LR ,FX%P'-%FLF'KG4B'L(.:8$P4(K>.6#I/,O1Q2W<K1=&
M(Q27:01]@*0K66C)BE4 -ZT46O7L]^?;7X.KWCIW9J7-+W!6ZY1<3]9,E$&*
ME,$,'F-W"!BZP.2(.DB_.H@)2Y'Y!5RI1#/95-P&[:\*<I/RPWEJ7: VTG4D
M7>J"ZA1.3ZN"AY>\\N/JVZ/TLYV0?\ FHQ7<E=L3ZN#U4[)%@/0=YG9>MN$!
M[NUU3]]686,HO,<?>^)PD\V-6JMOC;/D,H!47'B29])ZX8F_SLFO==J\*=\W
M>Z:M>+ "0J^]YJC?4[Y=H:%8.U\GP9VV"IOQT4^_LS5JAQ*"#I43[R3!TW@A
M\9I8AIO#;9IS-%]@T^"QD S&EJ 50X8;7Q7/TR4N35&LQ+(0'GF_8[UQ=G1[
MD#+(=\V%Y>>[ P3D^&3:"IV)C XRSU'W2V^8WP.[<;8=4=^A$-4:4F/JD)9$
M:48_X4(:N+#\# @('Q$AR<!&5]TP!OC$PTW;<U70N$W1E=9NCE#A5_5K_9G7
M^TD>#8S<='%7:@^OM?%!0%BP<TT9<4:WDRI;BL6X@Y=<WFH3P["A$QPD5Y;6
M7-EZ8(HN4<;0I2)'L]G05_IMUQ:]%896HYR;]MC JFB&:76I&Y=16RJ Z7[Y
M\E?3KHM?D@Q11G0 ',MWY\ ?8 (!! Q2*!VCO \9\2^P(2/^1-ZF-MP7)$'B
ME;,%)D\7MW!F9=5>;EYU9*F?F[[EQ5??D"[*X/=/V]G<X+$N%L7?@W)2-S?[
M]Y"/X=B*30>G,Q)0@T(."; =;F#24)I-&U*:L >E"7[VF.\&B-NX+S$%.I\+
M;=F3RH3W5)D0 W2C.XL##BG.7(4^T)62LHC26J%NMRP"J\%Q6<25-&I]*3\W
MWMK\'H2WI\LBO,'M2:= 4AJQ[6A4>,C&'I8JT+E2ELX70I_'(VY26L-2&Z(J
MNO@42W/%')WC\VF+3^UN5H'LC)2FP0@7TL"%Y4$2+!GQ/_C.\A=!P=&D.V28
MNBSB!KWP05F5IO_@>?(6!M:DV2+XZINH#/#>AQ^L?F]W@HFJ[3;"A1.VI6E9
MF-<_:M_1GTZCDX^]_W0"%J9+A7%O.\O2Q,U!K!_0A&J4--"QO8GO5^U;%"3V
MYG;LS63!'[?-FJ/SN1+-,Z1-U0ZHA-0#,\I82HFE\TR*3S!&IA";<J,Y&OWY
M4<W_8@K"0U(=$Q-*)$QJ!/W4&DVU4$=65:S:M/9BS4;R";N83]AH:TP+F;)Q
MT[9%2VD3T9(MT6RN0!?SH<^MD!P#R3'$!F=V0SCG.)IE"G0A&[IQ1$KR#H7H
M%&BU.;K\F__S\#00^D(W3L>0^Y1+A]Y$\-=5-:8U^33H3)N*DC9H*6@[5WIN
M/JW=DC(;NHEL+DL7V0+-YD/G-L*";UMJTYK/EI&?!ICO+J8W]3%S/,V62C2?
M6[L-AH-IDG(AD9T=#?83+J2!"\L-Y,:@WU<0+MP5%"P;\8'+NFH+/A!84X=,
MN7+_R]>7Y]S-O;0'.1+ORNU)X?5;)TXI#P4(JE.':L*%-' AL!6KVW_/JG,1
M9*FFZ0U3,!'885<:B(KOLBKW!CW/71=6[?OH_G[PFF6T*U5;I\AO'9-D"TXW
M[N".[4IX!Y#$\L$53!2J9U/%Z<J';_\)+/TC[O>.N=]6>[[PVR'V>D*FB.]Z
M(0XW<;B31G%TB=PL2_,+"F)G%YYI"SU9&9XL77K4#GK8@1=IV&,3MWJ'G]W_
M?NZORM13JB?H'1GFR;ACN2/VSS9[9<;4^O#:\:\NC9AI^N +[I .=C="%&YB
MWX.%#G%^]EHS81!3HRH:5K:X2V =/RKW\%^L/ R^?O/PP"F2!65I0<\Z;;CY
M].<F:C,R*NH$O'[\XO]D,E1-1HIT0MT*'=C&#?0\0*J(3JC2*?534 ;P$TME
M,JY<DN27Q4)ADKSR\H?E,&!G6)2W!*>%+N"/HC@PM_8;_AW *+J_K[S^5UDR
MN_A1YA\\B!YDF-K F'W>0Q>7(J?4_; /U"CK0DL63ZEK$$LVU:XU3*"2]TO'
M[K?P)Y/]Y.ZES\= 1Q^2]N%MF9:.A*=,"X%H@@$$Y548&M/4S/L0$U,XI=1T
MP;R0"E[B8:+:F-O.UBKKL,UIZ@M27A!V .#%@FIDYD79NAJN=596A1?T=GAP
M);<1U1!E9-WU6]'T_J?/QZV)(MCB+"W)>'@ HA&79RX6CY2_=-S^(KX.5'1X
MP#,TA2W7-,SHPX,J#"09B/8QS'0BA+IMK%P/>O!5,;25CPQ1Z.-MK@_0T4SV
MXT;O"*H\LD)5$SC@R)TJW>K(P.$M_.OX5+Z@3.!Q(1NBHAD#'=W#/,X5W!7E
M#&C@NO-%YMP3*HQZJ.:H;7Y_[ O9=O5+<0V)N%B_MJS= YKS?_^G=&H#9;PL
MKM@<Y;6J^/)PT[]Z.SH['QBRB@R#N@!2ZW+?$_>C;%FPHT8&3%T>KPYLY;.8
M5O-W8)AR>QCC@L8CV&*;\I':U ?<0H1C3NU'K%_84TK308*"^'0^K-B&I_/I
M1THV*($2%7!?<!3&,+'B:\E:ORN 6R*B@15^HAQSE4)J!QZPVECC=TKH!2E:
M'R,<%TU(<KN-='R1LWU??!?IL''Q*PRJ-3P\$/I]Q3)Y^SIX-@9VK7I(DL$H
M0-C^Q:I;A\%4I+]H X,RA@;LGO&R*M>-\:PEV<!UM :H>;-+=<'; _^HATSX
M+I(^40Z1!%50AB-XJH-4K0<2!_:K<'A@=5T8+]G$TM:ROV4<Z@(BX_4#&YZ0
M#FQY[<IBEQ)T-.[?C1=NO=D VL&J9=.8>QN.<.'G3+"D3)<\*AKHFH1@,E8/
M2WS9-8Y_.7\>4Q+>XB[OTVYC]=[2VF.\L853 W:F(%EPPL%+JGQ=_EG]_=D8
M]/%T"EGL ,+/7*; 'QX >5L(P\4A#H:49I.4*BNC+H+)Z.,7.S2CP2#6GV00
MS^KL1U:TL0]2$0-448:4AA$:!#N7!S1,1'7*M2D= V'\"64,,#8,Z@Z9X'0,
M50F0!3,0[.<,F#;\R^*OHG4L?/0T50, 8"S*AN6^4*)@(:LUI'H#6X,8+LQ^
M9P!73_ AQ@Q,!!#>'2J92O\RTY)5R=Y*L"!XG!OOD^_5RBWG[I0D$70\I=[/
M8M#VYP+LN9NV<P<<+']&77MKQ^>>;8XN=.;BY?$O\ZV?BT[?CJGAJES.5^5F
MFZ/B8Q%=LL/S/]DBZ%S!$1]>TV%LCL6KI6"F+NL\ R7 KENPF<2A_?\!)E>6
M7\1#WQ<T1Z5:O_;\<E>XOA9C,*3 AICA9C[7'#W?_JC\NBOUN*O%S*22L#OL
M6;I,C7\\D.Q8GGK#6 /7J<#0<1PUV7'4Q*DX5GOLJ1EC^YCJ@L8&<8]4;!ST
M07R"J![HN&^A23D.H#Y0D'W%MXXZ \41E4!U_&$#B0/=.CAN/>$>K,'ZIR<;
MEJWA"LA&M>**1UL#"V-\P> @[.6^8AL-H*>QGH#/4=^<:/\'U5JG9=U;$RA;
M>T88C_#PJ?&)NBR7;\<&"S8(7&K ^C0=C_;)"@3J6(XK0Q#O(M)- <:0)^EW
M:S$J%BO2V(,PX _P,9Z9K9F\=HDZ +KZ4A@>$:SA<"M(VW :S]-#_C'W#@]@
MSF VF>8,+RRMY\N,3^":6_/0^F /P>R!-H N,!GQ%&C;9O2L VM)04+/ YP+
MA#?WA"=D/>2AP.%!W]Y4R"($!=S$-@0FW\Y;1Q'O(1VU%22:%$ #R(H'ZME%
MS?B[LF$ZIX%L],#3L&.LPZ]3S]H&K[R CQ;;5 2.AR'H8-9C;+<%6:?Z'NGG
M[DLOEK%. 7S#HL#N J/E$X4M1._"J):@6/ TN@BL><':70V\^7HM,)6<* I'
MO<(G8#N!#2W93=1@*-C+#O$6[8+6 &>,K#UDNMO'(I@7ESHN"==MHVR\1^S9
MAN47[&;ONGSG8G2U@0*#@&C#5K%L4>CO0+6S3M8.M3;U9(PE+W2%A6'Y7@C[
M-(Z P$:L$T6;ML<=6MDRB8)A:\ NP'?FV]B)&2)!QW7Q6.3-LZ(M*_#!>+(@
M7/%;KK47^SFN:#]G4\\9'6-&L5K;XZ\88#1,R6"LWK$@=Z9L*X0QJJ;%Z*[[
M2./K8& ]QD Q/;YC5T>VSZ)B!QD\![-KV'PX/,!119<'O+TA-7.\*65+-8!G
M;;F9[E9T!S"[X$#UA"$&'GKK(]'"TPRS\8SFN,WOASMA97*O%!DV.>RL)?8H
M,ZGH"?Q*<Y0K:)+<?FC?"%P\KH6/$5ILCL[O;F_1XY^?O\LP[2MW=F,W8O\,
MSS)(:@?.LY)L[-E3DC[HC&,,!N@%';FR9!RH\8:N[*@7WFF>]X)?KN(]U<+)
M+-LNLS:.;"E: [:):+>4\+X)M=M8)H$XA'G"-\%4PCNR/8!9ZSB2T/;\B9Z\
M,&CN]HMP' &_3>CC9FG.9C4$Q4X;^X;JL/B$AYQ8$[(:_.-N?9:H?T'J !F?
M#@_N-1P20Z#TD6T!X@6[W\%Z=#A^VE:SVD!W[Z^SS#V/3'=$B2W26VY$&8?U
M-.OR%LO P\_H5M 29%7'EDZB51S6MM2!/<AX@+%4PIE( R$KM=@>F ,=.<>W
M+!:!@@!99X+I@@!00&-,,-J:['@B/5P1 D2TJLN C&W92@$F*=! @"'KX#_R
M2AB.KS9'-]FWXIM6&P[^=.(0'S #2YRZP\]-9T$6GF4"T_"3)92;H_Y+X>G/
M]]K7KWQKO(1$$_23V=2:HQ]J_K<HG[_]N,M&E6R>6JW^>(-N:U>77T:3]\>2
MU&>93;+ZDSF7FB/^VP-8$)7.=VYR25)2^?[)1)CFZ$V\?7FHLG^DBW;TS,DU
M1XUAZ2M_T?G5EU%XYJQ=([!X9WDW^CDLO?OGY_E+[>FE&(>=,!$XX2?%-4?&
M<_?V(J\J?XLMOTFEJA@A_,( \0_??W_[_:WX^^7*-\&Z2_4+X===:8Z^7'T?
MO/W]-GBH\]M8=V#)0_A%P"Z^K^N#<ET5OSYL91'^51)S*UBPAGQSU.)>Z^6O
MS&NOT$UXN\=@SGR?1(!:2)'!R')\2<NP'N@X\TN]:CC[!B:LT)>MDT5]S9"=
M>(9K$[?;V+^W@XD]'.?Q,^=G7N3&9)PH#AIJCKFNPE1!%[G^L="&O64'&JV@
MHC,_W MN<4PM(**"70=\58ID&[M]W O;L,)2EJ7N-?[!&K6\!<TPE2$]]B=,
MN6<%V7!C@8&)[4^0"?C.K9F<L95C5AU?XY/-6ROB!,/W[([;U*"/"6E%Z+RN
M2E< D@C6RF#._Y^][VQN6]D"^ZX9_0?$>3=C)Y >>_%][\Y0U;+5K.*6R7!
M B0A@0"-(HG\]3GG["X*"8)%!(O,E]S$(L'%[MG3JP;WU277-"YIPTM!!39
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M4WJDT(;_*$\AY;*32T3JZ&"ZV\U.GVOHY ?41;"-XC.V!FR!QVTH.[GGH1O
M]\DPIYWMN)+[;)&3@;+Q835<H>%H-CFZ@F"3 H]Z9O"-'$G8I5I!BIO2Y80W
M2^]CV8XL9PY3K+'AVV;'A\XI^@8*.-75_?8LJD<!$H=%WWLFBZH!0V/>6U97
M2^6[/)>:E?6B4XX[M^"SD&\KU;TO"SHY@$X(EQ@2<E\;1=8X$&6)P0^#G 1
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MZ4;.AJ^K[MCNWMXA-9MK^F$S]M?>'NSO#5VH?[ ZG.OUMULIYF(3"'R-)]:
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M<EN=?K%<7I;@P?%U+-\[UG<RK[T[AXV;A%&SK#.5<I-\)6D;8ME"5<X5X@H
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M\21Q<THQ$6KXE5CESA(0B3!U^'^XAI#+Y*?7$,1:/G"ST^D%_)!X1@YS!#D
M7&B4N>:W6KE0<Q[.FCZ'I .%4I1B(9/(+2>!9%Q;9&"=.?]?>2'KQQZ>?S_A
MD M@Q $Q)$QEWMUY$H"CV0RQH:28H)#UA/$DUHQ]CX:5LOYRL E7-X;IMK3A
M7/>,10ETE0^K(-.%N ^Z"XC]("F/LI-HYS)&V>HP:8^X$LIA5P)> +.3F7?B
MFN#,L!0.1%\YZTFH8?<!;5@  ,$71)L<;DI/<"),!8AU)-)XQT$Y<<C5.$K$
M$ #S\KLL7*MI$;&F,WLF_ A;R1=L($9V=X(P A,V3&"@+:"R^! L$6-C^L.B
M(EZ<&%X)IA90BG*@.'IS/7%S4'DRSC\I_<?<H!BV,R7<-X6TFJ-YK[,+E9D@
MM?'(*^0*!U>/@U-F PU)MVG)4=XGH @J%0\?#Z="!TGPI/W%S($J3?!^7-G,
M \DL]?7$QZD<'CQBC!C)SC*/RR,*C77$N3FU&G_471MVAV06XH+1B).JL>"Z
MQN+&+46W)5\/8L-^QK!1,EV39@V>P%I<D^2^I4-_C5AGR6%1:=ZX-^>5:B L
M3Z;84'*WB81=I.L]J10*<C'A<LBN\JL/_'1-[%V(NA2E?PRE8OB<0'!A<XRV
M16UV]Z6S0(Q%[<5@@EA'MU66)N$W3=[=B7. Y8.;/>._/N8_B+O-@(U\TA3#
M[1S"AJ_LMF+J U(<;[0GS?2T6POVKCF,0P2<!W=UC9NZ5OJ6+015_[%SW_B2
M;2I>X \2>_%WGX@-PSM/P@"QG7KL;A;1P:4J XZ,Q0^6I&)J[!"$+=,HVD3?
MCAAIQZ,M'#AL8AQEQK18VB^LQ;\3R.3[E@@-0E/IU*ECQQMNX\P2) \1U>[.
M&*,&E4F?$0-,8V;;SF/DS!VO>.M&SMCXQ"KUQ+R<S5?D?$QP2ZB*?&9,DDHW
M W;,'0--S<SP;JV7ST^GOTX?U@--QL9#5XDF8]6%#^/LX,"_/\:1&TX,'4:N
M;"@N,Q4D"^O)>@;JSSOEEU'Y;.;+,7D:''0A/ L8LN\=)X4K.8HT'8@VBBDE
M3QC?W1G#E8[F0YSUXTH5U5"_%L^?KX\JZXDXF\6FC+%\:@AXT^;[Q$..+#H?
M</EZ3Q>1X[7C3$_E3Z5N/E_N*MJK$$QF9O \>#8$K;7E3S&6DD"X7$DN5<IR
M)AO7?XXPC]D%"8/WYD6I]>-95X6+['WW^$NUT%AGE%H'SI6 4@FJEF+R6K;9
MT6B(I^?7E"N=?#Z]Z1MWUM%E:2H4FM+;-B50UI8#C2:UYF-MMAB>$X\PU?D0
M9OUXSN5]OI/--;+G9ER"_4H09AWXRRQ<)0#)[@X#V(8[RFI4!#E3&N5D>HA*
MEL(ZJW:F\?/Y6\F[U4X"CT;-/SNG"9:=%^3FO5[:KJ^!F2!MLX ;^6Q.KE82
MIF3[N:1^%P?0Y2[_7?L0E^,XT?&Q#BV6JO7!D9D[[C\^*0]GL4TQ5MIBJ3!%
MBZ5<?5 \^7%E'MQ_UX\?5MUBJ50?5/7/S\?W]U>%FWEZ5DUHXY.M#WZ>_KS5
M7XJ_7G+9E%LL%1;38NFP/C@[KVH_OI9Z%:V]PAY+<#G*64-[*?PX.+^;IUGD
MA,N!];_8+Q=VZ[!@>C-<SA)Z+&7J@\;=C].S^\=L7IFG]5<:/98 7O>_+LYJ
M>N?7^9?RV^JQ]% UC.I3-?/C] _JL50$ LO?W.9Z/[_;?65#>RR!3-2M[+GZ
M^>+DX2JWF3V6X S?!MG<R>"+F]6+2R;W]&?A!CDRH<FSXWH(9T(1RN0?U@=Y
M]_+XHF<5>S</:2A#08/ADA3771BX]%4G_^OX0#$KC3SK4,NW2TEYV&8)Q!JP
MJ& :IK31%25BZ7--P7GH"SX+[XS?MI455,6,CNM]UK"$Y"/OM1+)Y*#\?.S0
MJLZ4U!%D2EFM%B9D&0C'(&<FOE(P( =F4!'P><HKYM*(-"2>+U6(V+71_,>S
MI/=/BHY/>/VXC,="Q(Y<0$%F4<YFQIM]>">)=;S30''8.[!B*,9RW%=G%!;E
M7&$L'&5I7/ C,RLL?8S,K0<L!4;F%H:163F3C1LUF8"1A1FA..S#73$41[RE
M"QBKEDMRCJ/3QNFQ\E6COQ]2M%8G$(1P6MQ6A-@[[O8,JZ]I$I#.^\</T@$;
MY"E=&XJYZ<,*)H)UJ#<7B%E H!;ZZ_8B;8@<Y0EG.& '09/[[VYY?BL'&\]W
M)BL*2V]XFC"LKFHL<YU^V\2J.U#9#$.Z-U&/9X:5PUL1:OPRG/W=G<3O)0W.
MJO.*:<R"UIMZ#P.E.DN&I9=A-SK_&*)"B%*UV?@42IGU7,ON2X;>Q>+!P#4I
M#K*[(TYRRSJ0A=NVL8-Q"- K67,_)Z*)^(WV@L(DH-YF!S6<,)0I+;RA=12C
MQ9(PQ%>8ZQL"S+!R),VL&W4559O0@0.X&6SI,+R]*92>\/,3ROO]^HZ8-RU+
MORF7Y'QV1OWF:!HH)2LU:4(I%?TE"X#*5JKC_?]C])>3J6"5J+2D"ZO%ZR=E
M.1\[V"H!HPZF@5*R4I(FE%+0/[+8,J@\%I\^R!$-1,96M.-89L"Q0VSXK>LL
MYR!'F.KX9[D%AOK9\NZPY,QM&HK.NQ$;&!<6B8JDMK@=Q9446W=\_<"RX1NL
M[F]:GLW\ 0W/ 1GJ@%"_Q;Z^@&\NJ2J8YVYVL-C+-?J ;[P1K2QZML+W304%
M]^Z.:4EM3[$5H"&-O93>Y;E-B_43IEZ[P>JL76U#(ZI!F=U2GBQ;:1A]R?=/
ML]-2'U2^'M"&97AB,DW<DK@3%Q2Z)] -\',-W;*@?Z#NI?'>-*SW;ER-6C/L
M 6_Y'G"_OL@9JD2T--9:N $Z&>A*'-JXZ=;N#NN1#!H)D6[2)1$L)NP9=JR[
MT^QPL0P@1!9SX^X0*2V>*;"2##^:_EW!M H,5[P=#C'<^XOUJ1_I8S54W=51
MU,2>J(>&XCA7+0ZP*_L&+^[*<P&="&U#Q9'A2BD!8*1O\:A A/B>FE.]B+70
MFN)%R8Z&":]:0 5M?!I5"MN:K;'7F'3 TKB"ZW@5Q*_UC8$]YDXI$J-O2FS1
M;(PZ:R_885RDZ,9ZF$/=U,2EA@[_G:]88PL>\_5F0+_QFQI%S.Q<>]'/PGW>
MW%]%N_/UJG-P5YU_7^.3JJ;?U\+1&=34ZV247L0.7X/9X1WF]\MQK>J245MQ
MX+6&83T['Y>;;[7(8:FWS8ZF>H9H>B6D7\R]W&'B2#@2.EN.3*4:KIR:\ZWU
M0?/YI'M9:!X_GV'LV>MB%W!ZP4<I"+M*>U)B?%-Z?Z2!"FHX'^8(Q?+T+Y#C
MAM)SM(^2^-=0Z@TFU^#0[A2G;2?/;:8<IPSF.(E/;*9113[#E=C!H_C'THF&
MV5[E +A6]<OGNV_YFVZQ&>3UJ;H#AF,?U343-B\NV$\'#0HPXB2"3UG1DTPZ
M<>(TZFG!%3-->O*#K]J- &W\D/=$? FC!: +0NV_[_+)J8EC)F>+7;!<]OF'
M?R]H&X+/2]<H_9<ZBSS80D\'B_8(C*#PI<Q)QG:[\3Z7*<BY?$7.%8L?8BA:
M\(N_IIB-[BL>E;";F=CG ;KV45O73(><&J&$\(-^\,BUTJ<<<:! ]:I'[I]O
MFH.BUJ2^($WJ2H4?A1@P0X_8_B:T$"9ZQF>="VXNLJY'.\F_&[I>8DW^?XPG
M<1CEAX%$I,H_PBD0R+[W\"<3"^>7!++$#BM#&>I#H'J=IEX<IZE'26H6Y(O^
M)/=7,NTEKORO&(PN+Q6CQRB8Q'<6C>=1KO9N"$+Y3!Q2KQZ!DR"T;+2.JNFQ
M5;!+QNL15A2O*D5=%P(4 ':RV<,Z[H7B>CC9&P4/&HBJN@@T'%QELK731\?[
MF0OCHR_BWB6E3[[B7M&I2'%45>EC5UB<W1)%X&EA\>X?G,Y(PQQSA9'<S[#*
M^"I!/4[?CM$Y9I+3^0V3T[G)<GJ25K48T^--BO;<(D3[=))]/L1=AJ8]7@4H
MO0D5((Z$QJ@ LX#MC:H%KR&)L%J0S>UO'%5,W,TXI>)@)4J%0.S!LU;^?'W^
MK7-Y]Y"24A&+%8M4*FH]6S>D')OZ7$I/KYC" ?!:%>-DM2K&5E-XC::04CQN
ME5QOX3[7U6U?E--.6B3@$;RTEM7/Q12KA2K':J7Z0'\X\CK&Y=5MV4BMBFY9
MPXBH>P/EOV3_9HG&8;+:W5EX+GCL;E:<7)'+9(L204)B7(*GP&]RHY,K,Y0>
MDJV@R,P6Y=BLIP,+V"-.\;:M)YSBJ]"STE77U!N>(YV92%$XT NA,C2'"9[#
M3X/!26Q6$I\"S/KJL/'#"F\Q0F"V&#/FL\ <%\@,8^1\3 :R:U:HK.HV,&G+
MQIGR5'2"_PI2X?G08,<S7!:8BDZ!W^P;Q$RSKO*B=[UN:)B%Y=E^DT+1K04G
MA#-8\X;.H=Q0RLW'OO>)>4"T(%$ K]-ATNJ&+WUBV2<>:&*:&$,0JY$B(F"_
MB*A"2JLRLL('$&5B;*V+D8../Z34HKU0ZR;<S,34FUE/-XU)-/98KU(.2G*F
MF)&+Q?&9^0P>LL@ I<DO*N(,]=#G.9Y8MT'4IDB@H9OML4WYFPP>O,']AA,,
M$QMP$]4X9K[!!='C6?QGQ:1)7<C:\>",P4<9.N\W!%#A''UW)YFE5Y-8NO,*
MEBY%.#HVZQ]AZ7*$G^-:BOJD._#\EKG/P-R+BS OQ?BCFE^]Q=A4S7,[EJT/
MQI0QSRX0JC$"(7CIV&E:?ELMQ,AIA4&*T)BMQ]E8,+Q6@$P8L/-6!,BX-B?'
M]<&/_*?O_?O!KQ_WL7UV5MJ^K#A%^[),?7#7LP=?JY]^&]5DQTSZW<MJ]<&]
M<GQ<U.YKE:O'Q3?(*M0'_:/;([O9:.EN>?H&67-U+RLNIGM9KCZH?&U>/1]=
M%+[6E% RS+*[EU7J@V+N^/E9[W\ZTQ?6O6R->I0!I#]]Z]U^O6[<'2EI]-^9
MIT=9MCXX;1:-VH]O/740V]!O0WN4 :V_-(]JMP^GN>JG[)_3H^RH/NC:YP^7
M9V;VLQ';"6\#>I0=@-1H&$?%F^]][3R64:]_CS*@+-L]-]H_LQ>/;FG)Y)[N
M7"Z:L\SZ$\35;26U)'AMS..4XFMG)NO,.U)479U':<_%1<RYP4V6(>C#*8=R
MHL>:7,%=3=*^<XM(\RAD2G)AO/,&+%YN)/=L[4FW/,?HC^D.S(UP46DK^9Y6
MJ:$U 8KCF@KGN$4/-B%O9X+%J=;SAPVWEX5O!P[XI_AV+A2[V9%RQ7!E9ZQG
M!V RG6>'8X?P[+!BY@!IT)'@+]WH,S.[8QDJ%H-;N*&^E"NP[>Q+]S[:X3A6
MWSV#7[*PT2A/6TA>W;*\$K$,[L_S2BR$+V:GF/L;!UGFN><4+SH&Q$-XR"NV
M+]7,OG [ANLQV6.*SX%W=\+N2^Y1PS?Q)OAA-XF)S%3J*;K*EV$E_H3KY*K$
MA@1L\Z&?1>IGV8:&-T%K@-:+[0/@EP[9I=ASH4DMUF 1>&]H27HO7^L]&XX*
MOS61:,'Z=%A[!$=S 6>[W)&#@.&_T(5W\0,[J>+!S2N4&P.O!/EB=;'MY"0P
M^XQCPT5+E GZ;FZZ#-VE5EJ(=6I7-W4'>!V&2 '0/CN6)>X09\P9GU<U@PTO
MHHO"CBX@]/6&;N@N];=0^& -5^,=PH8JJ(/F&/ZHZ_ ;^;!U0!B=-==@KGA$
M0;A83B4N]>=S)< EH"EN4-&P; #(H^:*$=4FVR2?OMP*7/L:1MA@J]G,7V%1
M((;NLG?BSV3$7(T[#J,'8=MA+3)@/X[#\#2+:\*^8[:3/#QZB-F.;&5_=^<V
M$HW@M\<UTEA=B<9-F:&=DSJ)[^)MT^!HJ+SS>>[X8Y6/Q?5#(-3LA'$0B[&%
MW1T\+KR,+>=@T3'?S)A;C;ADX7V&CENE)TD:(-TJS:9EJT2(-%TY5OPRHI1H
MU,GNSE SM)A(@1"!C.VS41ZQ,G1PUKUXU+YDOF=^:\,Z/YNCDU@R'EY_P1V\
MQLV*K&9SB5)'H DVRFAHFCA&+)X@>:4:9^&26_#=$\LF"^<UL?8D*RU@\'3H
MU%64,<>;*]B^$*VD)!>K5;#7XAH(1-&#!I)/)1"9ZKOA$K$FZO,%5Z%ND4(C
MBS#FD'(3U:1PLA;J-XY&C)>,T"5T6UB");KX?@X^B07-%0*$=VXLPP!BH73O
MUW9RR(;YU6QOJP^RS>/:O=&\H2C0:QLX2-F1%@[91;9PF*D@?VP2[' /A5)]
M\..B>?:S:>9.KHQI>BB$M7]&'WX_!4XH?U8+A>UN5KJ;UW2KR"4$9T?./&<(
M8:ASY*1^%>/K;A;PYNTQ5G<,4;$F\9*UC3]0S+UL:7&+Q)MU(#+8J%Q0.E%T
M>^//4Q-3QMD6=&RO;#IZ<TNF?Q*9#C>PVO#C4'KA&SS%8NAPZO+M&2H3EP/<
M>1JCS9N%Y;&)QK@;L&&O$@W5/P,D[__U87O^[?EGY4:OZR^8R\?VPIKK"'_#
MC[%-_A[W#'Z4]C+[^2)>5JCX769;6<'_0H/45[0#'B3+CL'SQ/9DB]2@AI'@
MKU3(:>FG"II?'"XPMW&TRX5^.YKAF,F'8F='L,LG!9.DSDS'M3U<\D9W'EDL
M+=A9X!47/52\JR_/'<,^/OND#T73'.DJVB:]H;5UTZ3&[D.0+HYI'3AG)GBJ
M*9;3M<7(\MQ*_M;Z".1>ESR4E?- FM7QXSBWE)H6I6;3H=3$+EYQ]!N)?<]/
MOS<_'H[NKEJ=S.="T+5_R$DC1<W!-T_7,_<&2X?:PVW!BOOEPI;65W&J!2,Q
MI0GD)KUS>W6O9=-'Z;#I,^$/)6<,,F::O9<:>_[Q^_KWK_O;5O:A&61<"Q>M
MY'MG>:K@6V?,4>BGRHJ3!A86,G(VGY,+Q>R:L>176.#3#^IX3:!$4Z=.[5AW
M!_Q2-IY27_EHF=BI;3FC<T47Q,%&LRP=B:-"K(]\G3E1#-BF++%+QPS,X7C9
MI&3>+96EZH=Q9L*7B7V:4Z:^25;=VE+EXL"\$FJ-='?.[(\?,;ZEUEFI-;V*
M\"$LHB\QR0-S/)CJOPJ*'4HV86USUI=P%POQE1-O>3\3-[%E2[NSNQV6Y4]9
M4V-KBG#GPG9^8MDM3=]:7O-+F8,%2AE^&QXP%+_YB'Y95_74/$@9\\3MF8VB
MW1D-T/FXD8+L>)^N\(@!Y$IML6RV(I>+R[?$AE-0-I?@%HR!L<D=Q6*0B1.4
MK-86:?3%(.8J++]!I7#5?;'S[FFGD;H%-N.95Z[)E?:+I?&4NA63<XG)4-G\
M$A'*29>*?K2JGT[+-[]^*)U9S;(TA6M"2X&EPW[EU%S<SVU]*NLE?#?4+DL]
M""8H9YPQ-N6(H#2N?EDYRRL\Z1@W/S(DUH*%]:9D/(]QEW ? /_R4K;8G@O-
MLXO!2>OS:7O$8O/W\*K9B^E8=#/#<:4&6R&3D8OYJ1UZZ>+KJ@L)UH(H9XIP
M3])B?!UE4\)OJZ3LE,W#F>YBY>ID;G]\^Z.MO%X-:SA>H&TY+3:F;%F>?&XW
M?UUGVMI5?E;+<OU8Q6(LS]EN9N6,(KM?J6P9Q7HQBD5F!(R@XYWE*L90!G!:
MF@-F%4^1\;M^K&!1 9YIH+\D%I"0"UR0<YFLG,D6UY81;$28.KX2=VT*<8/_
M!7,JEOR_-3@[%@,O[7]K<%[D(%-2,=@,JQ/H]/)EBO3EG#80ZJ5E%$>/GXXP
MOXY?=;K]EV^-I^?>XZ3B:(W^-6&R'<)=4BVO86B;(\BG*YA..3LC+V=+5;F4
M30C[;BE\=11>6%U1=1IT7\X8=O?\\+':TA975/TV6<+,M=;+R XI35W8MV43
M2SOM4O%_=KAO+STEV5!=?B5W&C+A[-MWY>YWL51XJ"RBDOMM2H,I"KR7X-0I
MY>1<J2SG,]4U%@/KG.:RK?5>'R_VN%KO-'C<Z>UUYZ'R.=_!P=M_6-'WZ/S
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MPFNI:QURFE-K#/!F_<W%M/S-?TNB+;MK]6AHF_B;OH9/WIA'NKA /]OL+ND
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M="U5,SAA\(5880@5Z0_7N"N.XW79A2ZS;B3-VH[X)@YA\L0N#,Q;$YS^#F7
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MY<FRB:&AB1_,?-'!:F]2[C[E9*./Y@E^SPQWGYHZE@&F*/M5B+RVES7]NZ+
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ME68'M1\5^;'5;))*K4I#,&-B+A%L7!$<^_(PV'9W0+)K/3R>Q#WRJM0@<\L
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M=9$A]CI]Z?WU\=T'"?D)F:9-ND8)=$=-W&VHC@O,=DD%6WQ/U7H:S1I*4I"
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M[&N3I<I40:7L-J@T6U INPTJ_8%!I?'!BY!/N$H^81T9*D]40D_<'G;/H)
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M&_8IAEV(F8@Z\DQ!T9#;?W)HA+G696X[BL&0UU]8_H3(F?#93/C2)V"M'[/
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M6KI3.\M!7?%H2C57J^[FRNG0\@L+*N4*N\5<K7 _W'*/%5)ZO+Z]^'CM%?.
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M!<D'8P(3<7SS\@53CKFZN'T<A<8<070,$D=@@.2_.&<9##4L^&:7*$+XM\)
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M/%;:@@K*)4>R&WX+8Q%PF'N"2P\U]Y6.ZW!"BYY%_L=$7?;5*F9R\TRG5Z>
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M28BHE+3DF1$2:FIJF@LT;+2T;))7.*](_D]_",T  Q6)#*D'&0DO0,I 0L9
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MB:#D/7)F<9IS.YF8''P$$VR.F@"T$PF"&D'DIU4)V=.=')RV&0%XX8',P>[
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MM3YRJ-Y$6!BS?:G@5]5,LIBA_392V%GQ\ XV(.L!QOZ6E)J05D&/M#6YQ.R
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M@[VYC&RH(#(>%30DAY]AF"_%RTYF"!QX?$8"7GUW#;YMX,8T6()[P]AVH$L
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M-\A O9$4[<EST_;%[6AQ^]BET$X=78B!?AL!D(:1R"&AR591$<9HD\.(!P3
M9<[%:&:97! JNF'#Y3$EO?#%[^TG4Y/V<NG\1$H>T=.,L"[(X5$>C!33L6A_
M(SI95R0,8NW2*0[(D3%C<"PH]0\Q<ILV1E%Q->DB.YX4 0G9[H[RC\[>#A/=
M(0 B38SOQB'W$!P"WWW&$.Q)"&#!T%Z>;7TW6W&DW G/]T)6-EIPB3RWY+A,
M969X9+^ /AQB:V_6V)TQX@)HL]U7NK'"MHB.WS_:L8_CTR]QYB#]U9(,GI,[
MMJ53,%AN.X+/BUJH.88(&"%B@C1<O$4H+>IM.-Z(L'E%[']N6A!'@TXIOA*
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MMNJ(0,'9.CG+34-CV&MT2%9#CH)B>K.'VTW$=3DGZ=X]L)95:$=]VK"UR>8
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MZGZ9XOB8+>RAS,?06D_ET#/I-4!&9\HH#[IY?3LJOW)40'ML]A[K!3)S3NP
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M)%XSYV">WT?,3)A\[79JF,?XL[EU?FR.3GK P=V.\1=R&'9Z]:/ ;M[XYFZ
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M+<_4S-Y&.#6.:X/8#!%P7N;)KQ.???%:*OG9E"WWS%8JNW .=SA!D'YLC\F
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M2$RWLO5RT[4O$BRS'?8LO&-_H[YA=\@OPI*ZRLI,60?!;M#&QNJKF93>AUH
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M68\A,D(F#0\4@&;X9M+K.)  /%!X"R9XPZ?Y_A]2\B_KX 3K)XE#<4L:I 4
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M%#/L$*'O\WV#S?VH^LV(_EM)ZNQ?5D//GF6[H&MZ@T]!&NZOX(&N)?@N?2.
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M4K*K'.,8.8X@O:#B6*$^^67:;Y;][PP+_+]EV5\,^ZM=LP *#-33Y,%@ ,+
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M^&SD@W?/T^8FR/KO#PCQ.["5H \YCE@+8M4+8W18M=#/=-WR/$X](WLS,PM
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M6Y?F.MTJL-["EV58T3XWJG.8XY*L95ZF0SOCB0MK>2%"K^H*F1E]B7@-O38
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M3DW05TTMXSZ$22.BDU_4E^@8YPS)Y=V5"",I'&IG"M[I6@=Q!/LE.\W4WS/
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M;GY]7AHLL=*])E/8'MC!'Q6.06#DOI=5N"%?6#S16 >3"5J(I7MY6WN>,B8
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M,#(S,#8S,%]D968N>&UL4$L! A0#%     @ VH,(5VN@"L_7-@  T!D# !4
M             ( !BRD  &%V>&PM,C R,S V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( -J#"%<\[PM#HR0  *ED @ 5              "  95@  !A=GAL+3(P
M,C,P-C,P7W!R92YX;6Q02P$"% ,4    " #:@PA73S/F0+@E 0 NW L #@
M            @ %KA0  930X.#=?,3 M<2YH=&U02P$"% ,4    " #:@PA7
M*4K;8U0'  !G(@  $               @ %/JP$ 930X.#=?97@S,2TQ+FAT
M;5!+ 0(4 Q0    ( -J#"%=) 6P=4P<  %<B   0              "  =&R
M 0!E-#@X-U]E>#,Q+3(N:'1M4$L! A0#%     @ VH,(5T\+JF(=!@  GQH
M !               ( !4KH! &4T.#@W7V5X,S(M,2YH=&U02P$"% ,4
M" #:@PA7AZ*5S>*$  !KI   #0              @ &=P $ :6UA9V5?,# Q
M+FIP9U!+ 0(4 Q0    ( -J#"%? )]]QHEP  )QN   -              "
H :I% @!I;6%G95\P,#(N:G!G4$L%!@     +  L MP(  '>B @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
